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Chapter 1 
Introduction 
Nobody could have predicted the tremendous implications of the headline in The New York nmes of 
July 5, 1981: "Rare cancer in homosexuals". This article contained the first description of the disease 
"Acquired Immune Deficiency Syndrome" (AIDS) and marked the beginning of a pandemic by the 
Human Immunodeficiency Virus (HIV). (1) Three years after the first adults with AIDS were 
identified, similar disease features were reported in children. (2, 3) In general, HIV infection 
progresses more rapidly in children than in adults. This progression is associated with a higher viral 
burden, a more rapid depletion of CD4+ T-cell lymphocytes and impaired growth characteristics. (4-
8) HN infected children may be divided in three groups on the basis of disease progression: "rapid 
progressors" (±20%), "intermediate progressors" (±60%) and "slow progressors" (±20%). (9-12) 
The first group shows a rapid decrease in CD4+ T-cells and develops AIDS (CDC classification C 
(13)) within the first two years of life. In "intermediate progressors" a more gradual decrease in 
CD4+ T-cell counts is observed. These children don't have symptoms of serious immunosuppression 
until the age of 7-8 years. The "slow progressors" are asymptomatic at the age of 8 years and have 
a normal or slightly decreased CD4+ T-cell count. Symptoms associated with HIV infection in infants 
and children are dependent on the extent of immunosuppression. The Centers for Disease Control 
and Prevention have developed a pediatric classification system based on the seriousness of 
symptoms. (13) In children with intermediate and slow progression rates an asymptomatic medical 
history may be present possibly in combination with a slightly increased incidence of bacterial 
infections and lymphadenopathy. Pneumocystis carinii pneumonia (PCP) was the most frequently 
occurring opportunistic infection in HIV infected children during the initial period when HIV exposed 
and HN infected children in Europe and the USA did not routinely receive PeP-prophylaxis. (14) 
In the early SO's most of the HN infected children acquired infection by means of blood 
transfusion. With the introduction of HN specific antibody tests in 1985, testing of donor blood 
became possible thus preventing this mode of transmission. At that time the HIV-epidemic in the 
Western world was mainly spread through the homosexual population and relatively small numbers 
of HIV infected children were reported. However, since the early 90's the numbers of children with 
perinatally acquired HIV infection increased rapidly as a result of the spread of disease in the 
heterosexual population. (15) Mother-to-child transmission became the most important mode of 
infection in children not only in developing countries, but also in the Western world. In Western 
Europe the increase in HIV-1 infected children is mainly caused by migration of HIV infected women 
and children from countries with a HIV epidemic (sub-Saharan Africa and The Carribean). (16) 
The HN/AIDS epidemic has an enormous impact on the health and well-being of millions 
of children and adults all over the world, but especially in Africa and Asia. Ninety percent of the HIV 
infected people live in these parts of the world (Figure 1). At this moment women, of childbearing 
age constitute nearly half of the 40 million adults living with HN/AIDS. The risk of mother-to-child 
transmission of HIV can nowadays be easily reduced. Nevertheless, mother-to-child transmission 
during pregnancy, delivery and breast-feeding is still accounting for approximately 10% of the 16000 
new infections that occur each day worldwide. (15) 
In the first study (ACTG076) to prevent mother-to-child transmission in 1994, 
administration of zidovudine to pregnant women and to their children during the first 6 weeks of 
their lives resulted in a reduction of the transmission rates of 67%. A transmission rate of 22.6% 
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was found in the placebo group whereas in the group that received zidovudine a transmission rate of 
7.6% was observed. (17) In the Western World transmission rates may be reduced to almost 0% by 
means of treatment of the mother with HAART and by the administration of antiretroviral drugs to 
their children. An elective cesarean section prevents transmission during birth in mothers who have 
a detectable viral load at the time of birth. (18, 19) In developing countries where HAART is 
frequently not available it has become possible to reduce the risk of mother-to-child transmission by 
cheap medical interventions. Although the ACTG076 study provided a relatively easy way to reduce 
the risk of mother-to-child transmission, easier and less costly alternatives using short-course, 
single-drug regimens of zidovudine or nevirapine became available in 1999. (20, 21) In these studies 
the transmission rates were reduced with 50%. 
The millions of infected pregnant women give birth to many children that are not infected, 
but affected by the HN epidemic, because of ongoing disease in their parents. Living in a family 
with HIV infected parents and siblings that are infected is a social and psychological disaster for 
these children who will eventually erid up as orphans. Since the beginning of the HIV epidemic a 
total of 13.2 million children < 15 years have thus become orphans. (15) 
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Figure 1 Adults and children estimated to be living with HIV/AIDS as of end 2001 
In The Netherlands the University Children's Hospitals in Amsterdam, Rotterdam and 
Utrecht were confronted during the 1990's with gradually increasing numbers of HN-1 infected 
children from women in which the virus was transmitted by heterosexual contact. (22) Prevention 
programs resulted in a reduction of the transmission rates of HIV in homosexuals. Yet, 
simultaneously an increase in the number of heterosexually infected women from countries with a 
generalized HN-epidemic was observed. (22) 
The prevalence of HIV infection in pregnant women in Amsterdam increased from 0.2% in the early 
90's to 0.8% in 1999. Eighty percent of these women originated from countries other than The 
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Netherlands. (23) This also infiuenced the data on HIV infected children. During the period 1998-
2000 in 83% of the HIV infected children, the parents originated from countries with a generalized 
HIV epidemic. HIV infectons in children in The Netherlands are almost solely caused by type 1. 
Thusfar only one child with an HIV-2 infection has been identified. (24) This may be due to the 
smaller mother-to-child transmission rates of HIV~2 as well as to the lower prevalence of HIV-2 in 
comparison to HIV-1. (25, 26) 
The increasing number of HIV-1 infected children in The Netherlands urged a group of 
Dutch pediatricians, specialized in infectious diseases in 1997 to create a multidisciplinary Study 
Group for HIV-1 infected children in order to be able to provide optimal care for H!V-infected 
children. This team included experts from the fields of Pediatric Infectious Diseases, Pharmacology, 
Immunology and Virology. Since data on the treatment of HIV infected children were only scarcely 
available, it became clear that optimal care could only be provided in the context of a structured 
scientific approach to the diagnosis and treatment in which new developments from the different 
fields of experbse especially from frontline knowledge in adult infectous diseases could be rapidly 
transferred to the pediatric field. A study protocol on the treatment of HIV-1 infected children with 
indinavir, zidovudine and lamivudine was written on the basis of the excellent preliminary clinical, 
virological and immunological results in adults treated with this regimen. The relative immaturity of 
the immune system, differences in pharmacokinetics and pharmacodynamics of antiviral drugs and 
specific issues concerning adherence to therapy, complicated a simple extrapolation from results in 
adults to those in children. Therefore the study protocol contained strict clinical, virological, 
immunological and pharmacological monitoring criteria. This thesis contains the results of these 
studies and provides an overall insight in the current state of the art on the care, the epidemiology, 
the diagnosis and the treatment of HIV infected children. 
It is unacceptable that the improving possibilities to prevent mother-to-child transmission 
and to treat HIV infection are not yet available in developing countries and not even in second world 
countries (for example Romania). In 2001, pharmaceutical companies were urged to reduce the 
costs of antiretroviral drugs. However, to provide care for HIV infected children, not only 
antiretroviral therapy is needed, but also improvements in the infrastructure for health care, better 
health care education and a broader availability and use of vaccines against other infectious diseases 
are necessary. Without appropriate health care the administration of antiretroviral therapy will 
rapidly result in increasing numbers of non-compliant children, the selection of resistant virus 
mutants and in the subsequent failure of therapy. Since in The Netherlands 86% of newly detected 
HIV-1 infected children originate from a country with a generalized HIV epidemic, a spread of 
resistant virus mutants in these countries could subsequently result in an increase of children 
infected with resistant virus mutants in The Netherlands. Years after antiretroviral medication 
became available in the Western world, finally the United Nations, the governments of many 
countries and the multinational pharmaceutical companies have taken a first step towards the 
institution of a Global Health Fund to improve the health care, education and prevention all over the 
world. Hopefully, these improvements are in time to prevent a broad spread of resistant virus 
mutants. 
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Outline of this thesis 
Part one contains epidemiological studies on HIV-1 infection in children in The Netherlands. Since 
1995 a prospective surveillance of all children diagnosed with HIV infection or exposed to HJV has 
been performed in The Netherlands. Pediatricians monthly report these children to the Dutch 
Pediatric Surveillance Unit. Until 1997 the Department of Pediatrics of the Wilhelmina Children's 
Hospital (Utrecht) was responsible for the distribution of questionnaires and the data analysis. Since 
1998 this registration has been performed by the Department of Pediatrics, division of Pediatric 
Infectious Diseases and Immunology of the Sophia Children's Hospital (Rotterdam). In chapter 3 
we report the results of the program to prevent transmission of HIV by means of antiretroviral 
therapy to children of HIV infected mothers in The Netherlands in the period 1995-2000. In chapter 
4 we present the data on the cumulative number of children living in The Netherlands who were 
diagnosed with HIV-1 infection, on their mode of transmission, their risk factors and their clinical 
features from the start of the AIDS epidemic in the 1980's until 2000. 
In part two several studies dealing with the pharmacokinetics and pharmacodynamics of 
antiretroviral agents in HIV-1 infected children are presented. In chapter 5 we present a study on 
the pharmacokinetics and pharmacodynamics of the protease inhibitor indinavir in HIV-1 infected 
children. Since indinavir was administered three times a day in a fasting state, a simplified 
medication regimen was urgently needed. In chapter 6 we therefore present data on the 
pharmacokinetics of a combination of indinavir with low-dose ritonavir, which was given in a twice-
daily regimen without food restrictions. This study forms the basis for future studies with simplified 
twice-daily regimens in children. In chapter 7 we questioned whether therapeutic drug monitoring 
(TDM) is a useful tool to assess compliance in HIV-1 infected children. The data generated by TDM 
were correlated with the virological outcome. 
Part three contains the clinical, virological and immunological impact of highly active antiretroviral 
therapy (HAART) on HJV-1 infected children. Since the introduction of protease inhibitors in 1996, 
combination therapies including two reverse transcriptase inhibitors and a protease inhibitor have 
rapidly become standard therapy for HJV-1 infected adults. The data on efficacy of these 
combinations in children with HIV-1 infection are limited, and are predominantly derived from 
studies in which only small numbers of children are included. Chapter 8 provides an overview of the 
clinical studies using HAART in children and seeks to improve the understanding of factors, which 
may contribute to success or failure of HAART in children. In chapter 9 we report the clinical and 
virological responses to combination treatment with indinavir, zidovudine and lamivudine in HIV-1 
infected children until 24 weeks of follow up. In chapter 10 the long-term clinical, virological and 
immunological responses to HAART (containing indinavir or nelfinavir) are presented. Since data on 
long-term T-cell dynamics in HIV-1-infected children on HAART were not available, it was still 
unclear to what extent the number of CD4+ T-cells of HIV-1-infected children could be normalized. 
In chapter 11 we evaluated the extent of the long-term immune reconstitution in HIV-1-infected 
children who were treated with HAART during a period of 96 weeks. We analyzed changes in the 
number of CD4+ T-cells, CD4+ T-cell naive and memory subsets and CDS+ T-cell counts and 
compared those with the normal values that we previously reported for different age groups. In 
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addition to the quantitative analyses, the T-cell function after stimulation with CD3 mAb plus CD28 
mAb was analysed. 
Dysregulation of growth is a common feature of HIV-1 infection in children. Since growth 
seems to be one of the most sensitive indicators of disease progression, growth after the initiation of 
HAART is an important parameter. Growth characteristics of HN-1 infected children after the 
initiation of HMRT and the association between growth parameters and virological and 
immunological response to HMRT were studied. These data are reported in chapter 12. The 
etiology of the HN-1 related growth dysregulation is complex. Abnormal function of the thyroid 
gland, the somatomedine axis, the lipid metabolism and abnormal resting energy expenditure may 
also contribute to diminished growth. We therefore studied the endocrinological and immunological 
mechanisms underlying the recovery of growth in HIV-1 infected children treated with HMRT and 
present the results of these studies in chapter 13. 
Antiretroviral drugs such as indinavir need to be continued for many years thus underscoring the 
importance of a careful surveillance for long-term toxicity. Studies on the side effects of HMRT are 
presented in part four. Chapters 14 and 15 describe the occurrence of urinalysis abnormalities 
and nephrotoxicity in HIV-1 infected children treated with indinavir and study the relation between 
these side-effects and pharmacological parameters. Chapter 16 contains a study on changes in the 
lipid and glucose metabolism after the initiation of HAART in HN-1 infected children. 
Chapters 17 and 18 summarize the previous studies and bring the data in perspective in English 
and Dutch language, respectively. In Chapter 19 we briefly summarize our conclusions and we 
present our ideas concerning the future directions of care and research in children with HIV/AIDS. 
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Reduction of mother-to-child transmission 
of HIV-1 infection in The Netherlands 
during the period 1995-2000 
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Chapter 3 
Abstract 
Objectives: 1. Registration of the number of children born to H!V infected mothers diagnosed before 
the delivery and 2. Analysis of the efficacy of the prevention of mother-to-child transmission of H!V-
1 in the period 1995 to 1999. Design: Prospective registration from January 1995 to December 
1999. Methods: Dutch paediatricians reported monthly H!V-1 exposed children to the Dutch 
Paediatric Surveillance Unit. All reports were followed up with standard questionnaires. An additional 
retrospective study was performed because of incomplete registration. Results: We observed an 
increase in the number of children known to be exposed to H!V from 5 to 25 in 1999. At the same 
time, the percentage of H!V-1 infected children decreased from 20% to 4%. The number of 
pregnant HIV-1 infected women using highly active antiretroviral therapy increased during the 
studyperiod from 0% to 70%. Antiretroviral therapy was administered to 92% of the H!V-1 exposed 
children . Only 2% of the children received breastfeeding. Condusion: Despite an increase in the 
number of children known to be exposed to HIV, a decrease in the percentage of HIV infected 
children was observed. Only 4% of the children born in 1999 and known to be exposed to HIV was 
infected. We conclude that the Dutch guidelines to prevent mother-to-child transmission of HIV-1 
infection are well implemented and efficacious. 
Samenvatting 
Doe/: 1. Registratie van het aantal aan HIV geexposeerde kinderen waarvan van de moeder ten tijde 
van de zwangerschap bekend was dat ze HIV geTnfecteerd was en 2. Een evaluatie van het beleid 
dat in de periode 1995 tot en met 1999 gevoerd is om overdracht van H!V-1 infecties van moeder 
naar kind te voorkomen. Opzet: Prospectieve registratie in de periode 1 januari 1995 tot 31 
december 1999. Methode: Nederlandse kinderartsen meldden maandelijks via het Nederlands 
Signaleringscentrum Kindergeneeskunde ieder aan HIV geexposeerd kind. De meldingen werden 
gevolgd door toezending van vragenlijsten. Vanwege gebleken onvolledige melding werd een 
aanvullend retrospectief onderzoek verricht. Resultaten: In de periode 1995-2000 nam het aantal 
aan HIV-1 geexposeerde kinderen waarvan van de moeder ten tijde van de zwangerschap bekend 
was dat ze HIV ge"infecteerd was toe van 5 naar 25 per jaar. Het percentage HIV-geTnfecteerde 
kinderen daalde van 20% naar 4%. In de onderzoeksperiode steeg het gebruik van krachtige 
combinatie therapie door zwangere HIV-1 ge·infecteerde vrouwen van 0% naar 70%. Van de aan 
HIV geexposeerde kinderen kreeg 92% antiretrovirale therapie. Slechts 2% van de kinderen kreeg 
borstvoeding. Conc/usie: Ondanks een stijging van het aantal bekende aan HIV-1 geexposeerde 
kinderen werd een daling gevonden van het percentage met HIV-1 ge"infecteerde kinderen. In 1999 
werd slechts 4% van de aan HIV-1 geexposeerde kinderen geTnfecteerd. Wij concluderen dat de in 
Nederland genomen maatregelen bij HIV positieve zwangere vrouwen en hun kinderen om 
overdracht van infectie te voorkomen effectief zijn. 
In Ieiding 
De kans op verticale transmissie van humane immuundeficii?:ntie-virus (HIV) van moeder naar kind 
bedraagt zonder maatregelen 15-30% (1-4). Deze kans kan tegenwoordig tot minder dan 2% 
gereduceerd worden. In 1994 werd voor het eerst gerapporteerd dat de overdracht van HIV van 
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moeder naar kind significant gereduceerd kan worden (van 25,5% naar 8,3%) door toediening van 
antiretrovirale medicatie aan de zwangere vrouw en haar kind. (5, 6) Een electieve sectio caesarea 
bleek het transmissiepercentage verder omlaag te kunnen brengen naar 1-2%. (7, 8) Hetzelfde lage 
transmissiepercentage wordt waargenomen bij de pasgeboren kinderen van zwangere vrouwen bij 
wie door behandeling met krachtige antiretrovirale combinatietherapie tijdens de partus geen virus 
in het bloed meer aantoonbaar was. (9) 
In Nederland worden HIV ge"infecteerde zwangeren in daartoe gespecia!iseerde centra 
volgens richtlijnen van de Nederlandse Vereniging van Aids Behandelaren (NVAB) behandeld met 
antiretrovirale combinatietherapie. (10) Afhankelijk van de plasma virus concentratie vlak voor de 
partus wordt het kind vaginaal ( < 500 kopieen/ml plasma) dan wei door middel van een sectio 
caesarea ( overwegen bij viral load tussen 500 en 1000 kopieenjml en in aile gevallen bij > 1000 
kopieen;mt plasma) geboren. De neonaat wordt vervolgens gedurende 4 weken behandeld met 
zidovudine en lamivudine. Indien bij moeder tijdens de zwangerschap sprake is van onvoldoende 
reactie op de therapie (HIV-1 RNA >400 kopieenjml) of als moeder niet behandeld is en de HIV-1 
RNA verhoogd of onbekend is, wordt in overleg met een kinder-aidsbehandelcentrum afgeweken 
van de standaard duotherapie. (10) 
Sinds 1995 is via het Nederlands Signalerings-Centrum Kindergeneeskunde (NSCK), 
aanvanke!ijk tezamen met de afdeling kindergeneeskunde van het Universitair Medisch Centrum 
Utrecht/Wilhelmina Kinderziekenhuis en vanaf 1998 in samenwerking met het Academisch 
Ziekenhuis Rotterdam/Sophia Kinderziekenhuis, het aantal aan HIV-1 geexposeerde kinderen 
prospectief geregistreerd. In dit artikel worden de resultaten van deze registratie beschreven. 
Patienten en methoden 
Met ingang van 1 januari 1995 melden praktiserende kinderartsen maandelijks elke nieuwe patient 
(0-18 jaar) met tenminste een van de volgende inclusiecriteria bij het NSCK: bewezen aids, positieve 
HIV serologie, positieve viruskweek, positieve polymerasekettingreactie (PCR) op HIV-RNA, positieve 
p24 antigeenbepaling of een pasgeborene van een HIV positieve moeder met een nag onbekende 
HIV serostatus. Na melding van een HIV ge"infecteerd kind of een aan HIV geexposeerd kind wordt 
de betreffende kinderarts verzocht een vragenlijst in te vul!en met vragen over klinische en sociale 
kenmerken van het gemelde kind. 
De melding van aan HIV ge§xposeerde kinderen bleek echter onvolledig te zijn. Daarom werd in 
2000 een retrospectief onderzoek verricht waarbij de gegevens van alle kinderen van HIV 
ge·infecteerde vrouwen, geboren tussen 1 januari 1995 en 31 december 1999, via kinderartsen in de 
elf door de Gezondheidsraad aangewezen aids behandelcentra en de vier daaraan geaffilieerde 
ziekenhuizen achterhaald werden. Van de gemelde en opgespoorde aan HIV geexposeerde kinderen 
werd met behulp van een follow-up vragenlijst de HIV-status op de leeftjd van 18 maanden 
(negatieve HIV sero!ogie op de leeftijd van 18 maanden geldt als definitieve uitsluiting van een HIV 
infectie) vastgesteld. Aile gegevens werden anoniem verwerkt. 
In dit artikel worden de resultaten beschreven van de registratie van aan HIV geexposeerde 
kinderen van moeders met een voor de partus vastgestelde HIV-infectie. 
De HIV-status van de aan HIV geexposeerde kinderen werd als volgt gedefinieerd: 
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HIV geinfecteerd bij: 
• Aanwezigheid van HIV specifieke antistoffen bij kind ouder dan 18 maanden. 
• Twee maal positieve PCR (HIV-RNA en/of H!V-DNA) op twee verschillende bloedmonsters bij 
kinderen ouder dan een maand. 
• Aanwezigheid van HIV specifieke antistoffen bij kind jonger dan 18 maanden (met uitzondering 
van navelstrengbloed) in combinatie met een aids definierende ziekte. 
• Een positieve PCR (HIV-RNA en/of HIV-DNA), ook voor de leeftijd van een maand (met 
uitzondering van navelstrengbloed), in combinatie met een aids definierende ziekte (15). 
HIV negatief bij: 
Afwezigheid van HIV specifieke antistoffen bij kind ouder dan 18 maanden. 
• Twee maal negatieve PCR (HIV-RNA en/of HIV-DNA) op twee verschillende bloedmonsters bij 
kinderen ouder dan een maand, waarvan een afgenomen na de leeftijd van vier maanden. 
• En in aile bovenstaande gevallen het ontbreken van klinische of immunologische tekenen van 
een HIV-infectie en het niet ontvangen hebben van borstvoeding. 
Waarschijnlijk HIV negatief bij: 
• Een maal negatieve PCR (HIV-RNA en/of HIV-DNA) bij kinderen ouder dan een maand in 
combinatie met de afwezigheid van klinische of immunologische tekenen van HIV-infectie, geen 
borstvoeding. 
Onbekend bij: 
• Kinderen jonger dan een maand. 
Geen testresultaten bekend. 
Resultaten 
Gedurende de periode 1995 tot en met 1999 werden bij het NSCK 50 aan HIV geexposeerde 
kinderen gemeld, waarbij de HIV infectie van moeder voor of tijdens de zwangerschap was 
vastgesteld. Voor aile gemelde kinderen werden vragenlijsten ingevuld en geretourneerd. In het 
retrospectieve onderzoek werden aanvullend 37 aan HIV geexposeerde kinderen ge·includeerd. 
Tabel 1 toont de demografische en klinische kenmerken van de ge"includeerde kinderen 
(n=87, waaronder 1 gemelli) en hun moeders (n=86). 
Een meerderheid van de HIV ge"infecteerde vrouwen (59%) was afkomstig uit een gebied met een 
gegeneraliseerde HIV epidemie (Afrika ten zuiden van de Sahara of het Caribisch gebied). Acht (9%) 
kinderen bleken HIV geinfecteerd te zijn. Het advies om geen borstvoeding te geven lijkt goed 
opgevolgd te worden: slechts twee kinderen (2%) kregen borstvoeding. 
Tabe! 2 geeft een overzicht van de acht geTnfecteerde kinderen. Bij drie van de acht HIV 
ge"infecteerde kinderen was zowel moeder als kind met antiretrovirale therapie behandeld. Geen van 
de moeders van de geTnfecteerde kinderen was met krachtige antiretrovirale combinatietherapie 
behandeld. In totaal waren vier kinderen door middel van een sectio caesarea (SC) geboren. Slechts 
een SC was electief. Een SC geeft aileen een vermindering van transmissie als deze electief, dus 
voor aanvang van de partus en het breken van de vliezen plaatsvindt. (7, 8) De moeder van het kind 
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dat door middel van een electieve sectio geboren was, was tijdens de zwangerschap niet behandeld. 
Waarschijnlijk is hier sprake geweest van een intra-uteriene infectie. Deze hypothese wordt mede 
gesteund doordat er bij het kind direct na de geboorte een positieve HIV-RNA gevonden werd en 
doordat er sprake was van een snel progressief klinisch beloop. 
Tabei 1: Demografische kenmerken van de aan HIV-1 geexposeerde kinderen 
Kenmerk Aantal 
Jongens/meisjes 54/33 
Afkomst moeder (n=86) 
Gebied met een gegeneraliseerde HIV epidemie 51 
Europa Nederland 
Overig 
Overig 
Onbekend 
10 
7 
11 
7 
Zwangerschapsduur (mediaan, min-max) 
Geboortegewicht (mediaan, min-max) 
Partus 
38,9 (30,4-42,4) weken 
Vaginaal 
Elecf1eve sectio 
Spoedsectio 
Sectio onbekende reden 
Onbekend 
Borstvoeding 
Ja 
Nee 
Onbekend 
HIV-status kind (n=87) 
Positief 
Negatief 
Waarschijnlijk negatief 
Onbekend 
3065 (1150-4250) gram 
52 
11 
14 
5 
5 
2 
82 
3 
8 
32 
42 
5 
Tabel 2: Overzicht van de acht kinderen met H!V-1 infectie 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
Geboorte-jaar 
1995 
1996 
1996 
1997 
1997 
1998 
1998 
1999 
Thera pie 
moeder 
ZDV 
ZDV 
ZDV I 
3TC 
Profylaxe kind 
ZDV 
ZDV 
ZDV /3TC 
ZDV 
ZDV /3TC 
Sectio caesarea 
(reden) 
Nee 
Nee 
Ja (foetale nood) 
Ja (foetale nood) 
Nee 
Ja (foetale nood) 
Nee 
Ja ( electief) 
Borst-
voeding 
Nee 
Nee 
Nee 
Nee 
Nee 
Nee 
Ja 
Nee 
(%) 
(62)/(38) 
(59) 
(12) 
(8) 
(14) 
(8) 
(60%) 
(13%) 
(16%) 
(6%) 
(6%) 
(2) 
(94) 
(3) 
(9) 
(37) 
(48) 
(6) 
Bijzonder-
heden 
2 dgn post 
partum 
gestart 
met 
profylaxe 
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Van de 86 moeders werden 67 (77%) gedurende de zwangerschap behandeld met mono·, 
duo-, triple· of quadrupletherapie (Tabel 3). In aile gevallen kregen kinderen van behandelde 
moeders ook antiretrovirale therapie. In totaal kregen 81 (93%) kinderen profylaxe gedurende 2 tot 
6 weken post partum. De meeste kinderen werden gedurende 4 weken met zidovudine en 
lamivudine behandeld. In Tabel 3 zijn de verschillende gebruikte behandelingsstrategieen 
weergegeven. 
Tabel 3: Behandelingsstrategieen bij HIV ge·infecteerde moeders en hun kinderen 
Therapie 
HIV ge"infecteerde moeders 
Geen 
Mono 
Duo 
Triple 
Quadruple 
Onbekend 
Profylaxe kind 
Geen 
Mono zidovudine 
Nevlraplne (1 gift) 
Duo zidovudinej!amivudlne 
Zidovudlne/lamivudine en 1 gift 
Triple 
nevi rapine 
Aantal 
18 
18 
18 
29 
2 
1 
6 
27 
3 
47 
2 
2 
(%) 
(21) 
(21) 
(21) 
(33) 
(2) 
(1) 
(7) 
(31) 
(3) 
(54) 
(2) 
(2) 
Figuur 1 (A, Ben C) laat zien dat gedurende de periode 1995-2000 het absolute aantal bekende aan 
HJV geexposeerde kinderen toenam van 5 in 1995 tot 25 in 1999. In dezelfde periode daalde het 
percentage HIV geTnfecteerde kinderen na bekende expositie van 20% in 1995 tot 4% in 1999 
(Figuur 1A). In 1996, 1997 en 1998 waren deze percentages respectievelijk 17, 10 en 8. 
Het percentage behandelde moeders bleef gedurende deze periode ongeveer gelijk met een 
gemiddelde van 70% (range 67%-83%). De samenstelling van de therapie veranderde echter van 
80% monotherapie in 1995 tot 0% monotherapie en 70% triple of quadruple therapie in 1999. 
(Figuur 18) Oak de samenstelling van de profylactische therapie van de kinderen veranderde van 
60% monotherapie in 1995 tot 92% duo of triple therapie in 1999. (Figuur 1C) 
Discussie 
In de periode 1995 tot en met 1999 is het aantal aan HIV geexposeerde kinderen waarvan van de 
moeder ten tijde van de zwangerschap bekend was dat ze HIV geTnfecteerd was in Nederland 
toegenomen van 5 naar 25 per jaar. Deze stjging is niet gepaard gegaan met een stijging van het 
aantal kinderen dat na expositie ook HJV geTnfecteerd is geraakt. Het percentage geTnfecteerde 
kinderen is in deze periode zelfs gedaald van 20% naar 4%. Deze getallen komen overeen met 
hetgeen te verwachten is op grand van de ontwikkelingen in de kennis over pathogenese en 
behandeling van HJV-infecties en de daarmee gepaard gaande ontwikkelingen op het gebied van de 
preventie van verticale transmissie. Het lijkt waarschijnlijk dat de daling van 20% tot 4% in onze 
populatie voor een groat deel te danken is aan de toename van het gebruik van krachtige 
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combinatie therapie door de zwangere vrouwen, dat in deze periode steeg van 0% tot 70%. Door de 
krachtige combinatietherapie wordt een sterkere daling van de virusconcentratie in het plasma 
bereikt waardoor de kans op virusoverdracht vermindert. Hierbij dient echter aangetekend te worden 
dat ook bij een ondetecteerbare virusconcentratie in het plasma verticale transmissie beschreven 
wordt en dat de voorspellende waarde van de virusconcentratie in plasma voor de individuele vrouw 
slecht is. (12, 13) Helaas ontbreken in onze studie gegevens met betrekking tot de virusconcentratie 
in het bleed ten tijde van de partus. Sinds 1 januari 2000 zijn deze gegevens opgenomen in de 
vragenlijst. 
Bij de kinderen trad er een verschuiving op van monotherapie naar duotherapie met 
zidovudine en lamivudine. Dit is een afspiegeling van de invoering van een Nederlands 
neonatenprotocol waarin deze profylaxe voor de duur van 4 weken post-partum wordt geadviseerd. 
(10) In de beschreven periode is bij 5% van de kinderen afgeweken van de standaard behandeling 
met zidovudine en later zidovudine/lamivudine. Afvv"ijken van de standaard profyiaxe is een keuze die 
gemaakt wordt op basis van te verwachten problemen met resistentie. Dit dient vanwege de 
complexiteit in overleg met een kinderarts uit een kinder-aidsbehandelcentrum (Emma 
Kinderziekenhuis/Academisch Medisch Centrum Amsterdam, Universitair Medisch Centrum 
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Utrecht/Wilhelmina Kinderziekenhuis, Academisch Ziekenhuis Rotterdam/Sophia Kinderziekenhuis) 
gedaan te worden. 
In totaal werden acht kinderen (9%) met HIV ge"infecteerd ondanks het feit dat het bekend 
was dat hun moeders tijdens de zwangerschap HIV positief waren. Infectie bij het kind kwam relatief 
meer voor bij onbehandelde moeders en bij onbehandelde kinderen. Tach werden oak vier kinderen 
waarbij zowel moeder als kind antiretrovirale middelen had ontvangen met HIV ge'infecteerd. Geen 
van deze vrouwen had krachtige antiretrovirale combinatietherapie gekregen. Als mogelijke oorzaken 
voor het falen van de maatregelen kunnen genoemd worden: virologisch falen van het regime met 
resistentie tegen de gebruikte middelen, therapie-ontrouw, te laat in de zwangerschap gestart met 
de therapie en vroege intra-uteriene infectie. 
De stijging van het aantal bekende HIV geb::pose-erde kinderen zou theoretisch kunnen 
voortkomen uit een stijging van het aantal HIV geYnfecteerde vrouwen afkomstig uit gebieden met 
een gegeneraliseerde HIV epidemie, een actiever testbeleid onder zwangere vrouwen, een stijging 
van het aantal vrouwen dat door het succes van krachtige antiretrovirale combinatietherapie een 
kinderwens heeft of een combinatie van deze factoren. Inzicht in deze problematiek zal de komende 
jaren verkregen worden doordat de recent aangepaste registratie een vraag bevat over het kader 
waarin de vrouw getest is. 
Ondanks een daling van het percentage HIV ge"infecteerden onder de bekende 
geexposeerde kinderen werd er gedurende dezelfde periode in Nederland een stijging waargenomen 
van het aantal kinderen met een nieuw gediagnosticeerde HIV infectie. Hoewel van het merendeel 
van deze kinderen een of beide ouders afkomstig was uit een gebied met een gegeneraliseerde HIV 
epidemie, was het grootste dee! van deze kinderen tach in Nederland geboren. (14, 15) Een infectie 
had derhalve bij een actiever testbeleid onder zwangere vrouwen voorkomen kunnen worden. 
In Amsterdam is een universele HIV-screening van zwangere vrouwen kosteneffectief gebleken. (16) 
Of dit oak voor de rest van Nederland geldt, zal onderzocht moeten worden. Indien een universele 
HIV screening kosteneffectief blijkt, dan zal. bij invoering oak zorg gedragen moeten worden voor het 
verdwijnen van negatieve gevolgen van de kennis van deze diagnose, bijvoorbeeld met betrekking 
tot verzekeringsvoorwaarden. 
Een actever testbeleid zal tot gevolg hebben dat meer kinderen van HIV geinfecteerde 
moeders, waarvan een groat dee! oak zonder interventie niet ge·infecteerd zou raken, zowel intra-
uterien als neonataal blootgesteld zal worden aan mogelijk teratogene en toxische antiretrovirale 
middelen. Een Franse publicatie heeft hier in 1999 opschudding over veroorzaakt (17), maar 
zekerheid over het bestaan van een associatie tussen de door hen gemelde mitochondriale disfunctie 
en de antiretrovirale medicatie ontbreekt. Andere studies hebben deze bijwerkingen tot op heden 
niet kunnen bevestigen. (18, 19) Macht een associatie met mitochondriale disfunctie bestaan dan zal 
de afweging die gemaakt moeten worden tussen de nadelen van deze zeer zeldzame, maar ernstige 
toxiciteit en de voordelen van de grate mate van effectiviteit van perinatale profylaxe bij het 
voorkomen van een levensbedreigende ziekte uitvallen ten gunste van de voordelen van perinatale 
profylaxe. 
Wij concluderen dat ondanks een stijging van het aantal bekende aan HIV geexposeerde 
kinderen er een dating plaatsvindt van het percentage geexposeerde kinderen dat met HIV 
ge·infecteerd raakt. In 1999 werd slechts 4% van de geexposeerde kinderen ge"infecteerd. Hieruit 
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blijkt dat de in Nederland genomen maatregelen bij HIV positieve zwangere vrouwen en bij hun 
kinderen effectief zijn. 
Het is van groat belang dat de richtlijnen omtrent perinatale profylaxe bekend zijn en nageleefd 
worden. De registratie zal de komende jaren worden voortgezet waarbij de effectiviteit van de 
detectie van HIV-positieve zwangeren en de effectiviteit van de perinatale profylaxe bestudeerd 
zullen worden. 
De gegevens waarop dit onderzoek is gebaseerd, werden geleverd door aile kinderartsen in 
Nederland, van wie wij met name willen noemen: mw. dr. S.P.M. Geelen, Universitair Medisch 
Centrum Utrecht/Wilhelmina Kinderziekenhuis, Utrecht en dr. N.G. Hartwig, Academisch Ziekenhuis 
Rotterdam/Sophia Kinderziekenhuis, Rotterdam. 
Financiele steun voor de registratie via het NSCK werd verleend door de stichting Aidsfonds. 
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Abstract 
Objective: Prospective registration of the number of children diagnosed with aids and/or HN 
infection. Design: Prospective registration from January 1 1998 to December 31 2000. 
Methods: Dutch paediatricians monthly reported HN positive children to the Dutch Paediatric 
Surveillance Unit. All reports were followed up with standard questionnaires. Results: During the 
period 1998-2000 42 children were diagnosed with HIV-1 infection. This number was almost equal to 
the number of HN-1 infected children diagnosed during the period 1995-1997 (n=43). In 86% of 
the children one or both parents originated from a country with a generalised HIV epidemic. Of only 
2 children (5%) both parents originated from The Netherlands. Most children (81%) were infected 
by mother to child transmission. Of these children 48% (n=20) was born in The Netherlands. Only 
33% of the HN-1 infected children lived in one of the four major cities of The Netherlands. 
ConclusiOns: The increase in the number of newly detected HIV-1 infected children during the period 
1995-1997 reached a plateau during the period 1998-2000. This may be due to a more active 
approach in the testng on HN in pregnant women. Forty-eight% (n=20) of the children infected by 
mother to child transmission were born in The Netherlands. The risk on transmission of HIV could 
have been significantly reduced when the mother had been tested on an HIV infection and treated 
according to the current guidelines. 
Samenvatting 
Doe/: Registratie van het aantal met een HIV infectie gediagnosticeerde kinderen in Nederland. 
Opzet: Prospectieve registratie in de periode 1 januari 1998 tot 31 december 2000. Methode: 
Nederlandse kinderartsen meldden maandelijks via het Nederlands Signaleringscentrum 
Kindergeneeskunde ieder met een HIV infectie gediagnosticeerd kind. De meldingen werden gevolgd 
door toezending van vragenlijsten. Resultaten: In de periode van 1998 tot en met 2000 werd bij 42 
kinderen een HIV-1 infectie vastgesteld. In de periode 1995-1997 was dit aantal nagenoeg gelijk 
(n=43). Bij 86% van de kinderen was een of beide ouders afkomstig uit een gebied met een 
gegeneraliseerde HIV epidemie. Van slechts 2 kinderen (5%) waren de beide ouders van 
Nederlandse afkomst. Het merendeel (81 %) van de kinderen werd via verticale transmissie door hun 
moeder geTnfecteerd. Van deze kinderen was 48% (n=20) in Nederland geboren. Slechts 40% van 
de in Nederland geboren en door verticale transmissie geTnfecteerde kinderen woont in 88n van de 
vier grate steden. De overige 60% woont verspreid over nagenoeg aile provincies van Nederland. 
Conclusies: De stjging van het aantal kinderen dat in de periode 1995-1997 met een HN infectie 
werd gediagnosticeerd, lijkt af te vlakken in de periode van 1998 tot en met 2000. Dit is mogelijk 
een gevolg van een actiever testbeleid onder zwangere vrouwen uit risicogroepen. Van de kinderen 
die ge"infecteerd waren door verticale transmissie was 48% (n=20) in Nederland geboren. De kans 
op een HIV infectie zou bij deze kinderen aanzienlijk lager geweest zijn indien hun moeder tijdens de 
zwangerschap getest zou zijn op de aanwezigheid van een HIV infectie gevolgd door het inste!len 
van een beleid gericht op het voorkomen van verticale transmissie. 
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Inleiding 
Na een periode waarin weinig kinderen met HIV werden gediagnosticeerd, werd vanaf het begin van 
de jaren '90 een toename vastgesteld van het aantal meldingen bij kinderen in Nederland. (1) Twee 
oorzaken waren verantwoordelijk voor deze stijging. De eerste hiervan was de toename van het 
aantal door heteroseksueel contact met HIV ge'infecteerde zwangere vrouwen. (2) Indien een 
zwangere vrouw met HIV ge·lnfecteerd is, is de kans op overdracht van HIV van moeder op kind 
tijdens de zwangerschap en perinataal 15-30% indien geen interventie plaats vindt met 
antiretrovirale middelen. (3-6) Daarnaast hebben zich gedurende de afgelopen jaren mensen in 
Nederland gevestigd die afkomstig zijn uit gebieden met een gegeneraliseerde HIV-epidemie.(Afrika 
ten zuiden van de Sahara en het caribische gebied). In tegenstelling tot de situatie in de Westerse 
wereld wordt HIV in deze gebieden voornamelijk heteroseksueel verspreid. Geschat wordt dat in 
Afrika 10,9 miljoen mannen en 13,3 miljoen vrouwen met HIV geTnfecteerd zijn. (7) 
Om de HIV epidemie onder kinderen in Nederland te monitoren, is sinds 1995 via het 
Nederlands Signalerings-Centrum Kindergeneeskunde (NSCK), aanvankelijk tezamen met de afdeling 
kindergeneeskunde van het Universitair Medisch Centrum Utrecht,!Wilhelmina Kinderziekenhuis en 
vanaf 1998 in samenwerking met het Academisch Ziekenhuis Rotterdam/Sophia Kinderziekenhuis, 
het aantal HIV positieve kinderen prospectief geregistreerd. De resultaten tot en met 1997 zijn 
eerder in dit tijdschrift gepubliceerd. (1) In dit artikel worden de resultaten in de periode van 1998 
tot en met 2000 beschreven en vergeleken met de gegevens uit de voorgaande periode. 
Patienten en metihoclen 
Met ingang van 1 januari 1995 melden praktiserende kinderartsen maandelijks elke nieuwe patient 
(0-18 jaar) met tenminste €:€:n van de volgende inclusiecriteria bij het NSCK: bewezen aids, positieve 
HIV serologie, positieve viruskweek, positieve polymerasekettingreactie (PCR) op HIV-RNA, positieve 
p24 antigeenbepaling of een pasgeborene van een HIV positieve moeder met een nag onbekende 
HIV serostatus. Na melding van een HIV geTnfecteerd kind of een aan HIV geexposeerd kind wordt 
de betreffende kinderarts verzocht een vragenlijst in te vullen met vragen over klinische en sociale 
kenmerken van het gemelde kind. Aile gegevens werden anoniem verwerkt. 
In dit artike! worden de resultaten beschreven van de registratie van met HIV 
gediagnosticeerde kinderen in de periode 1 januari 1998 tot 31 december 2000. De resultaten van 
de aan HIV geexposeerde kinderen (zowel HIV negatieve als HIV ge'infecteerde kinderen) worden in 
een afzonderlijk artikel gepubliceerd. 
De HIV-status van de met HIV infectie gediagnosticeerde kinderen werd als volgt gedefinieerd: 
HIV ge·lnfecteerd bij: 
• Aanwezigheid van HIV specifieke antistoffen bij kind ouder dan 18 maanden. 
• Twee maal positieve PCR (HIV-RNA en/of HIV-DNA) op twee verschillende bloedmonsters bij 
kinderen ouder dan een maand. 
• Aanwezigheid van HIV specifieke antistoffen bij kind jonger dan 18 maanden (met uitzondering 
van navelstrengbloed) in combinatie met een aids definierende ziekte. 
• Een positieve PCR (HIV-RNA en/of HIV-DNA), oak voor de leeftijd van een maand (met 
uitzondering van navelstrengbloed}, in combinatie met een aids definierende ziekte (8). 
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De resultaten van de registratie in de periode 1998 tot en met 2000 werden vergeleken met de 
resultaten van de registratie in de periode 1982 tot en met 1997. 
Resultaten 
Gedurende de periode 1998-2000 werden 42 kinderen bij het NSCK gemeld. Van aile kinderen 
werden vragenlijsten door de meldend kinderarts ingevuld en geretourneerd. Sinds begin jaren 
negentig wordt de zorg voor HIV ge"infecteerde kinderen voornamelijk geconcentreerd in drie 
kinderaidsbehandelcentra {Academisch Medisch Centrum/Emma Kinderziekenhuis, Amsterdam, 
Universitair Medisch Centrum/Wilhelmina Kinderziekenhuis, Utrecht, en Academisch ziekenhuis 
Rotterdam/Sophia Kinderziekenhuis, Rotterdam). Hierdoor is met grate mate van zekerheid vast te 
steilen dat het aantal meldingen ook daadwerkelijk overeenkomt met het aantal met H!V 
gediagnosticeerde kinderen. 
Figuur 1 toont het aantal kinderen dat per jaar met HIV gediagnosticeerd werd. In de 
periode 1995-1997 werd een toename van het aantal met H!V gediagnosticeerde kinderen 
vastgesteld ten opzichte van de jaren daarvoor. Deze toename lijkt tot stilstaan gekomen te zijn in 
de periode 1998-2000. In de periode 1995-1997 werd bij 43 kinderen een HIV infectie vastgesteld 
tegen 42 in de periode 1998-2000. In aile gevallen ging het om een infectie met H!V type 1. Infectie 
met H!V type 2 werd in de periode 1982-2000 in Nederland slechts een maal bij een kind 
gediagnosticeerd. 
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Figuur 1: Het aantal met HIV gediagnosticeerde kinderen in Nederland gedurende de periode 1982-2000 
Tabel 1 geeft een aantal geselecteerde kenmerken aan van de met HIV gediagnosticeerde kinderen. 
Verticale transmissie was evenals in de voorgaande periode de meest voorkomende wijze van 
infectie overdracht. Van de kinderen die in de periode 1998-2000 gediagnosticeerd werden, werd 
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81% geTnfecteerd door verticale transmissie. In de periode 1995-1997 werd 58% van de via 
verticale tranmissie met HIV geinfecteerde kinderen in Nederland geboren. In de periode 1998-2000 
was dit percentage 48%. Zeventig procent van de moeders van kinderen die in Nederland geboren 
waren en door verticale transmissie geTnfecteerd waren, was afkomstig uit een gebied met een 
gegeneraliseerde HIV epidemie, 15% uit Nederland en 15% uit andere Ianden buiten Nederland 
(Marokko, Phillipijnen). 
Tabel 1: Kenmerken van de 159 met HIV gediagnosticeerde kinderen in Nederland 
Jongens/meisjes 
Overleden op moment van melding 
In Nederland geboren 
Afkomst 
Seide ouders Nederlands 
Een of beide ouders uit een gebied 
met een gegeneraliseerde HIV 
epidemie 
Een of beide ouders uit een ander 
Europees land dan NL 
Anders 
Onbekend 
Wijze van infectie 
Verticale transmissie 
Hemofilie 
Bloed (producten) transfusie 
Prikaccident 
Chinurgische ingreep 
Seksueel contact/misbnuik 
Onbekend 
Reden tot testen kind 
Kind vertoonde symptom en van HIV 
Infectie 
Maeder of beide ouders zijn HIV 
Geinfecteerd 
Een ander familielid is HIV 
Geinfecteerd 
Getest na hemofilie behandeling 
Tropenscreening 
Onbekend 
HIV+ HIV+ 
tjm 1994 1995-1997 
HIV+ 
1998-2000 
n=74 
37/37 
26 
so 
34 
29 
6 
4 
43 
12 
14 
1 
1 
3 
20 
28 
7 
17 
(36%) 
(69%) 
n=43 
29/14 
7 
27 
(46%) 5 
(39%) 33 
(8%) 2 
(7%) 3 
(58%) 31 
(16%) 
(19%) 3 
(1%) 1 
(1%) 
(4%) 8 
(28%) 27 
(39%) 11 
1 
(10%) 
1 
(23%) 3 
n=42 
21/21 
(16%) 0 
(63%) 20 
(12%) 2 
(77%) 35 
(5%) 2 
(7%) 3 
(72%) 34 
(7%) 1 
(2%) 
3 
(19%) 4 
(63%) 27 
(26%) 8 
(2%) 2 
(2%) 5 
(7%) 
(0%) 
(48%) 
(5%) 
(83%) 
(5%) 
(7%) 
(81%) 
(2%) 
(7%) 
(10%) 
(64%) 
(19%) 
(5%) 
(12%) 
Bij 64% van de kinderen werd een HIV-test verricht, omdat het kind symptomen van een HIV 
infectie vertoonde en bij 19% omdat moeder bekend was met een HIV infectie. Van de acht 
kinderen waarvan het HIV seropositief zijn van de moeder de reden tot testen was, was van drie 
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kinderen al voor de geboorte bekend dat de moeder met H!V geTnfecteerd was. Slechts een van 
deze moeders werd tijdens de zwangerschap behandeld (met zidovudine en lamivudine). Hierop 
wordt nader ingegaan in ons artikel over de verticale transmissie bij aan HN geexposeerde kinderen 
(Van Rossum et al. accepted Ned. Tijdschr. Geneeskd.). 
In label 2 is de leeftijd weergegeven waarop de diagnose werd gesteld bij in Nederland geboren en 
door verticale transmissie geTnfecteerde kinderen. Bij 75% van kinderen werd de diagnose v66r de 
leeftijd een jaar gesteld. Dit komt overeen met hetgeen te verwachten is op grond van het bekende 
hoge percentage HN ge'infecteerde kinderen dat in het eerste levensjaar symptomen van een HN 
infectie vertoont. (9) 
Tabel 2: Leeftijd van door verticale transmissie geTnfecteerde en in Nederland geboren kinderen op 
het moment van stellen van de diagnose 
Leeftijd 
< 1 jaar 
1-2 jaar 
3-5 jaar 
;:::: 6 jaar 
Onbekend 
1982-1994 
n=26 
19 (73%) 
2 (8%) 
2 (8%) 
2 (8%) 
1 (4%) 
Diagnose in periode 
1995-1997 1998-2000 
n=25 n=20 
15 (60%) 15 (75%) 
6 (24%) 2 (10%) 
4 (16%) 2 (10%) 
0 1 (5%) 
0 
Op basis van postcodes (aileen de cijfers van de postcode) werd geanalyseerd uit welke stad of 
provincie (indien de woonplaats niet een van de vier grate steden 
- Amsterdam, Den Haag, Rotterdam en Utrecht - was) de met HN gediagnosticeerde kinderen 
afkomstig waren. Opvallend is dat slechts een derde van de kinderen afkomstig is uit een van de vier 
grate steden. De overige kinderen zijn afkomstig uit nagenoeg aile provincies in Nederland. Van de 
in Nederland geboren en door verticale transmissie geTnfecteerde kinderen woonde 40% in een van 
de vier grate steden en 60% verspreid over zeven provincies. 
Discussie 
De stijging van het aantal nieuw gediagnosticeerde kinderen met een HN infectie die in de periode 
tot en met 1997 werd vastgesteld, is gestopt in de periode 1998 tot en met 2000. In beide periodes 
werden nagenoeg evenveel kinderen met een HN infectie gediagnosticeerd (43 in de periode 1995-
1997 en 42 in de periode 1998-2000). 
Bij 86% van de kinderen was een of beide ouders afkomstig uit een gebied met een 
gegeneraliseerde HN epidemie. Van slechts 2 kinderen (5%) waren de beide ouders van Nederlands 
afkomst. Dit suggereert dat de stijging van het aantal HIV infecties bij kinderen de afgelopen jaren 
niet zozeer een afspiegeling is van een toename van het aantal HN ge'infecteerde vrouwen van 
Nederlandse afkomst, maar met name veroorzaakt wordt doordat zich mensen in Nederland 
gevestigd hebben afkomstig uit gebieden met een gegeneraliseerde HN-epidemie. 
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Evenals in de periode 1995-1997 werd het merendeel (81%) van de kinderen via verticale 
transmissie door hun moeder ge"infecteerd. Van deze kinderen was 48% (n=20) in Nederland 
geboren. De kans op een HIV infectie had bij deze kinderen aanzienlijk gereduceerd kunnen worden 
indien hun moeder tijdens de zwangerschap getest zou zijn op de aanwezigheid van een HIV 
infectie. lndien de HN infectie van moeder tijdens de zwangerschap bekend is, bestaat de 
mogelijkheid tot medicamenteuze interventie bij zowel moeder als kind en eventueel een sectio 
caesarea in plaats van een vaginale partus als er ten tijde van de partus een meetbare hoeveelheid 
virus in het bleed aanwezig is. Het transmissiepercentage kan hiermee gereduceerd worden van 15-
30% tot 1-2 %. (10-13) 
Voor volwassenen geldt dat met name de vier grate steden (Amsterdam, Den Haag, 
Rotterdam en Utrecht) een relatief hoge prevalentie van HIV hebben. In 1997 werd Amsterdam voor 
volwassenen betiteld als epicentrum van de HN epidemie in Nederland. (14) De woonplaatsen van 
de HN ge"infecteerde kinderen liggen echter verspreid over het gehele land. Slechts 33% van de 
kinderen woont in een van de vier grate steden. De overige 67% woont verspreid over nagenoeg 
aile provincies van Nederland. De grotere spreiding van HIV ge"infecteerde kinderen is waarschijnlijk 
mede veroorzaakt door de verspreiding van asielzoekers over aile Nederlandse provincies. Deze 
spreiding brengt problemen met zich mee indien de kinderen in een stadium van de HIV infectie 
komen waarin behandeling met antiretrovirale middelen noodzakelijk is. Deze behandeling is zeer 
complex en vereist frequente bezoeken aan een van de drie kinderaidsbehandelcentra. Dit legt een 
grate druk op gezinnen in een moeilijke sociale en financiele situatie. Het centreren van HIV 
ge"infecteerde kinderen in de omgeving van een van de drie kinderaidsbehandelcentra verdient 
derhalve aanbeveling. Daarnaast is de ontwikkeling van zorgprotocollen om de samenwerking tussen 
eerster tweede en derde lijn te optimaliseren noodzakelijk om kinderen die verder van de centra af 
wonen tach optimale zorg te bieden. 
Aangezien het aantal patienten met HIV[aids in gebieden met een gegeneraliseerde HN 
epidemie nag steeds toeneemt, zal het percentage HIV geTnfecteerde vrouwen dat zich vanuit deze 
gebieden in Nederland vestigt naar verwachting verder stijgen. Dit kan resulteren in een stijging van 
het aantal HIV ge"infecteerde kinderen dat door verticale transmissie ge"infecteerd raakt. Het feit dat 
deze stijging tot op heden is uitgebleven, is mogelijk het gevolg van het actiever aanbieden van een 
HN test tijdens de zwangerschap gevolgd door interventie bij een positief testresultaat. Ondanks 
een gelijk aantal met een HN infectie gediagnosticeerde kinderen in de periodes 1995-1997 en 
1998-2000 is een daling waar te nemen in het aantal kinderen dat door verticale transmissie 
ge"infecteerd is en in Nederland geboren is. In de periode 1995-1997 werden 25 kinderen in 
Nederland geboren en door verticale transmissie ge"infecteerd. In de periode 1998-2000 was dit 
gedaald tot 20 kinderen. 
Wij concluderen dat de stijging van het aantal nieuw gediagnosticeerde kinderen met een 
HN infectie die in de periode tot en met 1997 werd vastgesteld lijkt af te vlakken in de periode van 
1998 tot en met 2000. Mogelijk is dit een gevolg van een actiever testbeleid onder zwangere 
vrouwen uit risicogroepen. Van de kinderen ge"infecteerd door verticale transmissie was 48% (n=20) 
in Nederland geboren. De kans op een HN infectie had bij deze kinderen aanzienlijk gereduceerd 
kunnen worden indien hun moeder tijdens de zwangerschap getest zou zijn op de aanwezigheid van 
een HIV infectie, gevolgd door een antiretrovirale behandeling van moeder en kind volgens de 
daartoe ontwikkelde protocollen. (15) 
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Abstract 
Objective: To evaluate the pharmacokinetics of indinavir in HIV-infected children as part of a 
prospective, open, uncontrolled, multicentre study in the Netherlands. Study design: HIV-1-infected 
children were followed for 6 months treatment with zidovudine 120mg/m2 q8h, lamivudine 4 mg/kg 
q12h and indinavir 33mg[kg metabolic weight (MW) q8h. Four weeks after start of treatment, the 
steady state pharmacokinetics of indinavir were determined by HPLC. If patients had an indinavir 
AUC below 10 or above 30 mg/L.h a dose increment or a dose reduction was made and 
pharmacokinetic measurements were repeated four weeks later. Results: 19 Patients started with 
the 33mg/kg MW q8h dose. The median ( + range) AUC was 10.5 (2.8-51.0) mg/L.h. The median 
AUC in 17 children treated with 50 mg/kg MW q8h was 20.6 (4.1-38.7) mg/L.h. Finally, 5 patients 
had a dose increment to 67 mg/kg MW q8h, resulting in a median AUC of 36.6 (27.2-80.0) mg/L.h. 
After 6 months of treatment, there were 11 children with an AUC below 20 mg/L.h of whom 5 (45%) 
had a detectable viral load, while this was the case in none of the 11 children with an AUC higher 
than 20 mgjl.h. Conclusion: The optimal dose of indinavir in children to obtain drug exposure similar 
to that observed in adult patients is 50 mg/kg MW q8h, which approximates 600mg[m2 q8h. It 
would even be better to adjust the indinavir dose based on an AUC greater than 20 mg/L.h. 
Introduction 
The advent of triple drug therapy, which includes two nucleoside reverse transcriptase inhibitors and 
one protease inhibitor or two nucleoside reverse transcriptase inhibitors and one non-nucleoside 
reverse transcriptase inhibitor, has markedly changed therapeutic options for HIV-infected 
individuals. So far, the large majority of clinical trials has been conducted in HIV-1 infected adults, 
whereas the use of triple dnug combination therapy in children has only recently been reported 
(9,12-14, 17,19). 
Differences in pharmacokinetics between children and adults should warn investigators that 
successful medical treatment in adults does not necessarily imply that this therapy will also be of 
benefit in children. Therefore, the use of new agents, such as the HIV-1 protease inhibitors, should 
be guided by detailed pharmacokinetic and pharmacodynamic evaluations when given for the first 
time to children. The goal of this approach is that efficacy and toxicity data should be similar to 
those reported in adults, or even better, if possible. With regard to HIV infection, suboptimal therapy 
should be detected as soon as possible, and interventions (e.g., dose modifications) should be 
applied immediately to prevent the emergence of drug resistance. 
We here report the pharmacokinetics of the HIV-protease inhibitor indinavir in children 
participating in a prospective, open, uncontrolled clinical trial. A detailed analysis of the clinical, 
immunological and virological effects is presented elsewhere (16). 
Materials and Methods 
Patients 
HIV-1 infected children between the age of 3 months and 18 years with a viral load greater than 
5,000 copies/mL (Roche Amplicor®) and/or a CD4 cell count below an age-specific threshold were 
included between April 1997 and July 1998. The study protocol was approved by the Medical Ethics 
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Committees of all participating hospitals and written informed consent was obtained from all parents 
or legal guardians. 
Pretreatment with zidovudine, didanosine andjor zalcitabine was allowed. Patients were 
followed for 6 months treatment of zidovudine 120mg/m2 q8h, lamivudine 4 mg/kg q12h and 
indinavir 33mg/kg metabolic weight qSh. The indinavir dose was based on the assumption that the 
use of metabolic weight (MW = body weight0·75) would better refiect the higher body clearance of 
drugs in children as compared to adults (10). An average adult weighing 70kg has a MW of 24 kg 
( = 70°·75 kg); the usual adult dose of indinavir is 800mg q8h, which is equal to 33 mg/kg MW (800 
mg I 24 kg MW) q8h. 
Indinavir was administered as 200mg or 400mg capsules (Crixivan®) or as 150mg or 
300mg capsules (prepared by the hospital pharmacy). If patients were not able to swallow the 
capsules, the indinavir capsules were opened and mixed with 5-10ml of water. Patients and 
caregivers were instructed to take the indinavir capsules on an empty stomachr or with a low-energy 
meal. 
Pharmacokinetics 
Four weeks after start of treatment, patients were admitted to the day-care unit of each hospital to 
determine the steady state pharmacokinetics of indinavir. Patients took indinavir on an empty 
stomach and blood samples were collected just before and 0.5, 1, 1.51 2, 2.5, 3, 4, 5r 6, 71 and 8 
hours post ingestion. Plasma was separated by centrifugation and samples were stored at -20 oc 
until analysis. Indinavir concentrations were determined in plasma by HPLC, as previously reported 
(2). In brief, 100 fll of plasma and 10 fll of an internal standard (125 flg/mL of methylindinavir 
dissolved in acetonitrile) were added to 400 )ll of acetonitrile. Each cup was vortexed for 1 minute 
and subsequently centrifuged for 5 minutes at 10,500 g. The supernatant was evaporated to 
dryness. The residue was dissolved in the eluent which consisted of acetonitrile-water (40:60, vjv). 
The water phase contained 50 mM phosphate buffer pH 6 and 4 g/L tetramethylammoniumchloride. 
The analytical column was an InertsiiTM ODS-2 C18 column. Ultraviolet absorption was monitored at 
210 nm.With this assay indinavir plasma concentrations can be measured between 0.05- 12.5 mg/L. 
If the plasma concentration was higher than 12.5 mg/L, the sample was 1:1 diluted with drug-free 
plasma and re-analyzed. This dilution protocol was validated. At an indinavir concentration of 
approximately 1 mg/L the accuracy of the assay is 97.7% with an inter- and intra-assay variation of 
3.1% and 4.8%, respectively. 
Pharmacokinetic parameters were calculated in Microsoft Excel® 97 by non-compartmental 
methods (6). The highest observed plasma concentration was defined as C""", with the 
corresponding sampling time as T """" The terminal, log-linear period (Log C versus T) was defined 
by the last data points (n > 2) by visual inspection. The absolute value of the slope (~/ln10) was 
calculated by least-square analysis. The elimination half-life (t•h) was calculated using the equation 
tv,=ln2/~- The Area under the C versus T curve (AUC) was calculated by using the trapezoidal rule 
for to tot ta. The target AUCo-sh of indinavir was based on adult values of 20 ± 10 mg/L.h (1) & 
(unpublished observations). If patients had an indinavir AUC outside this range a dose modification 
of 50-200% was made and pharmacokinetic measurements were repeated four weeks later. 
Pharmacokinetics parameters in the children were compared to a population of 15 HIV-1 
infected adults who are treated at the University Hospital Nijmegen. These patients were using 
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indinavir 800mg q8h as part of a triple drug regimen for at least 4 weeks. The patients were 
randomly selected from the outpatient population to assess the population pharmacokinetics of 
indinavir in adults. Patients took 800mg of indinavir on an empty stomach and blood samples were 
collected just before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours post ingestion. 
Pharmacokineticjpharmacodynamic relationships 
The relation between the plasma concentrations of indinavir and its therapeutic effect was 
investigated in patients who completed the 6 months period of the study. For those patients the last 
recorded AUC was related to the viral load response at 6 months. The group of patients was divided 
in two, based on an indinavir AUC higher or lower than the median value observed in adults 
(approximately 20 mg/L.h), and for each group the number of patients was counted that had an 
undetectable viral load ( < 500 copies/ml). 
Statistics 
All statistical tests were performed using SPSS for Windows version 8.0 (SPSS Inc. Chicago, II, USA). 
Mann-Whitney U test and Pearson's Chi-Square test were used for comparison of pharmacokinetic 
parameters between subgroups. 
Results 
Inclusion 
A total number of 27 patients was included in the prospective clinical trial. An 8-hour 
pharmacokinetic curve was recorded at least once in 25 (12 M and 13 F) of them. Two of the 
children stopped taking indinavir before a pharmacokinetic curve could be recorded at week 4. The 
median age of the 25 children was 6.0 years (range: 3 months to 16 years). 
Pharmacokinetics of indinavir 
19 Patients started with the 33mg/kg MW q8h dose. The median(+ range) AUCo.sh, was 10.5 (2.8-
51.0) mg/L.h. Other pharmacokinetic parameters are listed in table 1. For comparison, average 
values from a population of 15 HN-infected adults using 800mg of indinavir q8h are listed in the 
table too. Because the AUC was below 10 mg/L.h in 11 of the children, the indinavir dose was 
increased to 50mgjkg MW q8h in these patients (150% dose). In addition, 6 other children started 
treatment with this higher dose. The median(+ range) AUCo.sh in these 17 children was 20.6 (4.1-
38.7) mg/L.h (see also table 1). Finally, 5 patients had a dose increment to 67 mg/kg MW q8h 
(200% dose), resulting in a median ( + range) AUCo.sh of 36.6 (27.2-80.0) mg/L.h. Mean plasma 
concentrations of indinavir in the three dosing groups in children as well as the reference data for 
adults are depicted in figure 1. 
The weight-corrected apparent oral clearance of indinavir in children using the 33mg/kg 
MW qh8 dose was used to investigate factors that were related to the huge variation in the AUC 
values (coefficient of variation 85%). The median apparent oral clearance(+ range) of indinavir in 
the 19 children who started to use indinavir in the 33 mgjkg MW q8h dose level was 1.1 (0.3-4.6) 
L/(h.kg). There was no statistically significant difference between boys (n = 8) and girls (n = 11): 
1.6 (0.3-4.6) vs. 1.1 (0.6-4.1) Lj(h.kg)(p=0.96, Mann Whitney U Test). Although the variation in 
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clearance values was much larger in younger children than in older children, children below the 
median age of 6 years (n = 9) had a significantly higher apparent oral clearance of indinavir than 
children aged 6 years and older (n = 10): 2.5 vs. 1.0 lf(h.kg)(p=0.03, Mann Whitney U Test). The 
average adult value is 0.6 Lf(h.kg). There were no medications that were concomitantly used with 
indinavir that are known or suspected to have an influence on indinavir clearance. 
Table 1. Pharmacokinetic parameters of indinavir 
Parameter Children Adults 
lndinavir dose (q8h) 33 mg/kg MW 50 mg/kg MW 67 mg/kg MW 800 mg 
n= 19 17 5 15 
AUCo-ah (mg/L.h) 10.5 20.6 36.6 19.1 
(2.8-51.0) (4.1-38.7) (27.2-80.0) (8.5-33.3) 
CL/F (l/(h.kg)) 1.1 0.9 0.6 0.6 
(0.3-4.6) (0.5-4.7) (0.4-1.2) (0.4-1.4) 
Vd/F (Ljkg) 2.3 1.7 1.1 1.3 
(0.5-11.5) (0.5-6.8) (0.3-1.7) (0.6-3.2) 
Cmax (mg/L) 6.4 9.7 17.1 8.7 
(2.1-19.5) (2.3-17.0) (15.0-29.0) (3.6-15.8) 
Tmax (h) 1.0 1.0 0.8 1.0 
(0.5-2.0) (0.5-2.5) (0.4-1.6) (0.5-2.0) 
Cmin (mg/L) 0.04 0.07 0.17 0.13 
( <0.02-0.26) (0.02-0.21) (0.05-0.38) (0.03-0.29) 
Data are median values + ranges between brackets 
Pharmacokinetic-pharmacodynamic refabOnships 
The relation between the plasma concentration of indinavir and the antiviral effect of the treatment 
regimen was investigated in the 22 children who completed 6 months of treatment and in whom the 
pharmacokinetic parameters were available for the dose that they were using at that timepoint. 
There was no statistically significant difference between the AUC, the Cmax, or the Cmin values in the 
patients who responded to therapy (defined as a viral load below 500 copiesjmL) and those who did 
not respond to therapy (defined as a viral load above 500 copies/mL). However, there were 11 
children with an AUC below 20 mg/L.h in whom 5 (45%) had a detectable viral load after 6 months 
of treatment, while this was the case in none of the 11 children with an AUC higher than 20 mg/L.h 
(p=0.01, Pearson Chi-Square test, see figure 2). 
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Figure 2: The relation between the AUC of lndlnav/r and the virological response after 6 months of treatment. 
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Discussion 
The optimal dose of indinavir for HN-infected children has not yet been established. The first phase 
!/II study was performed using 3 different formulations: two kinds of suspensions of indinavir base 
and dry-filled capsules of indinavir. Because of the poor absorption of indinavir from the 
suspensions, further research was conducted only with the capsules containing indinavir sulphate, 
now marketed as Crixivan® capsules {9,14,15,19). Most children have been treated with an indinavir 
dose of 500mg/m2 q8h although this dose had to be reduced to 350mg/m2 q8h in the phase !/II 
study because of a high incidence of nephrolithiasis in children using the higher dose (14). 
We have evaluated three dose levels of indinavir in this study. We started with a dose of 33 
mg/kg MW q8h, but this resulted in low AUC values in a substantial proportion of the children. A 
dose increment to 50 mg/kg MW q8h resulted in AUC values that were comparable to values 
observed in adults. Five children received the highest indinavir dose of 67 mg/kg MW qh8, but this 
led to large increases in indinavir plasma concentrations and serious toxicity (nausea, vomiting) in 
these children. Therefore, the optimal dose appeared to be 50 mg/kg MW q8h. After 6 months of 
treatment 16 out of the 25 patients who are still on indinavir treatment are now using this dose. 70 
Percent of these children have reached the goal of an undetectable viral load ( < 500 copies/ml). 
We have chosen to use the MW of a child to calculate the indinavir dose. The use of MW 
instead of normal body weight is based on the assumption that metabolic clearance in children is 
higher than in adults, even when corrected for body weight. Although we had anticipated this 
higher oral clearance of indinavir in children, we made the wrong assumption that we should use an 
adult of 70kg to calculate the indinavir dose of 33 mg/kg MW ( =SOOmg/70°.75 kg. For most 
medications, children with an age of 10-12 years already receive the adult dose. In retrospect, it 
would have been better to use an estimated body weight of 45 kg of an 12 year old child to 
calculate the indinavir dose: MW is then 17.3 kg, 800mg divided by 17.3 kg MW results in an 
indinavir dose of 46 mg/kg MW q8h. This is close to the SO mg/kg MW that we have found in this 
study to be the optimal dose of indinavir. This dose results in a median AUC value of 20.6 mg/L.h 
which is just above the median adult value of 19 mg/L.h. An indinavir dose of 500mg/m2 q8h is now 
under investigation in a phase III clinical trial (15). Both methods used to calculate pediatric doses, 
i.e. metabolic weight and body surface area, are based on similar physiological mechanisms. 
Because pediatricians are more familiar with dosing based on body surface are, this may be 
preferred over dosing on metabolic weight. The SOmg/kg MW q8h that we found to be the optimal 
dose approximates a dose of 600mg/m2 q8h. 
Not only a higher metabolic clearance of indinavir in children may have resulted in the 
differences in clearance values between children and adults. Because indinavir is administered orally, 
impaired absorption of the drug may result in higher apparent oral clearances of indinavir. The 
reasons for possible malabsorption may be variable, but one of the mechanisms may be reduced 
solubility of indinavir at relatively high gastric pH values (11). Because it is known that children 
younger than 3 years have reduced gastric acid secretion ( 4), this may result in lower indinavir 
exposure. However, peak concentrations of indinavir were achieved rapidly and were often higher 
than what is seen in adults. Furthermore, dose increments would not lead to increased plasma 
concentrations of indinavir if drug solubility is problematic. In contrast, more than proportional 
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increases in Cmax and AUC were seen (table 1). This makes impaired absorption due to increased 
gastric pH unlikely. 
Yet another possible explanation of lower plasma levels of indinavir may be an increased volume of 
distribution. Young children have more total body water (80-90% of body weight) than adults (55-
60% of body weight)(4), so water-soluble drugs, such as indinavir, will have a larger apparent 
volume of distribution in children than in adults (table 1). 
In adults there is a number of observations showing that the height of the plasma 
concentration of indinavir is related to the antiviral response (3,17,18). Therefore, instead of using a 
fixed dose regimen for each child, it seems logical to monitor the plasma levels of indinavir shortly 
after the start of an indinavir-containing regimen and adjust the indinavir dose if deemed necessary. 
For adults a trough level of 0.1 mg/L has been proposed as the minimum effective concentration, 
which is equal to 75% of an average population value (3,8). These figures can be extrapolated to an 
AUC value of approximately 15 mgfL.h (75% of 20), but our data show that for children this will not 
be enough. The AUC threshold in children appears to be 20 mg/L.h, because none of the children 
with an AUC higher than 20 mg/L.h had a detectable viral load after 6 months of treatment (figure 
2). Not all the children with an AUC below this threshold of 20 mg/L.h can be considered as non-
responders, but it is dear that the risk of virological failure is much greater with these lower AUC 
values. The fact that a higher AUC of indinavir is needed in children than in adults to have a 
virological response, may be explained by the faster clearance of the drug in children than in adults. 
Table 1 illustrates that in order to obtain a similar AUC in both a child and an adult, a higher peak 
level and a lower trough level of indinavir can be observed in the child. Therefore, if trough levels 
are important to obtain a durable antiviral response (3,17,18), children will need higher AUC values 
than adults to obtain similar trough levels. It is remarkable that in this group of pediatric patients the 
success of combination antiretroviral therapy can be explained to a large extent by the plasma 
concentrations of only one of the three components of the drug regimen. A similar observation was 
found in adults 3. Because the majority of children used zidovudine+lamivudine as the nucleoside 
background, and this may have influenced the observed relationship between indinavir AUC and 
virological outcome, it cannot be concluded from our data that the target AUC of indinavir is also 
valid for other nucleoside combinations. 
There has been some concern that the risk of indinavir-induced nephrological toxicity 
(kidney stones, hematuria, flank pain) in children may be higher than in adults. As noted above, for 
that reason the maximum indinavir dose was originally reduced to 350 mg/m2 in the first phase I/II 
trial of indinavir in the US (14). Because urological toxicity is the result of precipitation of indinavir 
crystals and this is correlated with the height of the plasma level of indinavir (5), one would expect a 
high incidence of urological toxicity in our study because most children used an indinavir dose that is 
even higher than 500mg/m2• However, this was not the case. None of the children developed kidney 
stones, and only 3 children developed hematuria, which resolved after dose interruption. An 
explanation of this low incidence of urological toxicity in our children can not be given, but 
differences in the amount of fluid intake and climatological influences (higher temperatures in the US 
than in the Netherlands) are some of the possible reasons. 
In conclusion, we found that the optimal dose of indinavir in children to obtain drug 
exposure similar to values observed in adult patients is 50 mgjkg MW q8h, which approximates 
600mg/m2 q8h. Using this dose, 70 percent of the children reach the goal of an undetectable viral 
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load ( < 500 copies/mL) after 6 months of treatment, without the occurrence of serious adverse 
events. We also found that it would even be better to adjust the indinavir dose based on an AU Co-sh 
greater than 20 mg/L.h, because in that situation 100% of the children could be regarded as 
responders. 
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Abstract 
Design: Retrospective: case serie. Patients: Four HIV-1 infected children with virological failure on 
treatment with a single protease inhibitor containing therapy regimen. Interventions: Patients were 
switched to an indinavir (600 mg/m2 q12h) and low-dose ritonavir (100 mg/m2 q12h) containing 
regimen. Results: With the exception of one patient (who had extremely high plasma levels of 
indinavir and ritonavir), adequate plasma levels of indinavir and ritonavir were achieved. In addition, 
an improved virologic response was observed in the two patients without extensive prior treatment. 
In one patient pyrexia of unknown origin occurred, subsided after indinavir/ritonavir therapy was 
discontinued and returned after rechallenge with indinavir/ritonavir. Condusion: The combination of 
indinavir and ritonavir is currently the only protease inhibitor containing regimen without food 
restrictions. Our study shows that this regimen may be an alternative to the more complex and rigid 
single protease inhibitor containing medication schemes used in children with HIV-1 infection. 
However, in two of the four children drug related side-effects were observed. Controlled studies 
should be performed to evaluate the safety and efficacy of an indinavir/low-dose ritonavir regimen in 
the treatment of HN-1 infected children. 
Introduction 
The use of highly active antiretroviral therapy (HAART) in children has only recenW been reported 
and data are still limited, but HAART seems to be as successfully in children as in adults. The viral 
load becomes undetectable in a high percentage of the children and CD4 cell counts increase 
significantly. (1-8) Adherence to the rigid medication schemes is a major problem of HAART. Since 
the difficult medication regimens have to be continued for a prolonged period, the level of adherence 
may easily be reduced in time, which may lead to treatment failure. In children, in whom specific 
issues concerning compliance exists (i.e. evening medication in sleeping time, afternoon medication 
at school, forcing young children to eat), maintenance of compliance is further complicated by age-
related differences in pharmacokinetics and pharmacodynamics. A higher metabolic clearance and an 
increased volume of distribution in young children necessitate frequent dosing, while monitoring of 
the plasma levels of the protease inhibitor is required to achieve adequate drug exposure. Adequate 
plasma levels of protease inhibitors are important because of the relation between low plasma 
concentrations and virological treatment failure. (9) 
It is obvious that an urgent need exists for less frequent and less complex dosing schemes. 
The combination of indinavir with low-dose ritonavir is a possibility to accomplish a simplified BID 
regimen. Jndinavir is rapidly metabolised by cytochrome P-450 3A isoenzymes (CYP3A), whereas 
ritonavir is a potent CYP3A inhibitor. This combination results in lower peak levels and higher trough 
levels of indinavir and reduces the intersubject variability in area under the curve (AUC) and trough 
levels in adults (8). In addition, the bioavailability is not affected by regular meals containing 32% of 
calories from fat, which is another practical benefit of this regimen. (8) We here report four children 
failing on single protease inhibitor containing regimens, who were switched to a combination of 
indinavir with low-dose ritonavir. 
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Methods 
Four HIV-1 infected children of three different hospitals in whom protease inhibitor containing 
antiretroviral therapy failed, were switched to an indinavir and low-dose ritonavir containing 
regimen. Oral informed consent was obtained from the parents or care-givers. 
Medication 
Indinavir as single protease inhibitor (PI) is given as 500-600 mg/m2 every 8 hour. ( 4, lO)When 
combined with ritonavir the same dose is given every 12 hour. The pediatric dose of ritonavir as 
single PI is 350 mg/m2 every 12 hour; when given as low-dose with indinavir in adults the ritonavir 
dose is one sixth of the normal adult ritonavir dose (100 mg vs 600 mg). Because children have 
higher clearances of PI's, low dose ritonavir was given as one third of recommended pediatric dose : 
100 mg/m2 every 12 hour. No food-instructions were given. Indinavir was administered as 200 mg 
or 400 mg capsules or as syrup (10 mg/ml, developed in the university hospital Nijmegen, The 
Netherlands) in the case of patient 2, as this patient was not able to swallow capsules. The syrup 
was used within 14 days after preparation. Oral informed consent was obtained from the parents. 
Ritonavir was administered as syrup (80 mg/ml). 
In two children that used indinavir before start of indinavir/ritonavir, pharmacokinetics of 
indinavir q8h were determined before adding ritonavir. Two weeks after start of indinavir and 
ritonavir, patients were admitted to the day-care unit of each hospital to determine the steady state 
pharmacokinetics of indinavir and ritonavir. Blood samples were collected just before ingestion of 
indinavir/ritonavir and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 hours post ingestion. Indinavir and ritonavir 
concentrations were determined by HPLC, as previously reported. (11)Pharmacokinetic parameters 
were calculated by non-compartmental methods. (12) 
case reports 
Patients 
In Table 1 baseline characteristics and medication are listed. In patient 1 plasma HN-1 RNA load 
increased from undetectable to 1940 copies/ml after one year of treatment with indinavir, zidovudine 
and lamivudine. Two subsequent plasma HIV-1 RNA loads (three and five weeks later) were 
respectively 816 and 2630 copies/mi. Compliance seemed to be good. Because in this girl trough 
level (Cmin) of indinavir was low (0.03 mg/1, mean adults: 0.15) in the presence of an adequate 
peak level (Cmax) and area under the curve (AUC), ritonavir was added to achieve higher trough 
levels without increasing the peak level. The dosage of indinavir was 400mg (475 mg/m2) q12h, the 
dosage of ritonavir was 80 mg (100 mg/m2) q12h. Four weeks after the switch HN-1 RNA decreased 
to below 500 copies/mi. 
Patient 2 started at the age of 5 months with indinavir, zidovudine and lamivudine. In this 
patient AUC, peak level and trough level of indinavir were low (AUC: 7.41, Cmax: 3.78, Cmin: 0.06) 
and stayed low after increasing the dosage from 150 mg q8h (= 400 mg/m2 q8h) to 200 mg (= 550 
mg/m2 q8h). Low-dose ritonavir was added to the regimen 3 months after HAART was initiated to 
improve pharmacokinetics of indinavir. The indinavir dosage was 200 mg (510 mg/m2 ) q12h, the 
ritonavir dosage was 40 mg (100 mg/m2 ) q12h. 
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Patients 3 and 4 failed respectively after two and three years on medication schemes 
without indinavir. In these patients all medication was switched to a ritonavir/indinavir containing 
regimen because of high HIV-1 RNA loads and extensive prior treatment. In patient 3 the ritonavir 
dose was: 100 mg ( ~ 85 mg/m2) q12h, indinavir 600 mg ( ~ 510 mg/m2) q12h. In patient 4 indinavir 
and ritonavir were dosed as follows: indinavir 400 mg c~ 490 mg/m2) q12h, ritonavir 80 mg c~ 100 
mg/m2) q12h. 
Pharmacokinetics 
Figure 1 shows the pharmacokinetic parameters of indinavir in the 4 children. In patient 1 and 2 
pharmacokinetics of indinavir q8h are also presented (as patient 3 and 4 did not use indinavir before 
the start of indinavirjritonavir, pharmacokinetics of indinavir q8h are not available for these 
patients). Table 1 shows the phanmacokinetic parameters of indinavir and ritonavir. With the 
exception of patient 3 adequate values of AUC, Cmax and Cmin of indinavir were achieved. Levels of 
ritonavir are comparable with levels of ritonavir measured in adults on an indinavir/ritonavir 800/100 
mg BID regimen. (13) In one patient 3 extremely high levels of both indinavir and ritonavir were 
measured. We explored the possibility of accidently overdosing, but we could not find an obvious 
explanation of these high levels. 
Patient 1 Patient 3 
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Figure 1.: Plasma concentrations of indinavir (mg/L). 
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Age Gender Medication Treatment before Treatment other Indinavir Ritonavlr 
Patient (yrs) History Switch after Medication 
Switch AUC 0-24 Cmax Cmln AUC 0-12 em ax Cmin 
(mg/L.h) (mg/L) (mgfl) (mg/L.h) (mg/L) (mg/L) 
1 7 Female ZDV IDV, ZDV, 3TC R1V, IDV, - 68.36 7.98 0.23 14.98 2.66 0.38 
(8 months) (14 months) ZDV, 3TC 
2 0.8 Female - IDV, ZDV, 3TC R1V, IDV, - 90.32 9.39 0.49 21.55 3.50 0.49 
(3 months) ZDV,3TC 
3 10.2 Female ZDV,3TC NFV, d4T, NVP R1V, IDV, TMP-5MZ 265.64 19.57 4.63 88.72 12.46 4.22 
(56, 7 months) (18 months) ddl 
4 6.7 Female ZDV,3TC NFV, d4T, ddl R1V, IDV, - 94.88 8.65 0.31 19.58 3.21 0.53 
(15, 5 months) (17, 34, 34 months) NVP 
Adults treated with IDV 800 mg q8h 57.36 9.40 0.15 19.58 3.21 0.53 
Adults treated with IDV/R1V 800/100 mg q12h 100.40 8.30 1.25 11.79 2.06 0.56 
IDV = indinavir RTV = ritonavir ZDV = zidovudlne 
NFV = nelfinavir NVP = nevi rapine 
3TC = lamivudine d4T = stavudine 
ddl = didanoslne TMP-SMZ = trimethoprim-sulfamethoxazol 
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Side effects 
In 3 of the 4 patients side effects were seen. Patient 2 suffered from a rash, but the rash did not 
disappear until 2 months after switching indinavir/ritonavir into nelfinavir. 
Patient 3, the patient with extremely high levels of both protease inhibitors suffered from 
abdominal pain, hematuria, fever and a rash on her back. These complaints disappeared after 
discontinuation of indinavir and ritonavir. Ultrasonography of the kidneys was unremarkable. Patient 
4 complained of sleepiness during the day. Four months after the switch to indinavir and ritonavir 
pyrexia developed, showing a distinct pattern of spiking. Every six hours after taking indinavir, 
ritonavir and nevi rapine temperature spiked to about 40°C. The girl also presented with intermittend 
vomiting, slight loss of appetite and night sweats. Blood cultures, throatswabs, urine malaria screen, 
mantoux test, CMV and toxoplasmosis serology, stool virology, cat scratch virology and 
ultrasonography of the abdomen were unremarkable. After discontinuation of the medication the 
temperatures disappeared and reappeared after rechallenge. 
Discussion 
Combining indinavir with low-dose ritonavir improves the pharmacokinetic profile of indinavir in 
adults, resulting in a BID medication scheme without the necessity for food restrictions.(14) This 
combination is currently the only protease inhibitor containing regimen without food restrictions. 
Because of specific issues concerning compliance in children, an urgent need for such a simplified 
regime for children exists. 
We here report four children failing on protease inhibitor containing regimens, who were 
switched to indinavir combined with low-dose ritonavir. 
Administration of indinavir (500 mg/m2) combined with low dose ritonavir (100 mg/m2) resulted in 
increased trough levels in the presence of peak levels comparable with indinavir 600 mg/m2 q8h in 
three of the four children. The increased trough levels may result in more effective and more 
sustained virologic suppression, while peak levels are not increased and therefore side effects 
comparable to indinavir 600 mg/m2 q8h may be expected. In one child (patient 3) extremely high 
values of all pharmacokinetic parameters for both drugs were found. An explanation of these high 
levels can not be given, but a mistake in the administered amount of medication seems unlikely. An 
extremely low metabolic clearance is a possible explanation. 
Hsu et al describe pharmacokinetics of different regimens containing a combination of indinavir and 
ritonavir. (14) The combination of indinavir/ritonavir 400/400 mg has the lowest peak levels and 
may therefore have a lower incidence of urological complications (15), while the trough level is 
almost 3 times higher than with 800 mg q8h, which is important for viral suppression. As it is very 
difficult to make children drink ritonavir, because of its nasty taste, the proportion of indinavir and 
ritonavir 500-600/100 mg/m2 (800/100mg in adults) as described by Burger et al (13) was chosen 
to reduce the amount of ritonavir liquid. 
Side effects of this dual protease inhibitor containing regimen seem to be frequent as in three of the 
four patients side effects were observed. However, with exception of pyrexia of unknown origin in 
patient 4, the only severe side effects were seen in the patient with the extremely high levels of 
indinavir and ritonavir. The urological complaints of this patient may be explained by the association 
between high levels of indinavir and urological complications. (15) Patient 2 suffered from a rash. 
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However, the rash patient 2 suffered from is unlikely to be due to indinavir/ritonavir since the rash 
did not disappear after switching indinavir/ritonavir into nelfinavir. 
In conclusion, our data show that an indinavir/ritonavir 500·600/100 mg/m2 BID containing 
regimen may be a good alternative to the more complex and rigid single protease inhibitor 
containing medication schemes from a pharmacological point of view. However, the substantial 
toxicity in this small number of children needs further investigations. Controlled studies should be 
performed to evaluate the safety and efficacy of an indinavir/ritonavir BID regimen in children. 
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Abstract 
Introduction: Adherence to highly active antiretroviral therapy (HMRl) is required to obtain an 
optimal long-term virological response rate of HIV-1 infected children. An accurate assessment of 
the level of compliance is complicated by the limitations of the current methods. Plasma 
concentrations of protease inhibitors (Pis) outside the limits of the reference values indicate non-
adherence to antiretroviral therapy in adults. During a two-year follow-up period we studied 
routinely taken plasma protease inhibitor levels to assess compliance to antiretroviral therapy in HIV-
1 infected children. Methods: In 40 children (age: 3 months to 18 years) blood samples were taken 
at regular outpatient visits every 12 weeks after the start of HMRT and analyzed for plasma levels 
of indinavir or nelfinavir by HPLC and for plasma HIV-1 RNA load. The percentage of samples 
fulfilling the criteria for compliance was assessed for each child using three different methods. For 
each sample a concentration ratio was calculated by dividing the concentration in that sample by the 
time adjusted population value. According to method 1 concentration ratios below or above 
concentration ratio limits (CORALs) of population data obtained in adults were analyzed. This 
method is highly indicative of non-compliance in adults. Since many children have high PI levels 
method 2 evaluated plasma samples of Pis using only the lower CORAL. According to method 3 only 
children with plasma samples below the limit of quantification (0.04 mg/L) were considered non-
compliant. Differences in compliance rate between virological responders and virological non-
responders and between the two protease inhibitors were analyzed. The cumulative incidence of 
HIV-1 RNA levels >500 (copies/ml) in children was calculated. Results: Thirty-one children started 
treatment with indinavir and nine children with nelfinavir. The median compliance rates (interquartile 
range (IQR)) for indinavir as determined by methods 1, 2, and 3 were 54 (25-69)%, 67 (50-92)% 
and 80 (63-100)% respectively. For nelfinavir median (IQR) compliance rates of 60 (39-75)%, 100 
(67-100)% and 100 (100-100)% were observed. Compliance rates calculated with method 2 were 
significan~y higher in virological responders (p=0.04). Compliance rates calculated with methods 2 
and 3 were significantly lower in children using indinavir compared with those using nelfinavir 
(p=0.02 and p=0.02, respectively). Condusion: PI plasma levels below the lower CORAL are highly 
indicative of non-compliance for children on indinavir and nelfinavir and may thus be a useful 
method for the assessment of non-adherence to antiretroviral therapy in children. 
Introduction 
The institution of highly active antiretroviral therapy (HMRl) in HIV-1 infected adults and children 
has led to increasingly complex drug regimens. Adherence is required to obtain optimal suppression 
of the virus, which is necessary for an optimal long-term virological response. (1·3) Poor compliance 
is associated with several factors including: age (with adolescents being less compliant), the number 
of different medications, the number of doses of the medication, the extent to which the regimen 
interferes with the patient's life, the occurrence of side-effects in asymptomatic patients and longer 
duration of the disease. ( 4-10) All factors that are associated with poor compliance are also present 
in HIV infected children. Therefore optimalization of the use of HMRT in children poses a challenge 
for physicians involved in the treatment of children with HIV/AIDS. 
Overall compliance rates in adults are 75% versus only 58% in children. (11-14) The high 
percentage of children who do not adhere to antiretroviral therapy and the subsequent risk for 
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virological failure and long-term clinical failure underscores the importance of the development of 
methods to predict poor adherence. This may subsequently contribute to early intervention and 
optimalization of the antiretroviral regimen. The analysis of the level of adherence is complicated by 
the limitations of the current methods. Self-reported measures, electronic monitoring systems 
(Medication Event Monitoring System (MEMS)), pill counts, blood levels of protease inhibitors and 
refill history have been used. (11-16) However, all of them have their limitations. Recen~y Hugen et 
al. reported that plasma concentrations of protease inhibitors in adults outside the limits of a 
reference population strongly suggest non-compliance. (17) This method is objective, easy to 
perform and can be an attractive way to assess non-compliance in combination with other objective 
measures. This method has not yet been applied in children and is potentially complicated by the 
large interindividual differences in the pharmacokinetics of protease inhibitors in children. (18, 19) 
We here report the results of a study to assess adherence to antiretroviral therapy in HN-1 infected 
children by means of therapeutic drug monitoring of nelfinavir and indinavir and the association 
between plasma levels and the virological response rate. 
Methods 
Indusion and exdusion criteria 
PI naive children between the ages of 3 months and 18 years were eligible for enrolment in five 
participating centers between April 1997 and May 2000. HN-1 infected children with an HN-1 viral 
load of more than 5000 copies/ml and/or a CD4 cell count below the age-specific reference values 
were included. (20) 
Methods 
The study was approved by the medical ethical committees of all the participating centers. Written 
informed consent was obtained from parents or legal guardians. Blood samples were taken after a 
median (interquartile range (IQR)) time of 3.8 (3-5) hours after the ingestion of the protease 
inhibitor, at regular outpatient visits every 12 weeks after the start of HAART and stored at -20 °C. 
Time of blood sampling and time of the last administration of the protease inhibitor was recorded in 
the case record form. The concentrations of nelfinavir and indinavir plasma samples were analyzed 
by HPLC. (21, 22) Children were excluded when less than three samples were available. Plasma HN-
1 RNA quantitation was analyzed by a polymerase chain reaction assay (Roche Amplicor HN-1 
monitor test version 1.5) at the same timepoints as plasma drug levels. 
Medicaaon and pharmacoldneacs 
Medication was administered in the following doses: indinavir 400 mg/m2 q8h or nelfinavir 30 mg/kg 
q8h, zidovudine 120 mg/m2 q8h, lamivudine 4 mgjkg q12h. A day to day medication scheme 
including the times with food restrictions was given. 
At week 4, patients were admitted to the day-care unit to detenmine the steady state 
pharmacokinetics of indinavir or nelfinavir. When a dosage adjustment of indinavir or nelfinavir was 
necessary to normalize the area under the curve-concentration (AUC) curve to adult values 
(indinavir: 10-30 mg/L *hr, nelfinavir: 13-20 mg/L *hr), this procedure was repeated. 
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Statistical Analyses 
The percentage of samples fulfilling the criteria for non-adherence to antiretroviral therapy was 
assessed for each child using three different methods. Plasma levels of protease inhibitors in children 
were plotted in a concentration-time curve, which was derived from steady state population 
pharmacokinetics in adults. For each sample a concentration ratio was calculated by dividing the 
concentration in that sample by the time adjusted population value. According to method 1 
concentration ratios below or above concentration ratio limits (CORALs), consisting of the 5th and 
95tih percentile of population data obtained in adults, were highly indicative of non-compliance. For 
indinavir 800 mg q8h, CORALs were <0.23 and >3.3 mg/L. For nelfinavir 750 mg q8h and 1250 mg 
q12h, CORALs were <0.36 and 2.1 (mg/L). (17) Since many children have high PI levels method 2 
evaluated plasma samples of Pis using only the lower CORAL. Method 3 was based on a more 
traditional approach in which only children with plasma samples below the limit of quantification 
(0.04 mg/L) were considered to be non-compliant. Percentages were calculated by dividing the 
number of plasma levels within the limits defined by the 3 different methods by tihe number of visits. 
Virological responders were defined as children who had an HN-1 RNA level below tihe limit of 
detection of 500 copiesjml at week 12 and during follow-up. 
SPSS 9.0 (SPSS, Chicago) was used for statistical analysis. Differences in the compliance 
rates between virological responders and virological non-responders and between compliance rates 
and tihe two protease inhibitors were analyzed using the Mann Whitney U test (p-values are 2-
tailed). The cumulative incidence of HN-1 RNA levels >500 (copiesjml) in children was calculated by 
means of Kaplan-Meier analysis. The influence of a compliance rate <75% and ~75% was 
determined with the logrank test. The percentage of 75% was chosen, because Watson et al. 
observed a higher virological failure rate in children who were non-adherent (defined as <75% of 
antiretroviral therapy prescriptions filled). (12) 
Results 
Patient characteristics 
Forty children with a median (range) age of 5.4 (0.28-16.3) and a median (range) baseline plasma 
HN-1 RNA of 136,385 (2,680-2,480,000) were included. Thirty-one children started treatment with 
indinavir and nine children with nelfinavir. The median number of samples per patient (range) was 6 
(3-11) in the indinavir group and 4 (3-9) in the nelfinavir group. Twenty-two children were classified 
as virological responders and 18 as non-responders. 
Compliance rates 
Methods 1 (concentration ratios below or above CORALs), 2 (below lower CORAL) and 3 (below limit 
of quantification) resulted in median compliance rates (IQR) for indinavir of 54 (25-69)%, 67 (50-
92)% and 80 (63-100)% respectively. The median (IQR) compliance rates for nelfinavir were 60 
(39-75)%, 100 (67-100)% and 100 (100-100)%. The median percentages were highly variable 
between methods 1, 2 and 3. 
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RelabOn between compliance and virological response 
In Figure lA the compliance rates calculated with the three different methods in virological 
responders and non-responders are depicted. No difference between virological responders and non-
responders in compliance rote was observed when analyzed with method 3 (p=0.6). However, 
compliance rotes calculated w~h method 1 showed a trend to a higher compliance rote in virological 
responders (p=0.07) and compliance rates calculated with method 2 were significantly higher in 
virological responders. In virological responders a median (IQR) compliance rate of 85 (55-100)% 
was observed with method 2, whereas the median (IQR) compliance rate in non-responders was 67 
(25-75)% (p=0.04). 
Figure 1A Figure 1B 
120 120 
p=0.04 p=0.02 p=0.02 
100 100 
;£ ;£ 
~ 80 • 80 "§ 
• • g 60 0 60 
" 
iii 
c. 'a. 
E 40 E 40 0 0 
u u 
20 20 
0 0 
2 3 2 3 
Method Method 
o Virological responders D Virological non-responders oNelfina\oir Cl lndina\oir 
Figure 1A: The compli'ance rates calculated with the three different methods in virological responders and non-
responders are depicted. Error bars represent the interquartile ranges. 
Figure 18: The compliance rates calculated with the three different methods ln ch1ldren using indlnavir and in 
children using nelfinavir. Error bars represent the interquartile ranges. 
Figure 2 A, B and C show the cumulative incidences of patients with an HIV-1 RNA load > 500 
(copies/ml) in children with a compliance rate <75% and <:75% as calculated with methods 1, 2 and 
3. Children with a compliance rate <75% more frequently (method 1, 2 and 3: p=0.06, p=0.01 and 
p=0.2 respectively) had an HIV-1 RNA load >500 (copies/ml). 
Compliance rate and influendng factors 
Figure 1B presents the compliance rates calculated with the three different methods in children using 
indinavir and in those using nelfinavir. Compliance rates calculated with methods 2 and 3 were 
significantly lower in children using indinavir compared with those using nelfinavir (p=0.02 and 
p=0.02, respectively). 
Age1 ethnicity, prior treatment with antiretroviral medication and CDC classification stage 
were not related with compliance rates. 
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Figure 2A: Method 1 
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Figure 2C: Method 3 
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Figure 26: Method 2 
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F.igure 2: The cumulative inddence of paaents with 
an HIV-1 RNA load > 500 (copies/ml) in children 
with a compliance rate <75% (fi!led line) and ~75% 
(dotted line) as calwlated with method 1 (Rgure 
2.4)/ methOd 2 (Rgure 28) and method 3 (Rgure 
2C). 
Weeks after the initiation of HAART 
Discussion 
We studied the value of the measurement of the routinely determined plasma concentrations of 
indinavir and nelfinavir. The percentage of samples fulfilling the criteria for compliance was assessed 
for each child using three different methods. For each sample a concentration ratio was calculated 
by dividing the concentration in that sample by the time adjusted population value. According to 
method 1 concentration ratios below or above concentration ratio limits (CORALs) were defined as 
non-compliant. Since many children have high PI levels method 2 evaluated plasma samples of Pis 
using only the lower CORAL. According to method 3 only children with plasma samples below the 
limit of quantification were considered non-compliant. 
The compliance rates were highly variable between the 3 methods. When method 1 was 
used 22 of 31 (71 %) and 7 of 9 (78%) of the children using indinavir and nelfinavir were indicated 
as non-compliant respectively. However, when method 2 was applied the numbers of non-adherent 
children were reduced to 16 of 31 (52%) and 3 of 9 (33%). This reduction in the non-compliance 
rate may be explained by the deletion of one limit and by the higher peak concentrations of protease 
inhibitors that are observed in children. (18, 19) Compliant children with higher plasma 
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concentrations of the protease inhibitor due to pharmacokinetic differences between children and 
adults are considered to be non-compliant in method 1 whereas according to method 2 these 
children would be considered compliant. Since administering the medication too late can also cause 
higher plasma concentrations, in method 2 imperfect compliance (administration of the drugs, but 
not in time) is considered as good adherence. Therefore this may result in an underestimation of 
non-compliance. Method 3 also underestimates non-compliance, but a concentration below the limit 
of quantification of the protease inhibitor is highly indicative of non-compliance. 
A relation between adherence rate and virological response rate has been demonstrated in 
both HIV-1 infected adults and children treated with HAART. (11, 12) In our study a difference 
between the adherence rate to antiretroviral therapy in virological responders and non-responders 
was observed with method 2 and a trend to a relation was observed with method 1. This indicates 
that the determination of plasma levels of the protease inhibitors indinavir and nelfinavir followed by 
calculation as concentration ratio of the lower CORALs (method 2) in children may be a useful 
measurement for the assessment of compliance in children. The absence of a significant relation 
between virological response and non-compliance according to method 3 may be due to the limited 
number of children and due to still present detectable plasma levels of nelfinavir after 2 missed 
doses. (17) Another explanation might be a "white coat effect", which means that compliance may 
be better at the day the hospital is visited. Whether the measurement of plasma concentration levels 
below the limit of quantification has additional value remains to be evaluated in a study with a larger 
number of children. 
Children treated with nelfinavir showed significantly higher compliance rates compared to 
children treated with indinavir. For method 3 this may be explained by the fact that it takes more 
missed doses of nelfinavir (2.3) than of indinavir (1.3) before plasma levels become undetectable. 
(17) The difference observed with method 2 may be explained by a real difference in compliance 
rates between the two Prs. 
We conclude that the compliance rates calculated as the percentage of samples that 
fulfilled the criteria for compliance using only the the lower CORALs (consisting of the 5th percentile 
of population data obtained in adults) of indinavir or nelfinavir in children and virological response 
are associated. This method may therefore be a useful measurement for the assessment of non-
compliance in children. 
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Abstract 
Introdumon: Although the reduction in HIV-1-related deaths is similar in adults and children, the 
extent of the changes in two important surrogate markers (HIV-1 RNA levels and CD4+ T-cell 
counts) differs widely. In most pediatric studies virological response rates to highly actve 
antiretroviral therapy (HAART) are inferior to those in adults. This review provides an overview of 
the pediatric clinical studies using HAART and seeks to improve the understanding of factors, which 
may contribute to success or failure of HAART in children. Methods: An overview of all current 
articles on pediatric clinical trials using HAART is provided. Twenty-three papers were available. HIV-
1 RNA loads and CD4+ T-cell counts were used as primary outcome measures. Results: Virological 
response rates were highly variable both between the different antiretroviral drugs but also between 
different studies using the same medication. Four studies in which dosages of the administrated PI 
were adjusted after pharmacokinetic evaluation had superior virological response rates compared to 
those in which fixed dosages were used. Immunological response rates were more uniform than 
virological responses. In almost all studies increases of CD4+ T-cell counts are reported independent 
of the extent of the virological response. Side-effects of HAART were generally mild, transient and of 
gastro~intestinal origin. Significant percentages of patients with serum lipid abnormalities were 
reported in three pediatric studies. However, signs of clinical lipodystrophy were not observed. 
Condusion: The inferior virological response rates, which have been reported in HIV-1 infected 
children treated with HAART form a refiecton of the challenges which are encountered in the 
treatment of these children. Difficulties with adherence and with the pharmacokinetics of protease 
inhibitors in children require an intensive, child adjusted approach. A practical approach to therapy in 
institutions without tertiary top-reference care facilities may be induction therapy with a lopinavir 
containing regimen (lacking a need for therapeutic drug monitoring) to reduce high viral load levels 
followed by an easily tolerated maintenance regimen for example containing abacavir or nevi rapine. 
Introduction 
Since the introduction of highly active antiretroviral therapy (HAART) a reducton in the rate of 
progression of AIDS and HIV-1-related deaths has been observed among adults living in the Western 
world. (1, 2) The effectiveness of HAART in infants and children to reduce HIV-1-related deaths is at 
least similar, or even greater than that observed in adults. (1) 
The measurement of two surrogate markers, HIV-1 RNA levels and CD4+ T~celi counts, 
has become the basis for the prediction of clinical, virological and immunological responses in both 
HIV-1 infected adults and children treated with HAART. (2, 3) Although the reducton in HIV-1-
related deaths is similar in adults and children, the extent of the changes in these parameters differs 
widely. In most pediatric studies virological response rates to HAART are inferior to those in adults. 
(4-12) Since virological suppression is associated with long-term success of HAART, this may have 
major implications for the future health of these children. (13-15) 
The institution of optimal treatment regimens in HN-1 infected children poses a enormous 
challenge. First, large interindividual differences of pharmacokinetics of antiretroviral drugs, 
especially of protease inhibitors, complicate optimal dosing of antiretroviral drugs in children. 
Secondly, it is difficult to maintain adherence to combination therapy during many years. Problems 
such as the intake of evening medication during sleeping time or afternoon medication during 
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schoolr unwillingness of young children and adolescents to take medicationr poor palatability and 
side-effects of medication have to be dealt with. Thirdly, different viral dynamics may complicate 
optimal suppression of HIV-1. Viral load reduction in children following the introduction of HAART 
has a slower phase II decay rate in children in comparison with adults. (16) Baseline viral loads in 
children are higher, which may be a barrier to reach undetectable viral loads. (17-19) 
Despite the difficulties in the treatment of HIV-1 infected children and the poor virological 
responses in many studies, it has become clear that a similar rate of suppression of HIV-1 replication 
may be obtained in children during the first year of treatment as compared to that in adults. (20-26) 
The reasons for the highly variable therapy results in children are not well understood. This review 
provides an overview of the pediatric clinical studies using HMRT and seeks to improve the 
understanding of factorsr which may contribute to success or failure of HMRT in children. 
Methods 
An overview of all current articles on pediatric clinical trials using HMRT is provided. Search 
strategy: The Pubmed database (www.ncbi.nlm.nih.gov) was used to search for articles on pediatric 
clinical trials using HMRT. 
Selection criteria: articles not written in English were excluded. No selection on date was 
made. Articles with text word combinations: HIV-1 and children, HIV-1 infection and children, 
ritonavir and children, indinavir and children, nelfinavir and children, saquinavir and childrenr 
nevirapine and children and abacavir and children were selected. 
Twenty-three papers were available. HIV-1 RNA loads and CD4+ T-cell counts were used 
as primary outcome measures. 
Ritonavir 
In March 1996, ritonavir (RTV) was the first protease inhibitor approved by the US Food and Drug 
Administration (FDA) for the treatment of HIV-1 infected children (age 2 to 16 years). RTV has been 
available in a pediatric formulation (liquid) and leads when used as a single agent to a marked and 
rapid decline of plasma HIV-1 RNA levels. (27) However, the HIV-1 RNA levels gradually return 
toward baseline values after a few weeks of treatment, presumably because of the development of 
resistance. Virological response rates were sustained for a 24-week period after administration of the 
highest dose (400 mg/m2 q12h). (27) The virological response rates of combinations of RTV with 
one or two nucleosides were also modest with 16%, 14%, 32% and 42% below 400 copies HIV-1 
RNA/ml after 24, 52, 72 and 48 weeks respectively. (10, 11, 22, 27) CD4+ T-cells significantly 
increased in most children irrespective of the extent of the virological suppression. Toxicity by RTV 
consisted mainly of gastro-intestinal symptoms (nausea, vomiting). These symptoms were frequently 
reported as mHd and transient although in 4-23% more severe gastro-intestinal symptoms, fever or 
rash were observed. (10, 11, 22, 27) Thuret et al. reported an increase in the serum levels of 
triglycerides and cholesterol of 33% and 61% respectively after at least 12 months of therapy, 
although no clinical signs of lipodystrophy were reported. (11) In Table 1 the study results with RTV 
are summarized. The poor virological efficacy in children, the serious side-effects which are seen in a 
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high percentage of the children and the poor taste of the liquid formulation, form in important 
disadvantages in the use of this Pl. 
Indinavir 
In March 1996 the protease inhibitor indinavir (IDV) was registrated by the FDA for use in HIV-1 
infected adults. Although IDV thus far only has been available in a capsule formula, it is possible to 
dissolve IDV in water for use in infants and young children. (24) Indinavir has to be administered to 
a fasting child at least one hour before or two hours after the intake of food. 
Virological response rates of JDV combination therapy with two NRTI's differ widely. Mueller et al. 
reported that 6% of their 54 patients had an HIV-1 RNA load below the detection limit of 200 
copies/ml after 16 weeks. (28) After 96 weeks only 4 (12%) of the 33 patients that completed a 
follow-up of 96 weeks. (29) This very low response rate was probably due to the administration of 
IDV as monotherapy during the first 12 weeks. Van Rossum et al. and Vigano et al. reported higher 
virological response rates: 70% <500 copiesjml and 87% <400 copies/ml after 24 and 72 weeks 
respectively. (20, 24) In all these studies irrespective of the virological response rate immunological 
improvement was reported. Renal side-effects by IDV due to crystallisation of indinavir in the kidney 
were reported in 11 to 80% of the patients and varied from crystalluria and hematuria to 
nephrolithiasis. Nephrolithiasis was documented in 2 to 28% of the children. (4, 5, 7-9, 20, 24, 28, 
29) Gastro-intestinal symptoms formed the other major side-effects of indinavir. (4, 5, 7-9, 20, 24, 
28, 29) 
Van Rossum et al. demonstrated that the administration of IDV with low-dose ritonavir in a 
twice daily regimen results in a higher AUC and in higher trough levels of indinavir independent of 
food intake. (30) Pediatric studies on the efficacy of a twice daily regimen with indinavir and low-
dose ritonavir in children are ongoing. In Table 2 the pediatric studies with IDV are summarized. The 
results of these studies differ widely. The use of IDV has been associated with a virological response 
rate which is comparable to that obtained in studies with this protease inhibitor in adults. However, 
nephrotoxicity is a major side-effect of IDV. Since this side-effect is associated with high drug levels 
of IDV, pharmacokinetic monitoring is necessary to reduce the risk for nephrotoxicity. (31) Urinalysis 
should be routinely performed in children treated with IDV. Frequent dosing and food restrictions 
may result in poorer adherence. The combination of IDV and low-dose R1V results in a simplified 
regimen and should therefore be further explored in children. 
Nelfinavir 
Nelfinavir (NFV) was the third protease inhibitor approved by the FDA for use in HIV-1 infected 
children in March 1997. NFV has been available in a pediatric formulation (powder 50 mg/g). NFV 
has to be administered with food to guarantee an optimal absorption. NFV has been studied in 
combination with two NRTI's and with two NRTI's and a NNRTI. (21, 23, 32) The virological 
response rates in children treated with a combination of NFV and 2 NRTI's vary from 69% <400 
copies/ml and 44% <50 copies/ml in an intention to treat analysis (23) to 44% <400 copies/ml (33). 
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Table 1: Pediatric studies using Ritonavir (RTV) 
Author Regimen RTV dose Inclusion Number Follow Outcome Outcome CD4+ T- Toxicity Reference 
(q12h) criteria of up H!V·1 RNA cells 
patients (weeks) 
Mueller et RTV+ after 12 250, 300, 350 or Age 0.5·18 48 24 J. 2 10910 Med i 79 cells/mm3 Mild and transient (27) 
ai. weeks ZDV and/or 400 mg/m2 years, cop/ml (with nausea, diarrhea, 
ddl Naive, 400 mg/m2) abdominal pain 
CDC stage 16% <200 (98%) 
2, 3, B or C cop/ml 
Pelton et al. RTV+d4T or ZDV 350 mg/m PI naive, 43 52 t 1.6910910 Med i 588 cells/mm3 Vomiting, i liver (10) 
with of without HIV-1 cop/ml14% enzymes (9%) 
3TC RNA> <400 cop/ml necessitating 
50,000 discontiuation 
coples/ml 
and/or 
severely J. 
CD4+ cell 
count 
Thuret et al. RTV+ZDV or 350·400 mgfm' PI naive 22 72 t 1.5 log10 Med i 472 cellsjmm3 4% gastro-Intestinal (11) 
d4T+3TC cop/ml symptoms 
32% <400 necessitating 
copjml discontiuation 
i triglycerides or 
cholesterol in 33% 
and 61% 
respectively 
Nachmann RTV+ZDV+3TC or 350 mg/m' Age 2-17 297 48 42% <400 Med i 818 ceiisjmm' Grade 3: 23% (22) 
et al. d4T/RTV or years, cop/ml =33% of total T-cells (RTV/d4T) and 17% 
AZT/3TC PI naive, (RTV/ZDV/3 (RTV/ZDV/3TC) (RTV/ZDV/3TC): 
Clinically TC) and Med t 767 cells/mm3 nausea, vomiting, 
stable 27% =29% of total T-cells rash, fever, 
(RTV/d4T) (RTV/d4T) neutropenia 
Table 2: Pediatric studies using Indinavir (IDV) 
Author Regimen IDV dose Inclusion criteria Number Follow- Outcome Outcome Toxicity Reference 
(q8h) of up HIV-1 RNA CD4+ T-
natients ! (weeks) cells 
Rutstein et al. IDV+2 NRTI's 480 PI naive 28 (19 on 24 t 1.99iogw cop/mi Med t 202 IDV: 44% (4) 
(n"19) or (range: IDV) (IDV "RTV) cells/mm3 renal side 
I ~TV~2 NRT!s 333-571) 25% <400 cop/ml effects. 28% 
n-9 mo!m' neohrolitiasis 
Melvin eta!. IDV+2 NRTI's 500 PI naive 9 (5 on 28-52 ,!.. 1.7 log10 cop/ml Med t 499 80% (40% (5) 
(n"S) or mg/m2 IDV) 22% <400 cop/ml cells/mm3 when 
RTV+2 NRT!s misdosage is 
(n"4) excluded): 
renal 
comollcations 
Monpoux et al. IDV, d4T, 3TC 500 Severe immunodeficiency, 7 24 t 0.6 log10 cop/ml Med t 132 Vomiting (9) 
mg/m2 High viral load, clinically 14% <400 cop/mi cells{mm3 (n"1), mild t 
stable bilirubin 
PI naive 
Mueller et at. IDV+ after 12 250 Age 6 months-18 years, 54 16 1 0.07 log10 cop/ml Med I 60 Generally well (28) 
weeks: mg/m2 CDC stage B, C, 1, 2, (250 and 350 mg/m' ), cells/mm3 tolerated. 
ZDV+3TC or 350 Normal hematological and t 0.76 log10 cop/ml 13% 
mg/m2 chemistry parameters, (500 mgfm' ), hematuria, 2% 
or 500 Clinically stable 6% <200 cop/ml (on nephrolithiasis 
mg/m2 PI naive triple) 
Kline et al. IDV+d4T +ddl 500 Symptomatic HIV disease 12 48 t 2 log10 cop/ml Med t 317 33% nausea, (8) 
mg/m2 or immunosuppression cells/mm3 vomiting 
<': 1 year NRTI's 50% 
crystalluria. 
42% 
hematuria, 
80% pyuria, 
17% transient 
I iaundice 
W!ntergerst et IDV+ZDV+3TC 500 Age <18 years 15 24 t 1.6 logw cop/ml Med t NA (7) 
al. or mg/m2 PI naive 40% <400 cop/ml 101% above 
I IDV+d4T +3TC baseline 
Vlgano et al. IDV+d4T+3TC 500 Symptomatic HIV dlsease1 25 72 87% <400 cop/ml Med t 360 24% renal {20) 
mg/m2 Immunosuppression and cells/mm3 symptoms 
prior NRTI use =10% of 4% transient 
PI naive total T-cells jaundice 
(at month 
12) 
Van Rossum et IDV+ZDV+3TC 400, 5001 PI naive, 28 24 70% < 500 copjml Med t 100 41% side- (24) 
al. 600 or HIV·1 RNA >5000 cop/ml 48% <40 cop/ml ceHs/mm3 effects, mainly 
660 Immunosuppression =27% in gastro-
mg/m2 Age 3 months-18 years relation to intestinal 
normal Renal 
values symptoms In 
11% 
Jankelevich et al. IDV+ after 12 250, 350, Age 6 months-18 years1 33 96 J 0. 74 loQ1o cop/ml Med t 199 NA {29) 
weeks: or 500 CDC stage B1 C, 1, 2, 12% <200 cop/ml (on cells/mm3 
ZDV+3TC mg/m' Normal hematological and triple) 
After chemistry parameters, 
week 58: Clinically stable 
350 PI naive 
mg/m2 
Table 3: Pediatric studies using Nelfinavir (NFV) 
Author Regimen NFV dose Inclusion criteria Number Follow~ Outcome Outcome Toxicity Reference 
{q8h) of up HIV·l RNA CD4+ T~cells 
oatients I lweeksl 
Krogstad eta!. NFV+2 NRT!s 20-30 Age 0·13 years, 62 54 71% ~ J. 0.71ogw Remained 25% grade 1 or (32) 
mg/kg PI naive, (median cop/ml constant 2 transient 
Clinically stable 42) diarrhoea 
Grade 1 nausea, 
flatulence, 
anorexia, 
epistaxis, fever, 
neutropenia, 
abdominal pain, 
anemia and rash 
Funk et al. NFV+ZDV+3T 20-30 Antiretroviral naive, 16 48 Med t 2.8 log10 Med t 157 Initial transient (23) 
cor mg/kg CDC B, C, 2 or 3, cop/ml cells/mm3 diarrhoea, lack 
NFV+d4T +ddl HIV-1 RNA >20,000 (> 2 69% <400 cop/ml =33% of total of concentration 
years) (In) T-cells and rash. 
HIV-1 RNA > 100,000 ( < 2 44% <50 cop/ml Transient or 
years) (In) persistent t 
triglycerides or 
cholesterol in 
50% and 31% 
respectively 
Starr et al. NFV+EFV+2N 20-30 Age< 16 years, 48 57 Med t 2.71ogw Med t 74 25% moderate, (21) 
RTls mgjkg HIV-1 RNA >400 cop/ml, cop/ml ceUs/mm3 9% severe , 2% 
PI and NNRTI naive, 81% <400 cop/ml =3% of total life threatening. 
Ability to swallow capsules (AT) T-cells Most 
61% <400 copfml common:rash, 
(ITT) dlarhhea, 
70% <50 cop/ml neutropenia, 
(AT) biochemical 
53% <50 cop/ml abnormailities 
(ITT) 
Wiznla et al. NFV+d4T+3T 30 mg/kg Age 4 months-17 years, 193 24 1 44% <400 cop/ml 1: Med t 105 77% ;::grade 2 (33) 
C (!)or Stable CDC 1 or 2 cat. 2 50% <400 copjml cellsjmm3 Most comon: 
NFV+d4T+NV 55 mg/kg PI, NNRTI, d4T, 3TC naive, 3 63% <400 cop/ml 2: Med t 87 rash, nausea, 
P (2) or q12h Clinically stable 4 46% <400 cop/ml cells/mm3 vomiting, fever 
NFV+d4T+3T (n=12) 3: Med t 294 
C+ cells/mm3 
NVP 4: Med t 254 
(3) or cells/mm3 
~~;d4T+NV 
Table 4: Pediatric studies using Saquinavir (SQV) 
Author Regimen PI Inclusion criteria Number Follow" Outcome Outcome Toxicity Reference 
Dose of up HIV·l RNA CD4+ T-cells 
I patients (weeks) 
Hoffmann et al. A: SQV+RTV Failure of prior therapy 11 24 A: Med J. 1.4 logw A: Med 1' 23% 45% grade 1 or (35) 
SQV+RTV+>1 : including at least 1 PI, cop/ml above baseline 2 diarrhea 
NRTI (n=6) or 15- Age <14 years 20% <200 copjml = 91% !Increase 
B: 30mg/kg (AT) Med 1' 281 of triglycerides 
SQV+NFV+>1 +250-400 0% <50 cop/ml cellsjmm3 above normal 
NRTI (n=5) mg/m2 B: Med t 0.2 logw B: Med t 7% 55%mlld 
q12h cop/ml above baseline increase lever 
SQV+NFV: 0% <200 copjml = enzymes 
15- (AT) Med t 3 
30mg/kg cells/mm3 
+30-35 
mg/kg 
: qBh 
Kline et ai. 1: SQV- 1: SQV- Age 3-16 years, 1: 14 1: 72 1: Med t2.12 log10 1: Med 1'292 No differences (36) 
SGC+2NRT!s SGC PI naive, 2: 13 2:48 cop/ml cellsjmm3 betvveen 1 and 
2: SQV- 33mg/kg Naive to :<:1 prescribed 36% <50 cop/ml 2: Med 1'154 2. 
SGC+NFV+2N q8h NRTI 2: Med t2.58 logw cells/mm3 Generally mild: 
RT!s 2: SQV- CDC stage A, B, C, 1 or 2, cop/ml diarrhea (36%), 
SGC Normal hematological and 62% <50 cop/ml abdominal 
33mg/kg biochemical parameters discomfort 
+ NFV (16%), 
30mg/kg headache ( 16%) 
q8h 
Table 5: Pediatric studies using Nevirapine (NVP) 
Author Regimen NVP Inclusion criteria Number Follow- Outcome Outcome Toxicity Reference 
Dose of up HIV-1 RNA CD4+ T-cells 
patients I (weeks) 
Luzurlaga NVP 1.120 mg/m2/day or Age 2 months-18 years, 21 8 NA 43%~5% 5% Rash (40) 
eta!. 2. 240 mg/m2/day Immunosuppression, increase 
or CDC stage A, B, C 
3.120 mg/m2/day Prior antiretroviral 
first 14 days followed 
by 240 mg/m2/day 
treatment <6 weeks 
or 
4. <9years: 120 
mg/m2/day first 14 
days followed by 400 
mg/m 2/day 
Luzuriaga NVP+ZDV 120 mg/m2/day first Age 2-24 months 8 24 38% -!-t.Siog10 Stable of slight NA (6) 
et al. +3TC 28 days followed by Immunosuppression, cop/ml increase (88% 
400 mg/m2/day CDC stage A, B, C 25% <400 cop/ml was not 
Prior anitretroviral lmmunosuppre 
treatment <6 wekks sse d) 
Hainaut et 1. 120 mg/m'/day first Children born to HIV-1 4 NA 50% <50 cop/ml Persistent No side-effects [(41) 
al. ZDV+ddl+ 14 days followed by Infected mothers that normal CD4+ 
3TC 300-400 mg/m2/day became HIV-1 positive T ·cell counts 
2. during perinatal follow·up 
ZDV+3TC 
+NVP 
Table 6: Pediatric studies using Efavirenz (EFV) 
Author Regimen EFV Inclusion criteria Number Follow- Outcome Outcome Toxicity Reference 
Dose of up HIV·l RNA CD4+ T· 
I patients I Cweeksl cells 
Teglas et I. EFV + Median dose 13.3 mg/kg inclusion criteria not 33 24 weeks Med .1.1.2 logw Med i 128 42% of the (43) 
all NRTI included In paper cop/ml cells/mm3 children had 
(n= 24) 48% below at least one 
2. EFV 200 coples/ml dlstinguishab 
+PI 27% below le side 
+NRTI 50% copiesjml effect. Of all 
(n=9) children 15% 
suffered of 
cutaneous 
side effects, 
30% of 
nervous 
system side 
effects and 
6% of both. 
7 children 
stopped the 
study due to 
Intolerance 
Starr et al. NFV+EFV+ Mean dose at 2 weeks 11.7 Age < 16 years, 48 57 Med .1. 2.7 Med t 74 25% (21) 
2NRT!s mg/kg H1V-1 RNA >400 log10 cop/ml cellsjmm3 moderate, 
cop/ml, PI and NNRTI 81% <400 =3% of total 9% severe, 
Mean dose at 6 weeks 13.3 naive, Ability to cop/ml (AT) T-cells 2% life 
mgJkg swallow capsules 61% <400 threatening. 
cop/ml (ITI) Most 
70% <50 common:ras 
cop/ml (AT) h1 diarhhea1 
53% <50 neutropenia1 
cop/ml (1TI) biochemical 
abnormailities 
Table 7: Pediatric study using abacavir (ABC) 
Author Regimen ABC Inclusion criteria Number Follow- outcome Outcome Toxicity Reference 
Dose of up HIV-1 RNA CD4+ T-cells 
patients I (weeks) 
saez- I. 8 mg/kg q12h Age 3 months-13 205 48 I. Med 10.21 1: Med i-14 Nausea, (45) 
Llorens et ZDV+3TC years, !og10 cop/ml cells/mm3 vomiting 
al. (n= 103) CDC stage N,A,B,C, 1. 6% <400 =0.8% of total and cough 
2. PI discontinuation ;::.2 cop/ml T-cells more 
ABC+ZDV weeks before 2. Med 10.61 2: Med 199 frequent In 
+3TC enrollment, log 10 cop/ml cells/mm3 2 (46% and 
(n=102) Normal hematology 2. 11% <400 =3.1% of total 46A versus 
and chemistry cop/ml T-cells 30% and 
parameters, 25% resp.) 
CD4+% >15% Fever, 
diarrhea, 
nasal signs, 
rashes and 
ear/nosejthr 
oat 
infections 
occurred In 
;::.15% 
Grade 3 or 4 
lnfreauentlv 
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Administration of NFV plus a NNRTI (nevirapine or efavirenz) and two NRTI's is associated with 
excellent virological responses. (21, 33, 34) 
Wiznia et al compared the effectiveness of NFV, NVP, d4T and 3TC to NFV, d4T and 3 TC. 
The virological and immunological responses were superior with the four-drug regimen. (21, 33, 34) 
Moderate to severe (<o grade 2) side-effects were frequently observed in 25% to 77% of the 
patients. Adverse events included diarrhea, nausea, vomiting and rash. A transient or persistent 
increase in the serum levels of triglycerides or cholesterol was observed in 50% and 30% 
respectively, although no clinical signs of lipodystrophy were reported. 
Schuster et al. and Wiznia et al. reported that the administration of NFV in a twice daily regimen 
results in pharmacokinetic parameters which are comparable to those found in a three times daily 
regimen. (33, 34) However, pediatric studies on the efficacy of a twice daily regimen are not 
available. In Table 3 the pediatric studies with NFV are summarized. Nelfinavir is the only protease 
inhibitor with a pediatric formulation (powder) that is easy to use in very young infants as well as in 
older children. However, the co-administration with food may result in problems in children that 
refuse to eat or in children that have to be awakened for an evening dose. Again, the study results 
with NFV differ widely. In one study a virological response rate was demonstrated comparable to 
that obtained in adults. Combination treatment of NFV with EFV resulted in an excellent virological 
response rate. However, when children fail on this regimen, few alternatives are left, because of 
cross-resistance within these groups of antiretroviral medication. Gastro-intestinal side-effects are 
frequently associated with the use of NFV, but are mainly transient. Increases in triglycerides and 
cholesterol have been reported in 31 to 91% of the children which may have important 
consequences for their health. The efficacy of a twice-daily regimen, which seems possible from a 
pharmacokinetic point of view, should be studied. 
Saquinavir 
Saquinavir hard gelatin capsule (SQV-HGC) was the first HIV-1 protease inhibitor approved for use in 
HIV-1-infected adults by the FDA. The use of SQV-HGC has been restricted by poor bioavailability 
( 4% uptake of a single oral dose taken with food). To improve this pharmacokinetic profile SQV has 
been combined with RTV or with NFV. Both PI's are inhibitors of cytochrome P450 3A isoenzymes 
and therefore co-administration results in markedly higher plasma concentrations of SQV. 
Hoffmann et al. studied the efficacy of SQV with RTV and of SQV with NFV in 11 children 
with failure on prior therapy including at least one Pl. (35) The antiretroviral effect (HIV-1 RNA 
reduction and CD4+ T-cell increase) was more pronounced with the combination SQV/RTV than 
when SQV/NFV were given. This was probably due to the stronger inhibition of cytochrome p459 3A 
isoenzymes by ritonavir thus leading to higher trough levels of SQV in combination with RTV. 
Complete suppression of viral replication below quantifiable levels could not be achieved. Both 
regimens were well tolerated. Recently a new formulation of SQV that improves the low oral 
bioavailability of SQV-HGC, saquinavir soft gelatin capsule (SQV-SGC) has been approved for use in 
HIV-1 infected adults. Kline et al. evaluated the pharmacokinetics, tolerance, safety and activity of 
SQV-SGC with NFV in children older than 3 years and reported good tolerance, safety, and virological 
and immunological response rates. (36) In Table 4 the results of pediatric studies with SQV are 
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summarized. The combination of SQV-SGC with NFV results in a very promising virological 
suppression in the absence of serious side-effects. 
Nevi rapine 
Nevirapine (NVP) is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase with a 
favourable pharmacokinetic profile allowing twice daily administration. (37, 38) In adults once daily 
dosing results in similar exposure to NVP. (39) However, pharmacokinetic evaluation has not yet 
been performed in children. NVP is available in a pediatric formulation (liquid). 
Luzuriaga et al. studied the phanmacokinetics, safety and activity in HN-1 infected children 
in 1996. (40) Administration of NVP leads to a rapid and profound (:>50% of baseline) reduction in 
plasma p24 antigen levels in 10 of 12 children. However, at the lower dosage (120 mg/m2/day) 
antiviral activity was lost rapidly and appeared to be associated with the isolation of viruses with 
decreased in vitro sensitivity. At higher dosages a more durable antiretroviral activity was observed 
during the 8 weeks of monotherapy. Rash was the most common side-effect in 5% of the patients. 
Because the use of NVP in combination with other antiretroviral agents would likely provide more 
potent antiretroviral activity, Luzuriaga et al. studied combination treatment with NVP, zidovudine 
and lamivudine in 8 infants younger than 16 months. In this study a more durable response was 
found. (6) However, only 25% of the patients reached an HN-1 RNA load <400 copies/mi. Viruses 
with decreased sensitivity to nevirapine were isolated during the treatment period from five infants. 
(6) Hainaut et al. treated 2 vertically infected infants with NVP, ZDV and 3TC. In both infants an 
HN-1 RNA load <50 copies was observed. (41) 
Table 5 summarizes the pediatric studies with NVP. The development of class resistance 
with single step mutations in the reverse transcriptase gene remains a major therapeutic problem 
with this class of antiretrovirals. Since HIV-1 infected children tend to have higher baseline viral 
loads with a higher replication rate than adults, this is a major disadvantage in the treatment of 
children with a high baseline viral load. (42) However, the favourable pharmacokinetic profile 
allowing twice and possibly once daily dosing, a pediatric formulation with a taste that children like 
and the absence of major side-effects makes this drug a promising antiretroviral component for 
children with lower baseline viral loads. 
Efavirenz 
Efavirenz (EFV) was the second NNRTI to be approved for the use in children. A pediatric (liquid) 
formulation is currently available on a compassionate use basis. The pharmacokinetic profile of EFV 
allows for once daily dosing. In spite of this promising feature, little experience has been obtained 
with the treatment of HN-1 infected children with EFV. Star et all. conducted a study in children 
receiving EFV in combination with NFV and NRTI. (21) A total of 57 HN-1-infected children were 
included. After 48 weeks of treatment 76% of the children had plasma levels below 400 copies and 
63% below 50 copies. High viral loads at start of the study decreased the likelihood that plasma viral 
loads would become undetectable. Adverse effects of at least moderate severity included rash 
(30%), diarrhea (18%), neutropenia (12%) and biochemical abnormalities (12%). Mild central 
nervous system toxicity was found in 14% children, which resolved once EFV was given at bedtime 
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rather than in the morning. Since the patients in this study received a combination of NFV and EFV it 
is impossible to discriminate which of both drugs induced this toxicity. Teglas et al. conducted a 
study in 24 children receiving EFV and a NRTI and 9 children receiving EVF, a NRTI and a Pl. (43) 
After 6 months of treatment the viral load was below 200 copies in 48% of the children and below 
50 copies in 27% of the children. Fifteen children (42%) suffered of at least one clinically apparent 
side effect Five (15%) had mild diffuse cutaneous eruptions, 10 (30%) children suffered from 
nervous system side effects and two had both. The treatment was discontinued due to intolerance in 
seven children. Younger children experienced more side effects than older children. Table 6 
summarizes the results of studies with EFV. 
In children the use of efavirenz has been associated with serious adverse events. Rash and 
serious neurological problems are frequent side-effects. High viral loads at start of the study 
decreased the likelihood that plasma viral loads would become undetectable. Therefore, in our 
opinion efavirenz is not a first choice drug in children. 
Abaca vir 
Abacavir (ABC) is a potent nucleoside reverse transcriptase inhibitor (NRTI) that in combination with 
two other NRTI's results in a viral load of <400 copies/ml in 74% of treatment-naive adults after 48 
weeks of therapy. (44) It is available in a pediatric fonmulation (liquid). saez-Liorenz et al performed 
a randomized, double-blind study of ABC/ZDV/3TC versus ZDV/3TC in 205 antiretroviral therapy-
experienced HIV-1 infected children. (45) Virological, immunological and clinical response rates over 
the 48 weeks of the study indicate that the addition of ABC to ZDV/3TC provided increased antiviral 
activity over that provided by ZDV/3TC. However, as expected in antiretroviral therapy-experienced 
participants many of whom had received previous therapy with ZDV with of without 3TC, the degree 
of viral suppression provided by the ABC/ZDV/3TC regimen was modest, while improvement in 
immune response was moderate. Nausea/vomiting and cough occurred more frequently among 
children receiving ABC/ZDV/3TC. The hypersensitivity syndrome associated with the use of ABC was 
not observed in this study. Thus far only one child (3%) with a hypersensitivity reaction has been 
reported in a phase I study of ABC in HIV-1 infected children. (46) In Table 7 the results of the 
pediatric studies with ABC are summarized. The well tolerated pediatric formulation, the possibility to 
administrate this medication twice-daily and the low incidence of serious side-effects result in 
favourable qualities of ABC. However, studies on the efficacy of this drug in naive children are 
lacking. Since in adults poorer virological outcome has been associated with a high baseline viral 
load and children tend to have higher baseline viral loads, the efficacy of ABC in children should be 
studied. (42, 47) 
Discussion 
This review provides an overview of all current articles on pediatric clinical trials using HAART. 
Twenty-three papers mostiy with a small number of patients were available using 4 PI's (RTV, IDV, 
NFV and SQV), 1 NNRTI (NVP) and 1 NRTI (ABC). HIV-1 RNA loads and CD4+ T-cell counts were 
used as primary outcome measures, because these parameters have been demonstrated to be 
independent predictors of the clinical course in H!V-1 infected infants and children. (3) In addition, 
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these two surrogate measures were measured in all studies, while other clinical progression markers 
such as growth (48) were unfortunately often not available. 
Virological response rates were highly variable both between the different antiretroviral 
drugs but also between different studies using the same medication. The studies with the highest 
percentages of children reaching a viral load below the detection limits of 400 copies/ml were 
reported by Starr et al: NFV+EFV+2 NRTI's, Vigano et al.: IDV+d4T +3TC, Kline et al.: SQV+NFV+2 
NRTI's, Van Rossum et al.: IDV+ZDV+3TC, Funk et al.: NFV+2NRTI's and Wiznia et al.: 
NFV+NVP+2 NRTI's. (20, 21, 23, 24, 33, 36) The percentages of viral loads below the detection 
limit of 400 copies/ml varied between 63% and 87%, which is comparable with the data on HAART 
in adults. (25, 26) However, the majority of pediatric studies showed inferior virological response 
rates in comparison with those in adults. In studies using RTV, NFV, IDV, NVP or ABC virological 
success rates varied from 11% to 50% of the patients with a HIV-1 RNA load <400 copies/mi. (4-11, 
22, 27-29, 33, 45) 
Several factors may be associated with virological failure. These include pharmacokinetic 
parameters (low plasma blood levels of protease inhibitors are associated with virological failure (49, 
SO)), inadequate adherence to antiretroviral therapy and differences in baseline characteristics (prior 
antiretroviral treatment, younger age, and high baseline viral load). Since studies were often not 
comparable with respect to these factors, comparison of the results of the different studies is 
complicated. It is striking that all four studies in which dosages of the administrated PI were 
adjusted after pharmacokinetic evaluation resulted in superior virological response rates compared to 
studies in which fixed dosages were used. (21, 23, 24 .. 36) Interindividual pharmacokinetic 
differences result in inadequate plasma PI levels in a part of the children treated with a fixed dose. 
(27, 34, 51-53) Since virological response is associated with plasma protease inhibitor levels, these 
inadequate plasma PI levels may be partly responsible for the differences in virological response 
rates. (27, 28, 32, 51, 52) In our opinion, it is therefore imperative to measure PI pharmacokinetics 
in all children treated with a PI to determine the individual dosage necessary for pharmacokinetic 
values comparable with adult values. 
The combination of nelfinavir with either a NNRTI or SQV and two NRTI's resulted in 
optimal virological responses in a high percentage of the patients. These twice daily regimens may 
result in an improved adherence to HAART compared to three daily medication schemes. (21, 33, 
36) Lopinavir/ritonavir, which was recently approved by the FDA is also a very promising compound 
because of twice daily dosing and the excellent virological response rates. (54) Future possibilities 
for once daily -or even less frequent- dosing are very important to improve adherence to 
antiretroviral therapy. Administration of indinavir with two NRlTs also leads to a good virological 
response rate in a high percentage of the patients. (20, 24) However, in a majority of the studies 
with indinavir virological response rates were suboptimal. (4, 5, 7-9, 28, 29) Since these studies 
differed substantially in follow-up time, baseline characteristics of the patients and study design 
these variable results are not well understood. 
Analyses of T-cell repopulation in groups of children with different ages are hampered by 
the fact that CD4+ T -cell counts are highly dependent on the age of the patients. (55, 56) The 
calculation of CD4+ T-cells as a percentage of the total T-cell counts is therefore used in many 
pediatric studies. However, data generated in this way are influenced by the major changes in the 
numbers of CDS+ T-cells in HIV-1-infected patients. (57-59) Immunological outcome parameters of 
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the different pediatric studies are therefore not comparable. Nevertheless, immunological response 
rates were more uniform than the virological responses. In almost all studies increases of CD4+ T-
cell counts are reported independent of the extent of the virological response. CD4+ T-cell numbers 
in HIV-1-infected children on HAART recover more rapidly than CD4+ T-cells in HIV-1-infected 
adults. (12, 57, 60-63) The good immunological response to HAART has been attributed to the large 
volume of the thymus, which is still present in young children. (64, 65) The observation that CD4+ 
T-cell counts recover despite the presence of virological failure may possible be explained by the 
selection of certain viral variants with resistance to protease inhibitors that have in-vitro impaired 
replicative capacity. (66) Douek et al. also reported an increase in peripheral CD4+ T-cell counts in 
both virologic responders and non-responders on antiretroviral therapy. (67) However, they 
observed that the recovery of thymic function was affected by the degree to which virus suppression 
was achieved when thymic function was measured by quantifying T-cell receptor rearrangement 
excision circles in peripheral blood. 
Side-effects of HAART were generally mild, transient and mainly of gastro-intestinal origin. 
lipodystrophy syndrome is commonly reported in HIV-1 infected adults treated with antiretroviral 
therapy. The occurrence of this syndrome consisting of a fat-wasting condition associated with 
abnormalities of lipid metabolism and Impaired glucose tolerance has been reported in 1.5-83% of 
HIV-1-infected adults. (68, 69) Only two groups investigated the incidence of lipodystrophy in 
children. The incidences in these studies were 29% and 33%. (70, 71) In both studies lipodystrophy 
was associated with advanced disease at baseline. Jaquet et al. observed a combination of 
peripheral atrophy and central adipositas in only two of a group of 39 pubertal children. In the other 
children only one of these features was observed. (71) Significant percentages of patients with 
serum lipid abnormalities were reported in three pediatric studies. (11, 23, 35) However, the 
investigators did not report signs of clinical lipodystrophy. The consequences of the lipodystrophy 
syndrome for the future treatment of HIV-1 infected children are not yet clear, because little is 
known about the pathophysiology, although it is generally believed that lipodystrophy has multiple 
causes and modes of presentation. Furthermore, it still remains to be clarified whether this 
syndrome is attributable to antiretroviral drugs. Another concern in long-term treatment of HIV-1 
infected children is the observation of an increased rate of bone turnover causing bone mineral 
density decrease. The severity of osteopenia seems to be related to lipodystrophy. {72) Long-term 
data on the comparison between PI containing regimens versus NNRTI containing medication 
schemes with respect to lipodystrophy and bone mineral loss are necessary to evaluate the 
contribution of the different antiretroviral drugs to the development of these abnormalities. 
The inferior virological response rates, which have been reported in HIV-1 infected children 
treated with HAART form a reflection of the challenges which are encountered in the treatment of 
children with HIV-1/AIDS. Difficulties with adherence and with the pharmacokinetics of protease 
inhibitors in children demand an intensive, child adjusted approach. Since HIV-1 infection in children 
is a rare disease in the Western world, and experience in the treatment is often insufficient, it may 
be more practical to treat children with an adjusted regimen that is not dependent of 
pharmacokinetic evaluation. This could be achieved by initiating therapy with a potent regimen to 
reduce the viral load to undetectable levels. Lopinavir/ritonavir is a very potent protease inhibitor 
and could thus be part of this induction regimen. Since drug levels are about 40 times above the 
IC50, pharmacokinetic monitoring is not necessary. However, long-term treatment with 
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lopinavir/ritonavir in children is complicated by the poor taste of lopinavir/ritonavir and by serious 
changes of lipid metabolism. (54) After viral load has been significan~y reduced, an easy to use 
maintenance regimen with less side-effects could be introduced to maintain long-term adherence. 
This maintenance regimen may contain for example nevirapine or abacavir. Future studies with 
induction-maintenance regimens are needed. The goal of these studies is to ensure similar efficacy 
and toxicity compared to those reported in adults. 
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Abstract 
Objective: To evaluate the clinical, immunologic and virologic response to indinavir, zidovudine and 
lamivudine in children with HIV-1 infection. Study design: Twenty-eight HIV-1 infected children, 3 
months to 16 years of age with or without prior treatment wfth reverse transcriptase inhibitors and a 
viral load of more than 5000 copies/ml and/or a CD4 cell count less than the lower limit of the age-
specific reference value were treated with indinavir, zidovudine and lamivudine. Pharmacokinetics of 
indinavir were determined in each child. Results: The combination treatment was well tolerated in 
the majority of the patients. In three patients, a transient hematuria was seen. Clinical improvement 
was seen in all patients. The median baseline HIV-1 RNA was 5.11og10 copies/mi. After six months 
of therapy, 70% of the patients had a HIV-1 RNA load below the detection limit of 500 copies/ml, 
whereas 48% of the children had a viral load below 40 copies/mi. Relative CD4 cell counts in relation 
to the lower limit of the age-specific reference value increased significantly from a median value of 
79% at baseline to 106% after six months of therapy. The doses of indinavir necessary to achieve 
AUC-values comparable to adult values varied from 1250 mg/m2/day to 2450 mg/m2/day. 
Conclusions: HMRT consisting of indinavir, zidovudine and lamivudine in children reduced HIV-1 
RNA to less than 500 copies/ml in 70% of the children within six months. In most of the patients 
improved CD4 cell counts were observed, as was a better clinical condition (no invasive or 
opportunistic infections, increased weight gain). Side effects of the triple therapy were mild and 
mainly of gastro-intestinal origin. HMRT may therefore be used as successfully in children as in 
adults. 
Introduction 
Since its introduction in 1996, combination therapies which include two reverse transcriptase 
inhibitors and a protease inhibitor have rapidly become standard therapy for HIV-1 infected 
adults.(1) However, so far the data on efficacy of these combinations in children with HIV-1 infection 
are limited, and are derived from studies with only small numbers of children. The relative 
immaturity of the immune system, differences in pharmacokinetics and pharmacodynamics of 
antiviral drugs and specific issues concerning adherence to therapy, complicate the extrapolation 
from therapeutic results in adults to those in children. 
Recent studies in children with HIV infection treated with a combination of two reverse 
transcriptase inhibitors showed superior results as compared to monotherapy.(2-12) 
Alternatively, monotherapy with the protease inhibitor indinavir resulted in marked -but only 
temporary- reductions of viral load in antiretroviral therapy na'ive and experienced adult patients, as 
well as in children. (13, 14) 
Several small observational and retrospective studies reported that triple therapy including 
a protease inhibitor may be as effective in pre-treated HIV-1 infected children as in adults, as shown 
by a decrease of viral load and an increase of CD4 cell count similar to those in antiretrovirally 
experienced adults. ( 4, 15-20) The measurement of these two surrogate markers has largely 
become the basis for the prediction of clinical and virologic response in adults. (21) Plasma HIV-1 
RNA levels and CD4 lymphocyte counts are also independent predictors of the clinical course in HIV 
infected infants and children.(6) 
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Here we report the results of the initial six months in a prospective, open, uncontrolled, 
Dutch multicenter study, which evaluates the clinical, immunologic and virologic response to 
combination therapy with indinavir, zidovudine, and lamivudine in children with HIV-1 infection. 
Methods 
Inclusion and exclusion criteria 
Children between the ages of 3 months and 18 years were eligible for enrolment. Children were 
included when the plasma HIV-1 RNA test was positive on two subsequent occasions (children less 
than 18 months old) or when the HIV serology was positive (children more than 18 months old) in 
the presence of one of the following abnormal test results: a mean HIV-1 viral load of more than 
5000 copies/ml (mean of two measurements with less than four weeks in between) and/or a CD4 
cell counts below 1 year: < 1750/mm3, 1-2 years: <1000/mm3, 3-6 years: <750/mm3, >6 years: 
<500/mm3 (22). Patients were excluded when they had been treated with antiviral agents other 
than zidovudine and/or didanosine or zalcitabine. There were no restrictions with regard to gender, 
ethnicity, or route of acquiring HIV-1 infection. 
Study protocol 
The study protocol was approved by the medical ethical committees of all the participating centers. 
Written informed consent was obtained from parents or legal guardians. Blood samples were taken 
twice before triple therapy was started ( 4-2 weeks and 2-0 weeks prior to initiation of the study) for 
hematological parameters (hemoglobin, hematocrit, white blood cell count, differential blood cell 
count, platelet count), serum biochemistry (sodium, potassium, calcium, albumin, liver enzymes, 
creatinine, urea, amylase, total bilirubin), immunoglobulin analysis, including IgA, IgG and IgM 
serum levels, virologic and immunologic parameters. The same tests were performed at days 7, 14 
and 28 after initiation of triple therapy and after 2, 3 and 6 months. Urine was co!lected for analysis 
at all timepoints. At each visit a physical examination was performed, weight and length were 
measured and parents were asked for the presence of adverse events. length-for-age scores and 
weight-for-length scores were determined using the Dutch reference CUJVes for age and gender. 
(23) These scores were also available for twenty-one children in the lifespan before HAART was 
started (hospital medical records and/or the school doctor or health center). We defined response of 
growth to treatment as catch-up up growth to the original percentile or showing an end to the 
ongoing deviation. in children with an impaired growth (deviation from the original percentile of 
length-for-age score and/or weight-for-length score) at baseline. lymphocyte subsets were analyzed 
with the FACSCount System (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA).(24) 
Plasma HIV-1 RNA quantitation was analyzed by an in vitro (-PCR) test (most samples: Amplicor 
HIV-1 monitor test version 1.5 Roche Diagnostic Systems and a few samples: NASBA assay, 
nuclisensHIV-1 RNA; Organon Teknika Bmcte[, The Netherlands) with a lower limit of detection of 
500 and 400 copies/mi. If plasma HIV-1 RNA was below this lower limit, plasma samples were 
subsequently tested with a modified, ultrasensitive procedure that increases the analytical sensitivity 
of the Amplicor HIV-1 monitor test to a detection limit of 40 copies/ml.(25) 
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Medication and pharmacokinetics 
Medication was given in the following doses: indinavir 400 mg/m2 every 8 hours, zidovudine 120 
mg/m2 every 8 hours and lamivudine 4 mg/kg every 12 hours. Indinavir was administered as 
standard-capsules of 200 mg and 400 mg or as capsules of 150 mg and 300 mg, which were 
prepared at the pharmacy. When patients were too young to swallow capsules, indinavir capsules 
had to be opened by the caregivers and dissolved in five to ten milliliters of water. In children in 
whom problems were encountered with the ingestion of indinavir, the drug was changed into 
nelfinavir (30 mg/kg every 8 hours). Zidovudine was administered either as syrup (10 mg/ml) or as 
capsules of 100 mg and 250 mg depending on the child's age. Lamivudine was administered as 
syrup (10 mg/ml) or as tablets of 150 mg. The importance of taking the indinavir one hour before or 
two hours after meals was repeatedly emphasized. Low fat food and drinks were allowed in this 
period before and after the medication. Parents received a list with low fat food and drinks that they 
could give to their children in this period. A day to day medication scheme including the times when 
no fat food or drinks were allowed was also given. 
At day 28 patients, were admitted to the day-care unit to determine the steady state 
pharmacokinetics of indinavir. When a dosage adjustment of indinavir was necessary to normalize 
the area under the curve-concentration (AUC) curve to adult values (20 mg/L *hr, range 10-30 
mg/L *hr), this procedure was repeated. 
Compliance 
Drug- compliance was assessed by interviews of the parents, by measurement of indinavir plasma 
levels and by medication diaries, which were made for each child individually. When possible children 
who were old enough were asked to apply stickers in their diaries every time they took their 
medication. These diaries were checked at every visit. When there were problems with compliance, 
coaching of parents and children was intensified. 
In the analyses poor compliance was defined as the patients in whom the interviews of the 
parents, the medication diaries andjor plasma levels of indinavir showed that serious (i.e. more than 
one time) problems with adherence to the medication scheme existed. Patients with good 
compliance were defined as the patients in whom according to the interviews, the medication diaries 
and the plasma levels of indinavir no problems were found. 
Adverse Events 
Adverse events were defined as any clinical sign or symptom, or meaningful laboratory-test 
abnormality, excluding disorders associated with HIV-1 infection. All adverse events were rated 
according to severity and relation to study drug. 
Statistical Analyses 
The primary measures of antiretroviral-drug activity were the magnitude and duration of changes in 
plasma HN-1 RNA and CD4 cell counts over a period of 6 months. One child dropped out of the 
study within one week (lost to follow-up). As no follow-up data of this child were available, the 
remaining twenty-seven patients were included in the intention to treat analyses. In the 
determinations of the median change from baseline, viral loads of patients below the detection limit 
were considered to be 40 copies/mi. For occasional missing data in this intention to treat analysis, 
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the last observation carried forward method was used to obtain viral loads. In 5.4% of the patients 
one or more values at key analysis time points (median: 1, range 1 to 4) were missing. Relative CD4 
cell counts in relation to the lower limit of the age-specific reference value (22) were calculated by 
dividing the individual value at the different time points by the lower limit of the reference value. 
Changes of CD4 cell counts and viral load results were evaluated using the Wilcoxon signed rank 
test. The relation between the plasma HIV-1 RNA levels at month six and various characteristics 
(baseline viral load, prior treatment, compliance) was investigated using multiple linear regression 
analysis for normally distributed data. In this analysis both viral load results were logarithmically 
transformed, and allowed for the fact that various children at month six had an HN-1 RNA load 
which was actually lower than the detection limit (i.e. left-censored data). (26) All p-values are two-
tailed. 
Results 
Twenty--eight HN-1 infected children were enrolled at 5 centers between April 1997 and July 1998. 
The evaluation of the first 24 weeks is presented in this report. Base line characteristics of the 
twenty-seven children of whom follow-up data are available are presented in Table 1. The median 
age of the children was 6.0 years (range: 3 months -16.6 years), twelve patients were not 
previously treated and fifteen had received prior treatment with nucleoside reverse transcriptase 
inhibitors, mostly with zidovudine monotherapy for an average of 34 months (range: 8-118). The 
median HN-1 RNA level was 127,500 copies/ml (range: 725-761,500). Eight children were too 
young to swallow capsules and received indinavir dissolved in water. Despite its bitter taste, six of 
these young children had no problems with it. Two other infants had problems with the 
administration of indinavir necessitating a change of indinavir into nelfinavir within two weeks after 
start of the therapy. 
In 19 of 27 patients (70%) the dose of the indinavir had to be increased according to the 
pharmacokinetics to achieve AUC-values between 10 and 30 mg/L *hr. In nine patients the dose had 
to be increased to 1500 mg/m2/day, in six patients to 1800 mg/m2/day, in one patient to 2000 
mg/m2/day and in two patients to 2450 mg/m2/day. In seven patients 1250 mg/m2/day was 
adequate. Because two patients were administered nelfinavir at day 28, no steady state 
pharmacokinetics of indinavir were determined in these patients. The pharmacokinetics of indinavir 
will be presented in more detail elsewhere. 
Ginical results 
All patients improved in their overall condition as shown by increased activity, an increased appetite 
and well being, as reported by their caregivers. No serious invasive or opportunistic infections were 
seen. In 81% (17/21) of the children a deviation of the original percentile in the length-for-age 
and/or weight-for-length reference curve (5 children a deviation in the length-for-age curve, 2 
children a deviation in the weight-for-length curve and 10 children in both curves) was observed at 
baseline. A response (catch-up growth or the end of ongoing deviation) was seen in 76% (13/17) of 
these patients. None of the patients showed progression of their CDC- classification stage and no 
AIDS-defining events did occur. Two patients were admitted to the hospital for a short period (ten 
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days): one because of hematuria and vomiting and the other because of hematuria and 
hypertension. 
Table 1: Baseline characteristics of the study patients 
Baseline characteristics 
Median age in years (range) 6.0 (0.3-16.6) 
Sex, male/female 14/13 
Race/ethnicity: 
Non-white 23 
White 4 
Route of acquisition: 
Vertical 21 
Blood products 4 
Unknown 2 
N1 2 A1 3 B1 0 C1 0 
Clinical stage (CDC-classification)*: N2 3 A2 4 B2 5 C2 1 
N3 0 A3 4 B3 1 C3 4 
No prior treatment: 14 
Prior treatment with: 
Zidovudine 11 
Zidovudine/zaldtabine 2 
Median copies of HN RNA/ml plasma (range) 127,500 (725-761,500) 
Naive to antiretroviral therapy 210,000 (23,900-761,500) 
Experienced to antiretroviral therapy 23,250 (725-718,00) 
*Clinical and Immunologic categories as defined by the US Centers for Disease Control and 
prevention (CDC). (32) 
HIV-1 virologic responses 
The levels of the viral load after start of HAART are demonstrated in Figure 1. Figure 1A shows the 
levels of HN-1 RNA of the patients with a good compliance. Figure 1B shows the levels of the viral 
load from the eight children with a poor compliance and from the two children who switched to a 
different medication scheme within two weeks after the treatment was started. One of the latter two 
children had also a poor compliance. Table 2 shows the median changes from baseline of the viral 
load and the proportion of patients whose viral load levels decreased to less than 500 and less than 
40 copies/ml in an intention to treat analysis. 
In Figure 2, scatterplots of the changes in viral load from baseline to month 6 against the 
baseline viral load are shown. Figure 2A shows the change of HN-1 RNA from baseline to month 6 
in all patients. Although the number of patients with poor compliance is small, these patients have 
less change in HN-1 RNA load compared to the patients with good compliance. In almost all patients 
with good compliance throughout the range of baseline HN-1 RNA loads an optimal response is 
seen. The two patients with the highest viral loads had an almost optimal response 6 months after 
the start of combination therapy. In Figures 2B and 2C the patients with prior treatment are 
separated from the na·ive patients. In all pre-treated patients with a good compliance an optimal 
response was seen and in all pre-treated patients with poor compliance a suboptimal response was 
seen. However, three of the five patients with prior treatment and with a poor compliance had a 
high baseline viral load (median 260,000, range 725-718,000 copies/ml), whereas all pre-treated 
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patients with a good compliance had a relatively low viral load (median 43,985, range 2,680-
761,500). Using multiple regression analysis the plasma HN-1 RNA at month six did not significantly 
correlate with baseline viral load and prior treatment. In case of poor compliance the median HIV-1 
RNA load at month six was found to be 158-fold higher (p<0.001) as compared to patients with an 
adequate compliance. 
The reduction in log HN-1 RNA was found to be different between children whose initial 
dose appeared adequate compared with those whose AUC values required an increase in dose. 
Baseline HN-1 RNA and the initial response until two months after the start of the therapy did not 
differ between the two groups. However, three and six months after the start of the therapy a 
statistically significant difference (p= 0.026 and p= 0.014) was found. 
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Figure 1A: Levels of HIV-1 RNA in 18 patients who completed therapy without documented poor compliance. 
Note the non-linearity of the horizontal axis. Patients who were experienced to antiretroviral treatment are 
represented by the dotted curves. Figure 18: Levels of HIV-1 RNA of the seven pab"ents with documented poor 
compliance and the two pab"ents (grey curves) who switched to a different medication scheme within two weeks 
after the start of the therapy. One of the latter was also non-adherent (indicated by *). 
Pab"ents who were experienced to anb"retrovira/ treatment are represented by the dotted curves, 
CD4 cell counts 
Because absolute CD4 cell counts are highly dependent on the age of the patients and on the stage 
of disease of the patients1 relative CD4 cell counts in relation to the lower limit of the age-specific 
reference value were calculated. Figure 3A shows relative CD4 cell counts in patients of all age 
groups. In the whole group of twenty-seven patients the median relative CD4 cell count (range) was 
79 % (2-250) at the start of the therapy and 69% (2-208) after 1 month of therapy. After 3 months 
there was an increase to a median of 82% (4-278) and after 6 months a significant (p= 0.007) 
increase to a median of 106% (2-266) was seen. Figure 38 shows the absolute CD4 cell counts in 
three different age groups ( <2 years, 2-5 years and > 5 years). The median absolute CD4 cell count 
(range) of all patients was 0.61 (0.01-4.99) at baseline, 0.52 (0.01-3.19) after 1 month, 0.66 (0.02-
3.56) after 3 months and 0.71 (0.01-4.38) after 6 months of treatment (p= 0.04). 
If patients with documented poor compliance were excludedr increases of CD4 cell counts 
were also not significant at time points before six months of therapy; after one month the median 
relative CD4 cell count decreased from 74% (2-250) before start of the therapy to 68% (2-208). 
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After three months relative CD4 cell counts were 76% (14-278) and after six months 106% (40-266) 
(p= 0,009). Figure 3C shows the absolute CD4 cell counts in three different age groups ( <2 years, 
2-5 years and > 5 years). The median absolute CD4 cell count (range) in these patients was 0.61 
(0.01-4.99) at baseline, 0.51 (0.01-3.19) after 1 month, 0.64 (0.07-3.56) after 3 months and 0.78 
(0.2-4.38) after 6 months of treatment (p= 0.05). In patients with documented poor compliance no 
significant changes of the CD4 cell counts were seen. 
Table 2: Virologic results 
Weeks after Median change of viral load Viral load Viral load Viral load Viral load 
start of the from baseline (range) < SOOc/ml <40c/ml <500 c/ml in <40 c/ml in 
treatment Ail p <0.001 case of good case of good 
comoliance comoliance 
1 Tot: -1.26 (-2.45 to +0.70) 0% 0% 0% 0% 
Na: -1.29 (-2.45 to +0.70) 
Exo: -1.24 r:2.25 to o.ocn 
2 Tot: -1.69 (-3.05 to +0.26) 0% 0% 0% 0% 
Na: -1.76 (-3.05 to +0.26) 
Exp: -1.59 (~2.86 to 0.00) 
4 Tot: -1.91 ( -2.50 to +0.43) Tot: 330/o 0% Tot: 47% 0% 
Na: -1.98 (-2.50 to +0.08) (9/27) (9/19) 
Exp: -1.90 (-2.44 to +0.43) Na: 20% Na: 25% 
(3/15) (3/12) 
Exp: 50% I 16/12) Exp: 86% I r6i7l 
12 Tot: -2.63 (-3.56 to +0.85) Tot: 67°/o Tot: 370/o Tot: 950/o Tot: 530/o 
Na: -2.96 (-3.56 to -0.35) (18/27) (10/27) (18/19) (10/19) 
Exp: -1.94 (-3.13 to +0.85) Na: 80% Na: 33% Na: 100% Na: 42% 
(12/15) (5/15) (12/12) (5/12) 
Exp: 50% I 16!121 
Exp: 42% 
I r5i12l 
Exp: 86% 
I r6/7l I ~)'J/1% 
24 Tot: -2.78 (-4.09 to +0.85) Tot: 70°/o Tot: 480/o Tot: 950/o Tot: 680/o 
Na: -2.96 ( -4.09 to -1.10) (19/27) (13/27) (18/19) (13/19) 
Exp: -1.94 (-3.24 to +0.85) Na: 80% Na: 47% Na: 92% Na: 58% 
(12/15) (7/15) (11/12) (7/12) 
Exp: 58% Exp: 50% Exp: 100% Exp: 86% 
(7/12) (6/12) (7/7) (6/7) 
Tot= total of the patients/ Na- nawe to antiretrowral therapy at base/me/ Exp- expenenced to antiretrovJra! 
therapy at baseline 
Adverse Events 
Combination therapy was well tolerated by almost all children. In two children, medication had to be 
switched to another combination within two weeks after starting indinavir. This was due to vomiting 
in one child and because of extreme dislike of the medication in another infant that could not 
swallow capsules. Five other patients had complaints of vomiting, three of nausea, two had diarrhea 
and four patients had a skin rash. Three patients had loss of appetite, three patients loss of weight 
and 3 patients hematuria, which resolved after discontinuing medication for two days and re-
emphasizing the importance of adequate fiuid intake. In total eleven patients (41%) of the twenty-
seven patients studied had adverse events. 
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Discussion 
In this study the twenty-four weeks results of treatment of H!Y-1 infected children with highly active 
antiretroviral therapy (HAART) consisting of indinavir, zidovudine and lamivudine are reported. A 
good clinical response was seen in all children. No serious invasive or opportunistic infections 
occurred since the initiation of triple therapy. Impaired growth was seen in 81% of the children at 
baseline and responded to therapy in 76% of the children with impaired growth at baseline. Ps 
growth seems to be one of the most sensitive indicators of disease progression in children and 
weight gain may be another indicator of antiretroviral therapeutic efficacy, growth is an important 
parameter. (27-30)0ur results show that in spite of the specific problems encountered in treatment 
of HIV-1 infected children, i.e. possible differences in phanmacokinetics and pharmacodynamics 
between adults and children, the relative immaturity of the immune system in young children, and 
specific pediatric issues concerning therapy compliance, HAART can be used as successfully in 
children as in adults. Since we observed substantial interindividual differences in the 
pharmacokinetics of indinavir in children (manuscript in preparation), we propose to measure 
indinavir pharmacokinetics (and possibly also pharmacokinetics of other protease inhibitors) to 
determine the individual dosage necessary for an area under the curve which is comparable with 
adult values. Combination therapy reduced the plasma HIV-1 RNA load to less than 500 copies/ml in 
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70% of the children and to less than 40 copies/ml in 48% of the children within six months of 
therapy. Viral load reductions were observed to less than 500 copies/ml in 95% of the patients at 
month six and to less than 40 copiesjml in 68% of the children at month six after exclusion of 
patients with documented poor compliance. These results are comparable to results obtained in 
adults. Gulick et al. reported a decline of the viral load to less than 500 copies/ml in 90% of the 
patients at week 24 with the same HMRT regimen. (1) Our results are particularly reassuring 
considering the fact that no preselection of patients was made on the basis of expected problems 
with compliance. The virologic response rate in this study is better than the one obtained by a 
combination of zidovudine and lamivudine in children, which resulted in a viral load less than 500 
copies/ml in only 46% of the patients after six months. (2) Indinavir alone gave less pronounced 
reductions in viral load than indinavir in combination with zidovudine and lamivudine, with a 
maximum decrease of 1.35 log10 after 24 weeks with a dosage of 1500 mg/m2/day. These reductions 
could not be sustained, since after 8 weeks of indinavir monotherapy viral load increased to 
approximately 0.5 log10 copies/ml below baseline. (14) Data from other studies with HAART 
consisting of a combination of a protease inhibitor and two reverse transcriptase inhibitors in 
children are limited. With median declines of the viral load varying from 0.6 log10 to 2.3 log10 after 24 
weeks of therapy none of these studies describes a decline of the viral load comparable to the 
median decline of this study (2.8 log10). ( 4, 16-20) 
Besides the marked reductions of plasma RNA load, a significant increase of CD4 cell count 
was seen with a median relative increase from 79% of the lower limit of the reference value to 
106% after 6 months of therapy. Plasma HN-1 RNA and CD4 cell count are both surrogate markers, 
but recent studies in children showed that plasma HN-1 RNA level and CD4 lymphocyte counts are 
independent predictors of clinical course. As in adults a linear, age-independent relationship exists 
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between log10 plasma RNA and relative risk of disease progression, which strongly supports 
therapeutic efforts to achieve plasma virus levels as low as possible. (6) 
The combination of indinavirr zidovudine and !amivudine was generally well tolerated. In 59 
% of the patients no adverse events were seen. Adverse events were mild and mainly of gastro-
intestinal origin. Hematuria that resolved under adequate hydration and a short discontinuation of 
the indinavir was seen in only three patients. In contrast to adults where in 12% of the patients 
clinical nephrolithiasis was reported (l)r no nephrolithiasis was seen. 
In children special attention is needed to achieve good compliance in the ingestion of antiretroviral 
drugs. Even under study conditions, eight of twenty-seven patients (29%) had problems with the 
strict regimenr which resulted in less reduction in viral load. In order to facilitate compliance~ a 
pediatric formulation of indinavir is urgently needed. 
As low plasma concentrations of indinavir are a major and independent risk factor for 
virologic treatment failure (31), calibration of the pharmacokinetics of indinavir (data not shown) to 
adequate adult values makes this study unique and may be partial responsible for the good results. 
Although our results have not been obtained by a controlled trialr comparison with previous studies 
with indinavir monotherapy and therapy with two reverse transcriptase inhibitors makes it highly 
unlikely that these therapies would have resulted in comparable results. 
Taken together, our data show that combination therapy consisting of a protease inhibitor 
and two reverse transcriptase inhibitors is as efficacious and generally well tolerated in children as in 
adults. 
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Abstract 
Clinical, virological and immunological responses to treatment with either indinavir or nelfinavir and 
zidovudine and lamivudine were determined in 32 HN-1 infected children who participated for at 
least 96 weeks in an prospective, open, uncontrolled multicenter trial. The pharmacokinetics of 
indinavir or nelfinavir were determined and showed large interindividual differences. After 96 weeks 
of therapy, 69% and 50% of the patients had an HN-1 RNA load below the detection limit of 500 
and 40 copies/ml respectively. Virological failure was associated with poor compliance and younger 
age (independent of baseline viral load and pretreatment). Relative CD4 cell counts in relation to the 
median of the age-specific reference value increased significantly from a median value of 44% at 
baseline to 94% after 96 weeks. In a high percentage of the children clinical, virological and 
immunological response rates to combination therapy were optimal during the initial two years of 
therapy. 
Introduction 
Combination therapy consisting of one protease-inhibitor and two nucleoside-analogues has yielded 
impressive long-term clinical, virological and immunological improvements in HIV-1 infected adults. 
(1-6) However, in most pediatric studies virological response rates to HAART are inferior to those in 
adults. (7-15) Since virological suppression is associated with long-term success of HMRT, this may 
have major clinical implications for the future health of these children. (16-18) 
The institution of optimal treatment strategies in HIV-1 infected children poses a enormous 
challenge. First, large interindividual differences of pharmacokinetics of antiretroviral drugs, 
especially of protease inhibitors, complicate an optimal dosing of antiretroviral drugs in children. 
Secondly, it is difficult to maintain adherence to combination therapy during the years following the 
initiation of HAART. Problems such as the intake of evening medication during sleeping time or 
afternoon medication during schoolhours, unwillingness of young children and adolescents to take 
medication and poor palatability and side-effects of medication have to be dealt with. 
To date, there are no published data on the long-term follow-up (96 weeks) of HN-1 infected 
children, who are treated with HMRT. 
We here report the 96 weeks results of a prospective, open, uncontrolled, multicenter 
study on the clinical, immunological and virological response to therapy with either indinavir, 
zidovudine, and lamivudine or nelfinavir, zidovudine and lamivudine in 32 children with HIV-1 
infection. 
Methods 
PI naive HN-1 infected children with a viral load above 5000 copiesfml and/or a CD4 cell count 
below their age-specific reference value were included. 
The study protocol was approved by the medical ethical committees of all participating 
centers. Written informed consent was obtained from parents or legal guardians. Patients' medical 
histories, physical examination and laboratory analyses were analyzed twice before the initiation of 
the medication and after 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96 weeks. (3) lymphocyte 
subsets were analyzed with the FACSCount System (Becton Dickinson Immunocytometry Systems, 
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San Jose, CA, USA).(25) Plasma HIV-1 RNA quantitation was analyzed by an in vitro (-PCR) test 
(most samples: Amplicor HIV-1 monitor test version 1.5 Roche Diagnostic Systems and a few 
samples: NASBA assay, nuclisensHIV-1 RNA; Organon Teknika Boxtel, The Netherlands) with a lower 
limit of detection of 500 and 400 copies/mi. Plasma samples with an HIV-1 RNA <500 copies/ml 
were subsequently tested with an ultrasensitive Amplicor HIV-1 monitor test with a detection limit of 
40 copies/ml.(26) 
Medication and pharmacokinetics 
Medication was prescribed in the following doses: indinavir 400 mg/m2 q8h or nelfinavir 30 mg/kg 
q8h, zidovudine 120 mg/m2 q8h, lamivudine 4 mg/kg q12h. When patients were too young to 
swallow capsules, indinavir capsules were opened by the caregivers and were dissolved in five to ten 
milliliters of water. The importance of food restrictions (administration of indinavir one hour before 
or two hours after meals and administration with a meal) was repeatedly emphasized. A day to day 
medication scheme including the times with food restrictions was given. 
At week 4, patients were admitted to determine the steady state pharmacokinetics of 
indinavir or nelfinavir. When a dosage adjustment of indinavir or nelfinavir was necessary to 
normalize the area under the curve-concentration (AUC) curve to adult values (indinavir: 20 
mg/L *hr, range 10-30 mg/L *hr, nelfinavir: 13-20 mg/L *hr), this procedure was repeated. 
Compliance 
Drug- compliance was assessed by interviews of the parents, by measurement of indinavir or 
nelfinavir plasma levels and by medication diaries. The coaching of parents and children was 
intensified, when problems with compliance were encountered. When the interviews of the children 
or their parents, the medication diaries and/or plasma levels of indinavir or nelfinavir showed that 
serious (i.e. more than one time) problems with adherence to the medication scheme existed, these 
children were considered to be poorly compliant. Patients with good compliance were defined as 
those in whom according to the interviews, the medication diaries and the plasma levels of indinavir 
or nelfinavir no problems (or only problems at one visit) were found. 
Adverse Events 
Adverse events were defined as any grade clinical sign or symptom, or meaningful laboratory-test 
abnormality, excluding disorders associated with HIV-1 infection. All adverse events were rated 
according to severity and relation to study drug. 
Statisb"cal Analyses 
Children who started with therapy at least 96 weeks before the time that analysis was performed 
were included. In the analysis of the median change from baseline, viral loads of patients below the 
detection limit were considered to be 40 copies/mi. At each time point (week) we calculated the 
percentage of patients from which the values were below the detection limit (500 or 40 copies/ml). 
For occasional missing data in the intention to treat analysis, we considered the response value as 
greater than the detection limit concerned. Relative CD4 cell counts in relation to the median of the 
age-specific reference value (27) were calculated by dividing the individual value at the different 
time points by the median of the reference value. The calculation of CD4+ T-cell counts in relation to 
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the median of the age·specific reference value results in an independent parameter for the degree of 
CD4+ T-cell restoration. Because absolute CD4+ T-cell counts are highly dependent on the age of 
the patients, the magnitude of these changes depends on the age distribution of the cohort. In order 
to solve this problem, the number of CD4+ T-cells is commonly presented as a percentage of the 
total T-cell count. However, this parameter is influenced by the major changes in the number of 
CDS+ T-cells which are observed in HIV-1 infected patients. 
Changes of CD4 cell counts were evaluated using the Wilcoxon signed rank test. The 
relation between the plasma HIV-1 RNA levels at week 96 and various characteristics (baseline viral 
load, prior treatment, compliance and age) was investigated using multiple linear regression analysis 
for normally distributed data. In this analysis both viral load results were logarithmically transformed, 
and allowed for the fact that various children at week 96 had an HIV-1 RNA load which was actually 
lower than the detection limit (i.e. left-censored data). (28) All p-values are two-tailed. 
Z-scores to evaluate growth were used to express the deviation (in standard deviation (SD) 
units) from the Dutch reference curves for age and gender. (7, 8) 
Results 
Thirty-two HIV-1 infected children were enrolled at 5 centers. Baseline characteristics of the thirty-
two children are depicted in Table 1. The median age of the children was 5.4 years (range: 3 
months to 16.4 years), seventeen patients were not previously treated and fifteen had received prior 
treatment with nucleoside analogues (mostiy zidovudine monotherapy). The median HIV-1 RNA level 
was 136,385 copies/ml (range: 2,680-761,500). In table 2 the number of patients using either 
indinavir or nelfinavir at each time point are presented and if applicable the reason of switch or stop 
is mentioned. Twenty-seven patients started with an indinavir containing regimen and five children 
started with a nelfinavir containing regimen. Eight children were too young to swallow capsules and 
received indinavir dissolved in water. 
In eight children, indinavir was switched to nelfinavir after a median period of 48 weeks 
(range 2-72). In six children the medication was changed because of virological failure, in two other 
children because of toxicity (interstitial nephritis) and because of reluctance to swallow indinavir 
dissolved in water. In one child indinavir was switched to indinavir/ritonavir (500/100 mg/m2 q8h) 
after 60 weeks, because of virological failure. At week 72 indinavir/ritonavir was changed into 
nevirapine because of an interstitial nephritis. Five children were lost to follow-up (after 24, 24, 60, 
60 and 60 weeks). 
Twenty children (62%) were defined as children with a good compliance and twelve 
children met the criteria for poor compliance (38%). 
Pharmacokinetic results 
In eight patients a dose of 400 mgjm2 q8h of indinavir was adequate. In one patient indinavir was 
discontinued before pharmacokinetics were performed. In 18 of 26 patients (69%) the dose of the 
indinavir was increased in order to achieve AUC-values between 10 and 30 mg/L *hr. In eight 
patients the dose had to be increased to 500 mg/m2 q8h, in one patient to 550 mg/m2 q8h, in six 
patients to 600 mg/m2 q8h, in one patient to 660 mg/m2 q8h and in two patients to 800 mg/m' q8h. 
Large interindividual differences in the pharmacokinetics of indinavir have been observed and have 
been presented in more detail. (9) 
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Five children started with nelfinavir. In three children adequate AUC values of nelfinavir 
were achieved with doses of 17, 24 and 27 mg/kg q8h. In two children the dosage was increased 
from 30 mg/kg q8h to 40 and 45 mg/kg q8h. 
Table 1: Baseline characteristics of the study patients 
Median age in years (range) 
sex (male/female) 
Racejethnicity 
White 
Non-white 
Route of transmission 
Vertical 
Blood products 
Unknown 
Clinical stage (CDC classification)* 
N1 
N2 
N3 
2 
3 
1 
No prior treatment 
Prior treatment with 
HAART 
Zidovudine 
Zidovudine/zalcitabine 
Zidovudine/didanosine 
Zidovudinejlamivudine 
Zidovudinejlamivudine/didanosine 
IDV /ZVD/3TC 
NFV /ZDV /3TC 
NFV/d4T/dd1 
A1 
A2 
A3 
Median copies of HIV-1 RNA/ml plasma (range) 
Naive to antiretroviral therapy 
Experience with antiretroviral therapy 
3 
5 
4 
5.4 (0.4-16.4) 
18/14 
3 
29 
23 
4 
5 
B1 
B2 
83 
17 
11 
1 
1 
1 
1 
27 
3 
2 
1 
5 
1 
C2 
0 
136,385 (2,680-761,500) 
250,000 (23,900-761,500) 
29,300 (2,680-718,000) 
*Clinical and Immunologic categories as defined by the us Centers for Disease Control and 
prevention (CDC). (37) 
Oinica/ results 
2 
1 
Serious invasive or opportunistic infections were only seen in one patient with poor compliance. The 
BMI Z score increased significan~y (p=O.OS) during the follow up period from a median (interquartile 
range (IQR)) of -0.5 (-1.4 to 0.6) at baseline to 0.2 (-0.7 to 0.6) after 96 weeks of HAART. The 
median of height Z scores did not increase significantly, but height Z scores of fifteen (47%) 
individual children did increase during 96 weeks of HAART (data not shown). In the other children Z 
scores decreased. 
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Table 2: the distribution of the numbers of patients among the protease inhibitors at each time 
oint. 
Week IDV NFV 
0 
1 
2 
4 
8 
12 
24 
36 
48 
60 
72 
84 
96 
N= n= 
27 5 AlS, 
27 
26 
26 
26 
26 
21 
20 
19 
15 
5 
A16, 
IQO, 
804, 
805 
6 +A24 
6 
6 
6 
8 +Al9, 
+803 
10 +A17, 
+E02 
11 +A04 
11 
13 12 +A07, 
+!W., 
-A19 
13 12 
13 12 
HIV-1 virologic responses 
IDV/ 
RTV 
n= 
1 +E02 
0 -E02 
1 +A11 
0 -Ali 
0 
0 
NVP 
n= 
1 +All 
1 
1 
NFV/ 
RTV 
n= 
1 +Al9 
Stop/lost 
to follow up 
n= 
2 +A15 
-EO! 
2 
2 
5 +A01, 
+DOl 
-COl 
5 
5 
5 
Reason switch 
Taste IDV 
A19: virological 
failure, B03: 
wish of the 
patient, E02: 
virological 
failure, AlS: 
moved to other 
country, EOl: 
lost to follow up 
A17: virological 
failure, E02: 
possible toxicity 
A04: virological 
fallure 
All: virological 
failure,AOl: 
death, DOl: 
severe 
psychological 
problems, COl: 
lost to follow up 
A07: toxicity, 
A22: virological 
failure, All: 
toxicity, A19: 
virological failure 
The levels of the viral load after start of HAART in children with good compliance and children with 
poor compliance are demonstrated in Figure lA and lB. The median (IQR) changes from baseline of 
log1o HIV-1 RNA in all patients were -2.0 (-2.3 to -1.8) at week 4, -2.7 (-3.0 to -1.8) at week 12, -2.7 
(-3.1 to -1.8) at week 24, -2.7 (-3.2 to -2.0) at week 48 and -2.6 (-3.6 to -1.8) at week 96. Figure 2 
shows the proportion of patients whose viral load levels decreased to less than 500 and less than 40 
copies/ml in an as treated and an intention to treat (missing value equals failure) analysis. In 
children with a good compliance the percentages of children with an HIV-1 RNA below the detection 
limit of 500 and 40 copies(ml were higher compared to the children with a poor compliance: at week 
48 90% and 56% versus 42% and 1% respectively and at week 96 85% and 65% versus 1% and 
0% respectively. 
Multiple regression analysis of the parameters compliance, pretreatment, baseline viral load 
and age showed that compliance and age were significantly related with viral load. In patients with a 
poor compliance the log10 HIV-1 RNA was 2.5 (p<O.OOl) higher than in patients with an adequate 
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compliance. For age the log10 HIV·1 RNA at week 96 decreased 0.12 (p~0.02) for each year. 
Baseline viral load and prior treatment did not significantly correlate with the plasma HIV-1 RNA at 
week 96. 
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Figure 1A: Levels of HIV-1 RNA in 20 patients who completed therapy without documented poor compliance. 
Figure 18: Levels of HIV-1 RNA of the 12 patients with documented poor compliance. 
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Figure 2: The proportion of patients whose viral load levels decreased to less than 500 and less than 40 
copies/ml in an as treated and an intention to treat analysis. 
AT.· As Treated analysiS in which only children who were receiving treatment were induded 
ITT: Intention To Treat (Missing value = Failure) analysiS in which HIV-1 RNA levels were assigned a 
value of more than 500 or 40 copiesjml for all missing values, induding visits after discontinuation of 
treatment. 
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CD4 cell counts 
Figure 3A shows relative CD4+ T-cell counts of patients in three different age groups ( <2 years, 2-5 
years and > 5 years). In the group of thirty-two patients the median relative CD4 cell count (IQR) 
was 44% (29-68) at the start of the therapy and 72% (54-109) after 48 weeks. After 96 weeks a 
significant (p< 0.001) increase to a median of 94% (54-116) was observed. Figure 36 shows the 
absolute CD4 cell counts in three different age groups ( <2 years, 2-5 years and > 5 years). The 
median absolute CD4+ T-cell count (IQR) of all patients was 545 x 106 cells/L (285-903) at baseline, 
895 x 106 cells/L ( 493-1505) after 48 weeks and 980 x 106 cells/L ( 493-1402) after 96 weeks of 
treatment (p= 0.002). 
After 72 weeks CD4+ T-cell counts reach a plateau, which is equivalent to the CD4+ T-cell 
counts in healthy children. In children younger than 2 years absolute CD4+ T-cell counts even 
decreased after 72 weeks, reflecting the normal age-related strong decline of CD4+ T-cell counts in 
children at this age. 
The change of the CD4+ T-cell count as percentage of normal from baseline was not significantly 
different between the age groups at any time-point. 
The immunologic reconstitution (absolute CD4+ T-cell counts, CD4+ T-cell counts as 
percentage of normal, CD4+ T-cell counts as percentage of total T-cell count) was not different at 
any time-point in virologic responders (HN-1 RNA at week 48 < 500 copies(ml) and virologic non-
responders. 
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Figure 3A: Median relative (% of normal) CD4 cell counts of all pab"ents. Pab'ents are divided into three groups 
according to age related differences in reference values 
Figure 38: Median absolute CD4 cell counts of all patients. Pab'ents are divided into three groups according to 
age related differences in reference values 
Adverse Events 
Although seventeen (53%) out of the thirty-two patients had adverse events, combination therapy 
was well tolerated by almost all children. The majority of the adverse events were mild and occurred 
during the initial phase of the treatment. The most common indinavir related side-effects were: 
diarrea (n= 6), vomiting (n=6), loss of appetite (n=S), headache (n=3), abdominal pain (n=4) and 
110 
" 
Two year treatment results using protease inhibitor containing therapy 
hematuria (n=S), which resolved after discontinuing medication for two days and re-emphasizing the 
importance of adequate fluid intake. In two children, indinavir was switched to another antiretroviral 
agent (one to nelfinavir and one to nevirapine) because of an interstitial nephritis after 72 weeks. 
The renal function and renal ultrasounds normalized after the switch. Two children had nelfinavir 
related side-effects: diarrea (n=1) and loss of appetite (n=1). 
Clinically overt lipodystrophy was not observed. 
To compare the frequency of indinavir and nelfinavir related side effects, the number of 
episodes with one or more adverse events and the total number of weeks that patients used 
indinavir or ne!finavir were calculated. 0.4 indinavir related episodes with side effects per patientyear 
were observed versus 0.16 nelfinavir related episodes with side effects per patientyear. 
Discussion 
In this study the long-term clinical, virological and immunological response to HAART, consisting of 
one protease inhibitor (mostly indinavir) and two nucleoside analogues, was evaluated in thirty-two 
HN-1-infected children. Although twelve of thirty-two patients (38%) had problems with adherence 
to the regimen, a good clinical response was seen in all children. New serious invasive or 
opportunistic infections only occurred in one patient with poor compliance. The BMI Z score 
increased significantly during the follow up period. The median of height Z scores did not increase 
significantly, but height Zscores of fifteen (47%) individual children did increase during 96 weeks of 
HAART. Since growth seems to be one of the most sensitive indicators of disease progression in HIV-
1 infected children, growth is an important parameter. (10-13) 
Analyses of the virological response data showed that these are consistent with the 
previously observed finding that a similar rate of suppression of HIV replication can be obtained in 
children during the first year of treatment (1, 2, 6, 14) as compared to adults (15, 16). In addition, 
we demonstrated that virological suppression can be retained by the majority of the children during 
96 weeks follow-up. In 69% of the children HN-1 RNA was below the detection limit of 500 
copies/ml and in 50% of the children below the detection limit of 40 copies/ml after 96 weeks. Even 
in the conservative intention-to-treat analysis in which missing values were assigned a value of more 
than 500 or 40 copies/ml, 56% and 41% of the children had a viral load below the detection limit of 
500 and 40 copiesjml respectively. In contrast to the percentage of patients with a viral load <40 
copies/ml, the percentage of patients with a viral load <500 copies/ml decreased during the second 
year of follow up. This indicates that in children with a viral load between 500 and 40 copies/ml 
long-term virological outcome is worse compared to children with a viral load <40 copies/mi. Raboud 
et a! have reported similar observations in adults. (17, 18) It remains to be studied, whether a 
suboptimal virological response rate two years after initiation of HAART is associated with a 
decreased long-term clinical and immunological response rate. 
The virological results in our study are less good than those obtained in adults. Gulick et al. 
reported a decline of the viral load to less than 500 copiesjml in 78% of the patients and to less 
than 50 copies/ml in 66% of the patients at week 96 with indinavir, zidovudine and lamivudine. (16) 
However, it is difficult to compare data from a their study-population with data from this cohort in 
which no selection on the basis of expected compliance was made. The virological response rate in 
our study (69% <500 copies/ml after 96 weeks) is high as compared to those in most pediatric 
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studies. (19-27) All four studies which optimized the dosage of PI's on the basis of pharmacokinetic 
analyses showed superior virological response rates compared to those in which standard dosages 
were used. (1-3, 5) Interindividual pharmacokinetic differences result in inadequate plasma PI levels 
in a part of the children treated with a fixed dose. (3, 9, 28-31) Since virological response is 
associated with plasma protease inhibitor levels, inadequate plasma PI levels may be partly 
responsible for the differences in virological response rates. (9, 28, 29, 32, 33) We therefore advise 
to measure PI levels in all children treated with a PI to reach optimal AUC levels as have been 
determined in adults. 
The inferior virological results which have been reported in HIV-1 infected children treated 
with HAART (19-27) may be a reflection of the challenges which are encountered in the treatment of 
children with HN-1/AIDS. Difficulties with adherence and with pharmacokinetics of protease 
inhibitors in children demand an intensive, child adjusted approach. In addition, inferior virological 
results in children have also been attributed to high initial viral loads in children. Children tend to 
have higher baseline viral loads than adults (34), which have been associated with a smaller 
reduction in viral load (2, 14, 25). Interestingly, we found no correlation between baseline HIV-1 
RNA and virological response. However for age and virological response there was a significant 
correlation in a multivariate analysis. Younger children have significantly less viral load reduction 
regardless of compliance, pretreatment and baseline viral load. Due to the small sample size 
interpretation of this finding is difficult. 
CD4+ T-cell counts increased significantly after the initiation of the therapy from 545 x 106 
cells/L (285-903) at baseline to 980 x 106 cells/L ( 493-1402) after 96 weeks of treatment (p= 
0.002). The median CD4 cell count as percentage of normal (IQR) was 44% (29-68) at the start of 
the therapy and after 96 weeks a significant (p< 0.001) increase to a median of 94% (54-116) was 
seen. After 72 weeks of therapy CD4+ T-cell counts reached a plateau, which is equivalent to the 
CD4+ T-cell counts in healthy children. 
Immunologic reconstitution was observed to same degree in virologic responders (HIV-1 RNA at 
week 48 < 500 copiesjml) and virologic non-responders. 
The HAART regimens were generally well tolerated. In 47 % of the patients no adverse 
events were seen. The majority of the adverse events occurred during the initial phase of the 
treatment. They were mild and mainly of gastro-intestinal origin. Hematuria which resolved under 
adequate hydration and a short discontinuation of the indinavir was seen in five patients. In two 
patients an interstitial nephritis occurred after 72 weeks of therapy. Nephrolithiasis was not observed 
in contrast to the situation in adults where clinical nephrolithiasis was reported in 12% of the 
patients. (35) Since elevated plasma concentrations of indinavir have been associated with urological 
complications (36), calibration of the pharmacokinetics of indinavir (data not shown) to adequate 
adult values may have contributed to the low incidence of urological symptoms. 
Indinavir related side-effects seem to occur more frequently than nelfinavir related side-
effects (0.4 versus 1.6 episodes per patientyear) However, this study was not designed to compare 
nelfinavir and indinavir containing regimens. 
This study emphasis the need for special attention in children to achieve good compliance 
in the ingestion of antiretroviral drugs. Even under strict study conditions, twelve of thirty-two 
patients (38%) had problems with the regimen, which resulted in a decreased reducton of the viral 
load. A simplified dosing regimen may contribute to achieve an improved compliance. In conclusion, 
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our data show that in a high percentage of the children clinical, virological and immunological 
response is optimal after two years of therapy. 
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Abstract 
Objective: To evaluate long-term immune reconstitution of children treated with HAART. Design: 
Two prospective, open, uncontrolled national multicentre studies. Methods: We studied the long-
term immunological response to HAART in 71 HIV-1-infected children (age: 1 month to lS years). 
Blood samples were taken before and after HAART was initiated with a follow-up of 96 weeks. 
Lymphocyte immunophenotyping for peripheral CD4+ T-cells, CDS+ T-cells, naive and memory 
subsets was performed on whole blood samples. Relative CD4+ - and CDS+ T-cell counts were 
calculated in relation to the median of the age-specific reference. Results: The absolute CD4+ T-cell 
count, CD4+ T-cell percentage and CD4+ T-cell count as percentage of normal increased 
significantly (p<0.001) to a median of 939 x 106 cells/L (range 10-3520), 32% (range 1-50%) and 
S4% (range 1-161%) respectively after 4S weeks. This increase was predominan~y caused by naive 
CD4+ T-cells. We found a correlation between the increase of absolute naive CD4+ T-cell counts 
and age. However, when CD4+ T-cell restoration was studied as percentage of normal values, the 
inverse correlation between the increase of naive CD4+ T-cell count and age was not observed. In 
addition, no difference in immunologic reconstitution was observed at any time-point between 
virologic responders and non-responders. Conclusions: Normalisation of the CD4+ T-cell counts in 
children treated with HAART is age-independent, indicating that children of all age-groups can meet 
their CD4+ T cell production demands. In general, it appears that children restore their CD4+ T-cell 
counts better and more rapidly than adults, even in a late stage of HIV-1 infection. 
Introduction 
Highly active antiretroviral therapy (HAART) has only recen~y been applied in children infected with 
HIV-1. The use of HAART leads to a reduction in plasma HIV-1 RNA loads to undetectable levels in a 
high percentage of these children and results in a significant recovery of CD4+ lymphocyte counts. 
(1-6) 
In adults immune reconstitution following HAART shows a biphasic pattern consisting of an 
initial rapid redistribution of memory cells and a gradual slow increase in naive T-cells. (7, 8) 
Children with HIV-1 infection have a greater capacity to reconstitute their naive CD4+ T-cells when 
compared to HIV-1-infected adults treated with similar antiretroviral therapy. (6) This is not an 
unexpected finding, since naive T-cell recovery is believed to be thymus-dependent and thymic 
function diminishes with age. (9, 10) Increased production of naive cells is associated with thymic 
enlargement in children treated with anti-cancer chemotherapy as well as in children treated with 
HAART as shown on radiographs or by magnetic resonance imaging. (9, 11, 12) 
CD4+ T-cell numbers in HIV-1-infected children on HAART recover more rapidly than CD4+ 
T-cells in HIV-1-infected adults. (6, 11, 13-16) However, it is still unclear to what extent the number 
of CD4+ T-cells of HIV-1-infected children is capable to normalise, since data on long-term T-cell 
dynamics in HIV-1-infected children on HAART are not available. In a considerable number of HIV-1-
infected adults treated with HAART, CD4+ T-cell numbers stabilised or even slightly decreased after 
1 'h years of therapy, sometimes without having reached normal levels. (17) We evaluated the long-
term immune reconstitution in HIV-1-infected children who were treated with HAART, consisting of 
one protease inhibitor and two nucleoside reverse transcriptase inhibitors during a period of 96 
weeks. We analysed changes in the number of CD4+ T-cells, CD4+ T-cell naive and memory subsets 
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and CDS+ T-cell counts and compared those to the normal values that were previously reported for 
the different age groups. (1S, 19) 
In addition to the quantitative analyses, T-cell function after stimulation with CD3 mAb plus 
CD2S mAb was analysed. 
Methods 
Patients 
Seventy-one HIV-1-infected children were enrolled in two prospective, open, uncontrolled, studies to 
evaluate the clinical, immunological and virological response to combination therapy with either 
indinavir, zidovudine and lamivudine or nelfinavir, stavudine and lamivudine. Inclusion and exclusion 
criteria for these studies were equal and have previously been described in detail. (3) Children 1 
month to 18 years of age, with or without prior treatment with reverse transcriptase inhibitors, and a 
viral load of more than 5000 copies/ml or a CD4+ T-cell count less than the lower limit of the age-
specific reference value were eligible for enrolment. Study protocols were approved by the medical 
ethical committee of all participating institutions. Written informed consent was obtained from the 
parents or the legal guardian. Blood samples were taken before HAART was started (2-0 weeks prior 
to initiation of the study) and 1, 2, 4, S, 12, 24, 36, 48 and 96 weeks after the initiation of 
combination therapy. Medication was given in the following doses: indinavir 400 mg/m2 q8h, 
nelfinavir 30 mg/kg qSh, zidovudine 120 mg/m2 qSh, lamivudine 4 mg/kg q12h and stavudine 1 
mg/kg q12h. Multiple dose pharmacokinetics of either indinavir of nelfinavir were determined four 
weeks after HMRT was initiated. A dosage adjustment of indinavir or nelfinavir was done when 
necessary to adjust the area under the time concentration (AUC) curve to adult values. 
Immunophenotyplng and T-ee// function ln vitro 
Lymphocyte immunophenotyping of peripheral CD4+ and CDS+ T cells was performed on lysed 
whole blood samples by fiow cytometry using triple staining. Lymphocytes were phenotyped as naive 
and memory CD4+ and CDS+ T-cells by three-color immunofiuorescence fiow cytometry using 
combined staining with CD45RA and CD 62L (L-selectin) or CD27 monoclonal antibodies (mAb). T 
cells expressing both CD45RA and CD62L or CD27 were considered truly naive cells, whereas cells, 
which lacked either CD45RA and CD62L or CD27 were regarded as memory cells. (20, 21) 
Previously, it has been demonstrated that naive and memory subset distribution as measured with 
either CD45RA and CD62L mAb or CD45RA and CD27 mAb yielded identical results. (22) 
T-cell function was determined in whole-blood lymphocyte culture (23). Proliferative 
responses to CD3 mAb plus CD2S mAb were measured after 4 days of culture by means of the 
incorporation of 3H-thymidine added 24 hours before harvest. (24) Proliferative capacity was 
calculated as counts per minute (CPM) per 103 CD3+ T-cells and results are expressed as percentage 
of the median of 3450 healthy adult donors (24). 
Plama HIV-1 RNA determination 
Plasma HIV-1 RNA levels were measured by an in vitro nucleic acid amplification test (AMPUCOR 
HIV-1 MONITOR Test (Roche Diagnostic Systems) with a lower limit of quantification of 500 
copies/ml, by the NASBA assay (Nuclisens HIV-1 RNA; Organon Teknika, Boxtel, The Netherlands) 
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with a lower limit of quantification of 400 copies/ml or by the Quantiplex b DNA test (Bayer, The 
Netherlands) with a lower limit of quantification of 50 copies/mi. The test used at baseline was also 
used at every follow-up visit. The on-treatment-analysis method was used to calculate percentages 
of patients with an HIV-1 RNA below the lower limit of quantification (LLQ) of 500 copies/mi. 
Statistical analysis 
All patients with analyses made at baseline (in ten patients in which baseline values were missing, 
analyses at week 1 were considered as baseline) and at least 12 weeks of follow-up were included. 
SPSS 9.0 (SPSS, Chicago) was used for statistical analysis. Because absolute CD4+ T-cell counts are 
highly dependent on the age of the patients and on the stage of disease, relative CD4+ T-cell counts 
(total CD4+ T-cells and naive CD4+ T-cell counts) in relation to the median of the age-specific 
reference values (18, 19) were calculated by dividing the individual value at the different time-points 
by the median of the reference value at the different time-points. Results are expressed as 
percentage of normal. Since CD4+ T-cell percentage of total T-cells is influenced by changes in the 
number of CDS+ T-cells, calculation of CD4+ T-cell counts as percentage of normal, results in a 
parameter that is independent of CDS+ T-cell count. Correlation coefficients were obtained by 
Spearman rank correlation. Differences between paired variables were analysed with the Wilcoxon 
signed ranks test and between groups with the Mann-Whitney Utest. All p-values are two-tailed. 
Results 
Baseline characteristics of the seventy-one patients are presented in Table 1. Forty-two of 71 (59%) 
patients were not pre-treated and 29 of 71 (41%) patients had received prior treatment with 
nucleoside reverse transcriptase inhibitors (mostly with zidovudine monotherapy for an average of 
32 months). Thirteen children with prior zidovudine therapy were placed on the stavudine arm, 
whereas the other sixteen children with prior zidovudine therapy continued zidovudine. Baseline viral 
load and prior treatment did not significantly correlate with the plasma HIV-1 RNA at week 96. The 
change from baseline in absolute CD4+ T-cell count, CD4+ T-cell count as percentage of total T-cells 
and CD4+ T-cell count as percentage of normal was not significantly different between children with 
or without prior treatment at all time points. Thirty-seven children completed 96 weeks of follow-up. 
Four children were lost to follow-up, one child died and the other twenty-nine children who did not 
complete 96 weeks of follow-up entered the study-cohort shorter than 96 weeks before the time of 
analysis. 
Plasma HIV-1 RNA 
The medians and interquartile ranges (IQR) of the viral load after start of HMRT and the 
percentages of patients with a viral load below the LLQ in responders and non-responders are 
depicted in Figure 1. Virologic responders were defined as those who either reached an undetectable 
viral load ( <500 or <400 copies/mil or had a > 1.5 log reduction in viral load compared to baseline 
at week 12 after the initiation of HAART which was maintained during the follow-up period. Fifty-six 
patients were qualified as responders and fifteen as non-responders. In the virological responders, 
HIV-1 RNA was below the LLQ in 79% of the children after 12 weeks and in 91% after 4B weeks. 
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Thirty-seven children completed 96 weeks of follow-up, thirty-one of these children were classified 
as responder and six as non-responder. 
Table 1: Baseline characteristics of the study patients 
Characteristic 
Number of patients 
Age in years* 
Route of acquisition: 
Vertical 
Blood products 
Heterosexual 
Unknown 
Clinical stage (CDC-
classification) t: 
N11 
N2 5 
N3 1 
HAART 
IDV{N0/3TC 
NFV/d4T/3TC 
NFV/ZDV/3TC 
NFV/d4T/dd! 
Median HIV RNA (copies/m!) * 
T -cells absolute (106 ce!ls/L) * 
Number of patients 
CD4+ T-cells 
Naive" CD4+ T -cells 
Memory§ CD4+ T-ce!!s 
% of total T cells 
%of normal 
CDS+ T-cells 
Naive CDS+ T -cells 
Memory CDS+ T-cells 
% of total T cells 
%of normal 
* Median (range) 
71 
5.1 (0.1-17.5) 
58 
6 
3 
4 
A1 6 
A213 
A33 
32 
26 
11 
2 
82,000 (620-27,000,00) 
All age groups 
n = 71 
471 (0-3580) 
211 (0-2880) 
205 (1-2613) 
17 (0-60) 
41 (0-143) 
1147 (60-7369) 
257 (17-1312) 
800 (24-6477) 
44 (12-78) 
140 (7-920) 
< 2 years 
n = 1S 
767 (81-3580) 
967 (47-2880) 
570 (5-2613) 
22 (7-60) 
31 (3-143) 
1680 (640-5436) 
753 (363-1312) 
734 (166-4131) 
34 (16--78) 
168 (64-494) 
B1 2 
B2 6 
B3 5 
2-5 years 
n = 17 
561 (2-1490) 
226 (0-1237) 
229 (2-426) 
17 (0-51) 
43 (0-115) 
1070 (60-7360) 
246 (17-883) 
744 (24-6477) 
36 (12-60) 
134 (7-920) 
C1 3 
C2 12 
014 
;:: 5 years 
n = 36 
370 (0-1140) 
167 (0-616) 
193 (1-646) 
17 (0-51) 
41 (0-114) 
1030 (150-4860) 
188 (26-773) 
816 (119-4228) 
52 (23-73) 
154 (19-744) 
t Clinical and immunological categories as defined by the US Centers for Disease Control and Prevention (CDC). 
(25) 
:1: Defined as CD45RA+/CD62L+ or CD45RA+/CD27mAb+ CD4+ T-cells 
§ Defined as CD45RO+/CD62L- or CD45RO+/CD27mAb- CD4+ T-ce!!s 
Naive and memory CD4+ T -cell responses 
The median absolute CD4+ T-lymphocyte counts at baseline varied widely among patients (Table 1). 
According to the CDC guidelines (25) 14 of 71 (20%) patients did not show immunosuppression 
(CD4+ T-cell count <:25% of total T-cell count), 28 of 71 (39%) patients showed moderate 
immunosuppression (CD4+ T-cell count 15-24% of total T-cell count) and 29 of 71 (41%) patients 
showed severe immunosuppression (CD4+ T-cell count <15% of total T-cell count) at baseline. 
The absolute CD4+ T-cell count and the CD4+ T-cell percentage both increased significantly 
(p<0.001) to a median of 939 x 106 cells/L (range 10-3520) and 32% (range 1-50%) respectively 
after 48 weeks of therapy (Figure 2A). In all age groups the increase of total absolute CD4+ T-cell 
counts was mainly caused by the increase of the naive CD4+ T-cell subpopulation. Memory CD4+ T-
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cells did not increase significantly. Therefore the increase of the CD4+ T-cell counts in children was 
not biphasic as in adults. After an initial increase of the total CD4+ T-cell counts and naive CD4+ T-
cell counts, a decrease was seen at week 8 in children younger than 5 years. Outliers could not 
explain this decrease. After 48 weeks CD4+ T-cell counts reach a plateau consisting of values 
equivalent to the CD4+ T-cell counts in healthy children. In children younger than 2 years absolute 
CD4+ T-cell counts even decreased after 48 weeks, reflecting the normal age-related strong decline 
of CD4+ T-cell counts in children at this age. 
The increase of the CD4+ T-cell percentage in the three age groups is depicted in Figure 
2B. The ratio of naive and memory CD4+ T-cell counts for the total group increased significantly 
(p=0.003) from 0.67 (range 0.04-4.88) to 1.70 (range 0.09-6.69) after 48 weeks, refiecting the 
increase mainly consisting of naive CD4+ T-cells. 
CD4+ T-cell counts expressed as percentage of normal, increased significantly (p<0.001) 
from 44% (range 0-143%) to 84% (range 1-161%) after 4B weeks. The change of CD4+ T-cell 
count from baseline was not significantly different between the age groups at any time-point. 
Responders 
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Figure 1: Medians and interquart1le ranges (IQR) of HIV-1 RNA with a lower limit of quantification (LLQ) of 500 
copies/ml in virologic responders and non-responders after the initiation of HAART. The number of patients which 
are analysed and the percentage of values below LLQ are indicated. 
CD4+ T-ee// response and age 
High CD4+ T-cell recovery rates have been associated with younger age. (6, 11, 13-16) Indeed a 
tendency to an inverse correlation was found between the increase of absolute naive CD4+ T-cell 
counts and the age of the children after 4, 24 (Figure 3A) 36 and 48 weeks of HAART (r= -0.31, p= 
.03; r= -0.34, p= .02; r= -0.47, p= .01; and r=-0.33, p= .04 respectively). 
We subsequently analysed the increase of naive CD4+ T-cell count relative to the median 
of the age-specific reference values. (18, 19) Interestingly, when CD4+ T-cell restoration was 
studied as percentage of normal values, the inverse correlation between the increase of naive CD4+ 
T-cell count and age was not observed after 4, 24 (Figure 3B) and 36 weeks. 
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patients which are analysed is depleted. Figure 2B: The increase of CD4+ 
T-cell counts as percentages of total T-cell counts in three age groups (<2 
years, 2-5 years and >5 years), 
Chapter 11 
Thus, younger children produce more cells in absolute numbers. However, they need to produce 
more CD4+ T-cells in order to normalise their CD4+ T-cell counts. One may therefore conclude that 
older children are able to normalise their CD4+ T-cell counts as well as younger children. 
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Figure 3A Relation between the change of absolute naive CD4+ T -cell count and the age of the children after 24 
weeks of HAART. The correlation coeffident was calculated by the Spearman rank-correlation method Figure 38 
Relation between the change of naive CD4+ T-ee/! counts as percentage of normal and the age of the children 
after 24 weeks of HAART. The correlabOn coeffio"ent was calculated by the Spearman rank-correlabOn method. 
CD4+ T -cell response and virologiC response 
The immunologic reconstitution (absolute CD4+ T-cell counts, CD4+ T-cell counts as percentage of 
normal, CD4+ T·cell counts as percentage of total T-cell count) was not different at any time-point 
in virologic responders and virologic non responders. Figure 4A shows the change from baseline of 
CD4+ T-cell counts as percentage of normal in responders versus non-responders. 
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non-responders. Figure 48: Change from baseline of CDS+ T -cell count as percentage of normal ln virologic 
responders versus non-responders. 
CD4+ T-ee// response and baseline CD4+ T -cell count 
124 
TherapeubC immunereconstitubOn in HIV-1 infected children 
Strongly immunosuppressed adults have poor recovery of CD4+ T-cell counts. (17) Therefore, we 
analysed in our patients the relation between baseline CD4+ T-cell counts and the increase of CD4+ 
T-cells. We observed a inverse correlation between baseline CD4+ T-cell counts and the change 
from baseline of CD4+ T-cell counts as percent'lge of nonmal after 2, 4, 36, 48 and 96 weeks (r= -
0.25, p= .05; r= -0.25, p= .05; r= -0.49, p= .001; r=-0.42, p= .01; and r=-0.41, p= .04 
respectively). Thus, children with lower baseline CD4+ T-cell counts showed a larger increase of 
CD4+ T-cells after the initiation of HAART. Recovery to normal values was seen even in children with 
very low CD4+ T-cell counts ( <10 x 106 cells/L) at baseline. 
CDS+ T-ee!! responses 
Neither the median absolute CDS+ T-cell counts, nor the CDS+ T -cell percent3ge of tot'll T-cells nor 
the CDS+ T-cell percent3ge of normal did change after the initiation of therapy. No significant 
difference was found between virologic responders and non-responders in CDS+ T-cell counts as 
percent3ge of normal (Figure 4B). 
T-ee// responses to CD3 plus CD28 mAb stimulation in vitro 
To study functional recovery of T cells during HAART, T cell proliferation in vitro was analysed An 
increase ofT-cell responses to CD3 plus CD2S mAb stimulation in vitro from a median (IQR) of 136S 
(675-2716 (cpm/103 T-cells)) at baseline to a median (IQR) of 2325 (14S0-3542 (cpm/103 T-cells)) 
after 4S weeks was observed (p=0.06). Expressed as percent'lges of the median of 3450 healthy 
adult donors the T-cell response increased from a median (IQR) of 6S% (33-134%) at baseline to 
115% (73-175%) at week 4S (p=0.06). 
Discussion 
In this study the long-term immunologic response to HAART, consisting of one protease inhibitor and 
two nucleoside analogues, was evaluated in HIV-1-infected children. CD4+ T-cell numbers in HIV-1-
infected children on HAART recover more rapidly than CD4+ T-cells in HIV-1-infected adults as has 
been published by others. (6, 11, 13-16) This good immunological response to HAART has been 
attributed to the functioning thymus present in young children. Our study is the first in which 
recovery of CD4+ T-cell counts is related to reference values for lymphocyte subpopulations. In 
general, absolute CD4+ T-cell counts are used in pediatric studies regarding T-cell repopulation 
during HAART1 since CD4+ T-cells as percentages of total T~cell counts are influenced by the major 
changes in the number of CDS+ T-cells which are encountered in HIV-1-infected patients (6-S). 
However, analyses ofT cell repopulation in groups of children with different ages are hampered by 
the fact that CD4+ T-cell counts are highly dependent on the age of the patients. (1S, 19) Reference 
values of younger children ( < 2 years) are much higher and have a large range compared to older 
children (> 2 years). (1S, 19) Hence, younger children need to produce larger numbers of CD4+ T-
cells to achieve their normal age-related CD4+ T-cell counts. The calculation of CD4+ T-cell counts 
as percentage of normal absolute values thus results in an independent parameter for the degree of 
CD4+ T -cell restoration. 
Using this method it appears from the dat3 that CD4+ T-cell counts in older children are 
restored to the same degree relative to their normal values as in younger children. This is in 
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agreement with the correlation between thymic size and the increase in naive CD4+ T-cell numbers 
(9, 26), because younger children, who have a larger thymus, need to produce more naive CD4+ T-
cells to recover and maintain normal CD4+ T-cell counts. 
Analyses of absolute CD4+ T-cell counts showed that our data are consistent with the 
previously observed finding that the repopulation of absolute CD4+ T-cell counts is more rapid and 
more complete in children than in adults. (6, 11, 13-16) Even children with extremely low CD4+ T-
een counts at baseline did reach normal values during the follow-up period. 
Reconstitution of the immune system in these children is predominantly caused by the production of 
naive CD4+ T-cells. The initial increase of memory CD4+ T-cell numbers as obseJVed in adults, is 
not seen in children. (7, 8) 
In addition to the quantitative improvement of the immune system, T-cell function after 
stimulation with CD3 mAb plus CD28 mAb also improved. Since proliferation ofT-cells was expressed 
as thymidine incorporation per 103 T-cells, circulating T-cells had an increased capacity to proliferate 
after the initiation of HMRT. This indicates that there is also functional improvement of T cells 
during HAART. 
A remarkable finding was the absence of differences between virologic responders and 
virologic non-responders in respect to immunologic reconstitution despite the long term follow-up of 
96 weeks. Similar observations have previously also been reported by others. (13, 15, 22, 27) The 
phenomenon could be explained by the selection of certain viral variants with resistance to protease 
inhibitors that have in-vitro impaired replicative capacity. (28) Douek et al. also reported an increase 
of peripheral CD4+ T-cell counts in both virologic responding and non-responding children on 
antiretroviral therapy. However, they obseJVed that the recovery of thymic function was affected by 
the degree to which virus suppression was achieved when thymic function was measured by 
quantifying T-cell receptor rearrangement excision circles in peripheral blood. (29) 
Our results indicate that normalisation of CD4+ T -cell count in HIV-1-infected children on 
HAART is age-independent, suggesting that thymic function allows the children in all age groups to 
meet their widely different CD4+ T-cell production demands. Remarkably, HAART had a beneficial 
effect on immune reconstitution regardless of virological success, even when children were in an 
advanced stage of HIV-1 infection. 
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Abstract 
Introduction: Growth failure is a common feature of children with human immunodeficiency virus 
type 1 (HIV-1) infection. Children who are treated with mono or dual NRTI therapy show a 
temporary increase in weight gain and linear growth rate. In adults protease-inhibitor-containing 
antiretroviral therapy is associated with a sustained weight gain and increased body mass index. 
Experience with protease inhibitors and growth in children is stili limited. The data mainly deal with 
short-term effects on growth. Objective: To evaluate the effect of highly active antiretroviral therapy 
(HMRT) on growth in children with human immunodeficiency virus type 1 (HIV-1) infection. Design 
& Methods: We analyzed selected growth parameters, clinical data and laboratory results as part of 
a prospective, open, uncontrolled, multicenter study to evaluate the clinical, immunologic and 
virologic response to HMRT consisting of indinavir, zidovudine, and lamivudine in children with HIV-
1 infection. Height and weight were measured at 0, 12, 24, 36, 48, 60, 72, 84, and 96 weeks after 
initiation of HMRT. Information about the children's growth before enrollment in the study was 
retrieved from the hospital medical records and or the school doctor or health center. The body 
mass index (BMI) was calculated. Z-scores were used to express the standard deviation in SD units 
from the Dutch reference curves for age and gender. Viral loads and CD4+ T cell counts were 
examined prospectively and related to these growth parameters. Z-scores were also calculated for 
CD4+ T cell counts to correct for age-related differences. A z-score of 0 represents the PSO, which is 
exactly the age/ sex-appropriate median. A height z-score of -1 indicates that a child's height is 1 
standard deviation below the age- and gender-specific median height for the normal population. 
Virologic responders were defined as those who either reached an undetectable viral load ( <500 
copies/mL) or had a >1.5 log reduction in viral load compared to baseline at week 12 after the 
initiation of HMRT, which was maintained during the follow-up period. 
Results: Patients: Twenty-four patients were included (age 0.4 - 16.3 years at baseline), with a 
median HIV-1 RNA load of 105,925 copies/ml ( =5.03 log), a median CD4+ T-cell count of 0.586 x 
109/L (median z-score: -2.28 SD), a median height z-score of -1.22, a median weight z-score of -
0.74 and a median baseline BMI z-score of -D.32. Eleven patients were naive to antiretrovirai 
therapy and 13 had received prior treatment with NRTI mono therapy. Twenty children used 
indinavir and 4 children nelfinavir as part of HMRT. Virologic and immunologiC responses to HAART: 
Seventeen children were virologic responders and seven children virologic nonresponders. In 
patients naive to NRTis median baseline viral loads were significantly higher than in pretreated 
patients (p=0.02). However, at weeks 48 and 96, there was no significant difference between the 
viral loads of both groups. At baseline, there was no significant difference in CD4+ T cell z-scores 
between virologic responders and nonresponders or between naive and pretreated patients 
(p>0.05). During 96 weeks of HMRT, the increase of CD4+ T cell z-score was significantly higher in 
responders than in nonresponders (p=0.008). The increase in CD4+ T cell z-score was not 
significantly different for naive and pretreated patients (p>0.05). Heigh~ weight and BMI z-score 
changes: We found that there was a trend towards a significantly increased z-score change during 
96 weeks of HMRT compared to the z-score change before HMRT initiation for height (p=0.052) 
and weight (p=0.056), but not for BMI (p=0.627). Growth and virologic response to HAART: When 
the data were analyzed seperately for virologic responders and nonresponders, virologic responders 
showed significant increases in height and weight (p=0.035 and p=0.022 respectively). The height 
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and weight of virologic non-responders did not change significantly. The BM! did not change 
significantly in responders or in non responders. Growth and immunologic response to HMRT: The 
increase of weight and BMI z-scores from baseline correlated positively with the CD4+ T cell z-score 
increase from baseline. It did not correlate with absolute CD4+ T cell count increase. Height z-score 
increase did not correlate with CD4+ T cell z-score or with absolute CD4+ T cell counts. Growth and 
prior NRTI treatment: The height z-score decrease from week -48 to baseline was significantly larger 
in naive than in pretreated patients (p;Q.OO?). The weight and BMI z-score change from week -48 
to baseline was not significantly different for pretreated and naive patients. From baseline to week 
96, the height and weight z-score change increased significantly in naive patients (p;0.033 and 
p;0.026 respectively) but not in pretreated patients compared to the change from week -48 to 
baseline. The BMI z-score did not change significantly over 96 weeks of HMRT for naive or 
pretreated patients. Growth and clinical stage of infection: The clinical stage of infection according to 
the CDC classification correlated negatively with the BMI z-score and the weight z-score at baseline 
but not with the height z-score. Thus, children with the most severe clinical disease had the lowest 
BMI and weight z-scores at baseline. The BMI z-score increased more in children with more 
advanced clinical infection at baseline, who had lower BMI at baseline. The clinical stage of infection 
did not correlate with the change in weight z-score from baseline to week 96 (p>0.05). 
Conclusions: HAART has a positive infiuence effect on the growth of H!V-1-infected children. This 
effect is sustained for at least 96 weeks. Height and weight are favorably influenced in children in 
whom HAART leads to a reduction of the viral load of at least 1.5 log or to less than 500 copies/ ml 
and to an increase in the CD4+ T cell z-score. In contrast to the increase of the BMI in adults on 
HMRT, BMI did not increase in all children effectively treated with HMRT. BMI increased more in 
children with an advanced stage of infection and a poor nutritional status at baseline. Data from 
pretreated and naive patients were difficult to interpret, since the baseline characteristics of these 
two groups differed too much. 
Introduction 
Growth failure is a common feature of children with human immunodeficiency virus type 1 (H!V-1) 
infection. (1-8) The etiology of this H!V-1-related growth failure is complex. It is not only caused by 
an inadequate caloric intake, since increases in caloric intake do not seem to increase lean body 
mass or accelerate the rate of linear growth, but only increase weight and fat mass. (9,10) 
Previously, a correlation with viral load was recognized. (11) Abnormal function of the thyroid gland, 
the somatomedine axis, the lipid metabolism, and abnormal resting energy expenditure may also 
contribute to the diminished growth. (12,13) Growth seems to be one of the most sensitive 
indicators of disease progression in children with AIDS. The absence of growth indicates a poor 
prognosis, also in children who are treated with antiretroviral regimes.(14-19) Poor growth 
commonly precedes a decline in CD4+ T-cell count and the subsequent development of opportunistic 
infections. (20,21) Several studies have shown that weight gain may be an important indicator of 
antiretroviral therapeutic efficacy. (22,23) Children who are treated with mono or dual therapy 
containing zidovudine, didanosine, or zalcitabine show a temporary increase in weight gain and 
linear growth rate. (24-26) In adults protease-inhibitor-containing antiretroviral therapy is associated 
with a sustained weight gain and increased body mass index. (27) Experience with protease 
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inhibitors and growth in children is still limited; it mainly consists of short~term effects on growth. 
(28-31) The objective of this study was to evaluate the effect of highly active antiretroviral therapy 
(HAART) consisting of one protease inhibitor and two nucleoside analogue reverse transcriptase 
inhibitors (NRTls) on the long-term growth profile of HN-1-infected children. 
Methods 
Selected growth parameters, clinical data and laboratory results were analyzed as part of a 
prospective, open, uncontrolled, multicenter study to evaluate the clinical, immunologic and virologic 
response to HAART consisting of indinavir, zidovudine, and lamivudine in children with HIV-1 
infection. (32) The study protocol was approved by the medical ethical committees of all the 
participating centers. Written informed consent was obtained from parents or legal guardians. 
Children> 3 months of age with HIV-1 infection and one of the following 2 items: a decreased CD4+ 
T-cell count {<1 year: <1 ,750/mm3 , 1-2 years: <1 ,OOO/mm3 , 3-6 years: <750/mm3 , >6 years: 
<500/mm3 ) or a HIV-1 viral load > 5,000 copies/ml were included. Growth data prior to HMRT 
initiation also needed to be available in order to be included. Height and weight measurements that 
were and blood samples for virologic and immunologic parameters were obtained twice within a 
month before the start of HAART. and after 12. 24, 36, 48, 60, 72, 84, and 96 weeks of treatment. 
Height and weight measurements were obtained by a single investigator using the same scales and 
the same metal measuring rod every time. Information about the children's growth before enrollment 
in the study was retrieved from the hospital medical records and or the school doctor or health 
center. Height and weight measurements obtained closest to 24 and 48 weeks before HMRT 
initiation were entered into the database. 
Virologic responders were defined as those who either reached an undetectable viral load 
(<500 copies/ml) or had a >1.5 log reduction in viral load compared to baseline at week 12 after the 
initiation of HAART, which was maintained during the follow-up period. 
The BMI was calculated from height and weight values as defined by BMJ:;:; weight 
(kg)l(height (m))'. BMI provides an indication of the nutritional status of the patients. Compared to 
the two other measurements for weight-for-height, i.e. kg/m and kg/m3, BMI has the desired lower 
correlation with height and higher correlation with weight and skinfold thickness. (33) Z-scores were 
used to express the deviation in SO units from the Dutch reference curves for age and gender. 
(34,35) The z-scores for weight, height, and BMI were calculated by means of the SDS software 
program (version 2.0, Erasmus University, Rotterdam, 1996). Reference growth curves were not 
available for most countries from which the patients originated. Therefore, Dutch reference growth 
curves were used. Since we only discuss change in z-scores over time and not absolute z-scores, 
this does not present any problems. Z-scores were also calculated for CD4+ T cell counts to correct 
for age-related differences. (36) A z-score of 0 represents the P50, which is exactly the age/ sex-
appropriate median. A height z-score of -1 indicates that a child's height is 1 standard deviation 
below the age- and gender-specific median height for the normal population. 
The viral load was measured using the Roche Amplicor HIV-1 Monitor test. (37) CD4+ T 
cell counts were obtained by standard flow cytometric methods. Statistical calculations were 
performed with the SPSS statistical analysis software program (version 1 0.0). The relations between 
growth parameters, CD4+ T lymphocyte counts. CD4+ z-scores, and viral loads were analyzed using 
the Wilcoxon signed-rank test, Mann-Whitney U test, and Spearman rank correlation test. All p-
values are two-tailed. 
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Results 
Population characteristics 
Twenty-four HIV-1-infected children were included. They all completed at least 96 weeks of HAART. 
Baseline characteristics of these 24 children are presented in table 1. The median age of the children 
was 5.2 years (range: 4.6 months- 16.3 years). Eleven patients were not previously treated and 13 
had received prior treatment with NRTis, mostly zidovudine mono therapy for an average of 30 
months (range: 8.4- 106.2 months). Pretreated children were significantly older at baseline than 
NRTI-naive children (p=0.002), with a median age of 7.4 years and 2.0 years, respectively. Twenty 
children received HAART containing indinavir and 2 NRT!s and 4 children received HAART 
containing nelfinavir and 2 NRTI's. In 5 children indinavir was changed to nelfinavir and in 1 child to 
indinavir and ritonavir and later to nevirapine because of a viral load rebound after a median duration 
of 48 weeks. In 2 other children indinavir was changed to nelfinavir because of long-term side 
effects. 
Table 1: Baseline Characteristics of Study Patients (n;24) 
Median age in years (range) 5.2 (0.4- 16.3) 
Sex (male/female), n; 11/13 
Race/ethnicity, n; 
Non white 19 
White 5 
Route of acquisition, n= 
Vertical 
Blood products 
Unknown 
CDC dassification*, n= 
N 1/2 
A 1/2/3 
B 1/2 
c 2/3 
No prior treatment, n= 
Prior treatment with, n; 
zidovudine 
zidovudine/ zalcitabine 
Log10 copies of HIV RNA/ml plasma, median (range) 
CD4+ cell count in ld'/L, median (range) 
CD4+ z-score in SD, median (range) 
Z-score in SD, median (range) 
Height 
Weight 
BMI 
16 
4 
4 
2/3 
2/3/4 
1/4 
2/3 
11 
11 
2 
5.03 (3.42 to 5.87) 
0.586 (0.010 to 3.580) 
-2.28 (-13.75 to 0.26) 
-1.22 (-3.84 to 1.25) 
-0.74 (-3.13 to 2.26) 
-0.32 (-3.88 to 2.03) 
*Clinical and immunologic categories as defined by the US Centers for Disease 
Control and Prevention (CDC). (38) 
Virologic response 
The median baseline plasma viral load of 5.03 log10 copies/ml (range, 2.43-5.88) decreased to less 
than 2.70 log10 copies/ml by week 48 and remained below the level of detection until at least week 
96. In patients naive to NRTis (n=11) median baseline viral loads were significantly higher than in 
pretreated patients (n;13) (p=0.02). However, at weeks 48 and 96. there was no significant 
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difference between the viral loads of both groups (Table 2). Seventeen children were virologic 
responders and seven children virologic non responders. 
Table 2:Viralload at baseline, 48 weeks and 96 weeks after HAART initiation in Log copies per ml, 
median (25'" and 75"' percentile) 
Patients Baseline Week 48 Week 96 
All 5.03 (4.29-5.60) <2.70 (<2.70- <2.70) <2.70 (<2.70- 3.29) 
Naive 5.41 (5.16- 5.85)* <2.70 ( <2.70- <2.70) <2.70 ( <2.70- 2.85) 
Pretreated 4.47 (4.09- 4.93)* <2.70 (<2.70- 2.76) <2.70 (<2.70- 3.47) 
Responders 5.16 (4.32- 5.66) <2.70 (<2.70- <2.70)" <2.70 (<2.70- <2.70)• 
Non-responders 4.94 (4.24- 5.29) <2.70 ( <2.70- 3.80) ~ 3.29 (3.08- 4.34)" 
*significant difference, p= 0.02, A significant difference, p=0.024, # significant difference, p<O.OOOl 
Immunologic response 
Absolute CD4+ T cell counts per age group are shown in figure 1a. The median baseline CD4+ T 
cell z-score was -2.28 SO (range, -13.75 to 0.26). At baseline, there was no significant difference 
between virologic responders and nonresponders or between naive and pretreated patients (p>0.05). 
During 96 weeks of HAART, the increase of CD4+ T cell z-score was significantly higher in 
responders than in nonresponders (p=0.008) (Figure 1b). The increase in CD4+ T cell z-score was 
not significantly different for naive and pretreated patients (p>0.05). 
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Figure ;.a: CD4+ T-cell count change in different age categories during 96 weeks of HAART. Figure 1b: CD4+ 
T -cell z-score change in responders and non-responders during 96 weeks of HAART. 
Height, weight and BMI z-score changes 
Using data from all patients regardless of virologic response and prior treatment, the effects of 
HAART on growth were determined. We found that the height z-score decreased in the 48 weeks 
before HAART initiation with a median (range) of -0.088 SO (-1.88 to 1.17) to a median of-1.22 SO 
at baseline. From baseline to 96 weeks after the initiation of HAART the height z-score increased 
with a median (range) of 0.20 SO (-0.72 to 1.29) to a median of -0.95 SO. The weight z-score 
decreased from week -48 to baseline with a median (range) of -0.041 SO (-4.10 to 1.96) to a 
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median of -0.74. From baseline to week 96 the weight z-score increased with a median of 0.34 SO(-
0.83 to 2.13) to a median of -0.60. The BMI z-score change from week -48 to baseline decreased 
with a median (range) of -0.12 SO (-4.1 0 to 1.96) to a median of -0.32 SO. From baseline to week 
96 the median (range) BMI z-score change was 0.28 SO (-1.75 to 3.60) to a median of 0.19 SO. We 
found that there was a trend towards a significantly increased z-score change during 96 weeks of 
HAART compared to the z-score change before HAART initiation for height (p=0.052) and weight 
(p=0.056), but not for BMI (p=0.627). 
Growth and virologic response to HAART 
The median change in height z-score decreased in the 48 weeks before HMRT initiation. Children 
with a higher viral load at baseline showed a larger decrease (p<0.0001) of the height z-score in the 
48 weeks before HAART initiation than children with a lower viral load. From baseline to week 96 
height z-score and weight z-score changes increased significantly in virologic responders, but not in 
non responders compared to the change from week -48 to baseline (Figures 2a~d). 
BMI z-score did not increase significantly over 48 or 96 weeks of HAART in responders or in non-
responders. (Figure 2e and 2f) However, the BMI z-score change increased significantly more in 
virologic responders than in nonresponders to HAART (p=0.024 after 96 weeks). 
Growth and immunologic response to HAART 
During 96 weeks of HAART, the change in height z-scores from baseline did not correlate with the 
change in C04+ T cell z-scores or absolute CD4+ T cell counts. 
The change in weight z-scores from baseline correlated positively with the change in CD4+ T cell z-
scores at week 24 (r-0.693, p<0.0001), 36 (r-0.543, p=0.007), 48 (r-0.628, p=0.001), 60 (r-540, 
p=0.009), 84 (r-0.496, p=0.019) and 96 (r-0.408, p=0.048). The change in weight z-scores only 
correlated with the change in absolute C04+ T cell counts at week 36 (r-0.439, p=0.032). 
The change in BMl z-scores correlated positively with the change in CD4+ T cell z-scores at al time 
points from week 12 onwards except at week 84: week 12 (r-0.476, p=0.019), 24 (r-0.671, 
p<0.0001), 36 (r-0.508, p=0.011), 48 (r-0.592, p=0.003), 60 (r-0.443, p=0.039), 72 (r-0.520, 
p=0.013), 84 (r-0.369, p=0.091) and 96 (r-0.501, p=0.013). The change in BMI z-scores did not 
correlate with change in absolute C04+ T cell counts. 
Growth and prior NRTI treatment 
The height z-score decrease from week -48 to baseline was significantly larger in naive (-0.41 SO) 
than in pretreated (-0.04 SO) patients (p=0.007). From baseline to week 96, the height z-score 
change increased significantly in naive patients (p=0.033) but not in pretreated patients compared to 
the change from week -48 to baseline. 
The weight and BMI z-score change from week -48 to baseline was not significantly different for 
pretreated and naive patients. The weight z-score change increased significantly over 96 weeks of 
HAART for naive patients (p=0.026) but not for pretreated patients. 
The BMI z-score did not change significantly over 96 weeks of HAART for naive or pretreated 
patients. There was no significant difference between naive and pretreated patients either. 
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Figure 2: Growth before and during HAART in (a, c and e) responders and {b, d and f) non-responders. 
Growth and clinical stage of infection 
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The clinical stage of infection according to the CDC classification (38) correlated negatively with the 
BM! z-score at baseline. Thus, children with the most severe clinical disease had the lowest BMI z-
scores at baseline. The BMI z-score increased more in children with more advanced clinical infection 
at baseline, who had lower BMI at baseline. 
The clinical stage of infection at baseline also correlated negatively with weight z-score but not with 
the height z-score. Children with advanced clinical infection had lower weight for their age and 
gender at baseline. The clinical stage of infection did not correlate with the change in weight z-score 
from baseline to week 96 (p>0.05). 
Discussion 
The results of this study indicate that children with HIV-1 infection show a trend to an increase in 
height and weight (p=0.052, p= 0,056 respectively) after the initiation of HAART. However, when the 
children were divided into virologic responder and nonresponder groups, the responders showed 
significant increases in height and weight, whereas nonresponders did not. The BMI did not change 
significantly in responders or in non-responders, although it increased more in responders than in 
nonresponders. Increasing CD4+ T-cell counts favorably influenced weight and BMI. Clinical stage of 
infection was also correlated with the increase of BMI from baseline to week 96 of HAART. BMI z-
scores increased more in children with an advanced clinical stage of infection at initiation of HAART. 
The energy expenditure previously needed to combat infection was possibly used for catch-up 
growth. CD4+ T cell z-scores then relate to BMI and weight only indirectly. 
In HIV-1 infected adults receiving HAART, BMI increased significantly more in responders 
than in nonresponders, but BMI also increased significantly overall, in responders and in 
nonresponders. BMI increase consisted mainly of increased fat mass. Lean body mass did not 
increase significantly. (27) We are not aware of any previously published studies on the influence of 
HAART on BMl in HIV-1-infected children. However, in a recent study in HIV-1-infected children 
protease inhibitors were found to cause a significant increase in weight-for-height and a dramatic 
improvement in lean body mass over a short interval and had no immediate influence on fat mass, 
although there was a trend toward increased fat mass, with longer follow-up time. (28) This suggests 
that in the children whose BMI increased in our study, namely the children with an advance stage of 
clinical infection and responders to HAART with a high increase in CD4+ T cell count, lean body 
mass also increased. The difference of the effect of HAART on body composition between children 
and adults could be attributed to the fact that children are still growing so their metabolism is 
different, but more research is needed into this. 
Height did not increase significantly in responders until week 96 while weight already 
increased significantly at week 48. This is a normal reaction to the correction of a growth-retarding 
disorder: catch-up growth first affects weight followed by height. (39) 
At the initiation of HAART viral loads correlated negatively with height z-score change in the previous 
year and the clinical stage of infection correlated negatively with BMI z-score and weight z-score. 
Children with high viral loads and severe clinical infection also had poor grow parameters. These are 
all associated with a poor prognosis. Although the number or percentage of CD4+ T cells has a 
larger influence on prognosis, increasing growth rates also contribute to a better prognosis. 
(16,18,19,22,23) 
Height and weight z-score change over 96 weeks compared to z-score change in the 48 
weeks before HAART initiation increased more in responders than in non-responders. It also 
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increased more in naYve patients than in pretreated patients. Although this could be interpreted as a 
confounder, it is more likely to be the result of previous antiretroviral therapy. Pretreated patients 
seem to have already reached a higher height z-score change during the 48 weeks before HAART 
initiation. This may have been caused by the treatment with NRTis. Weight z-score change in the 48 
weeks before HAART initiation was not significantly different between naive and pretreated patients. 
We concluded from the observation that weights increased in naive patients and not in pretreated 
patients. However, a difference was observed in baseline viral load and age: pretreated patients 
were significantly older and had a significantly lower viral load. This complicates the comparison 
between these two groups of patients. 
Similar results in height and weight gain as observed by our group were reported in three 
other studies on the effects of HAART in children. (28,30,31) However, the follow-up time of these 
studies was only 24 weeks. A positive influence on growth has been observed as a result of NRTI 
mono therapy or dual therapy during this same period. (14,22,24,40-46) The effect on growth of 
mono therapy cannot be sustained after 24 weeks of treatment. There is no data, which support that 
dual therapy has a sustained effect on growth beyond 24 weeks. The current study shows that the 
positive effects of HAART on growth can be sustained for at least 96 weeks. Therefore, the effect on 
growth lasts longer in patients receiving HAART than in patients receiving mono or duo reverse 
transcriptase inhibitor therapy. There seems to be a relation between the time that an antiretroviral 
therapy is successful in the suppression of viral load and the time that the positive effect on growth 
by this therapy can be maintained. Ogino et al. (22) also raised this point when they described the 
effect of zidovudine resistance on growth. 
Dreimane et al. (29) retrospectively reviewed 27 HIV-1-infected children receiving HAART 
for a mean follow-up time of 20 months. They also found increased z-scores for height and height-
velocity, but not for weight. This difference in findings may be attributed to the low number of 
responders to HAART in their study (10 out of 27) compared to the high number of responders (17 
out of 24) in our study. It could also be attributed to the fact that they used another protease inhibitor. 
Unfortunately, they did not mention which protease inhibitor was used in their patients. Miller et al. 
(28) found that ritonavir had a weaker effect on weight with a stronger effect on height compared to 
indinavir and nelfinavir. 
Conclusion 
HAART has a positive effect on height and weight in children with HIV-1 infection. This effect is 
sustained for at least 96 weeks and is associated with the successful application of HAART, resulting 
in long-term viral load reduction of at least 1.5 log copies/mL or viral load suppression below 500 
copies/mL and an increase of CD4+ T-cell counts. The sustained effects of HAART on growth may 
positively influence the child's quality of life and will predictably contribute to a better prognosis. The 
mechanism of increased growth during antiretroviral therapy is yet unknown. Contrary to the BMI 
increase in adults treated with HAART, BMI in children does not increase in all patients successfully 
treated with HAART, but only in those with a low BMI at tnitiation of HAART. More research is 
needed to investigate whether those factors causing growth failure in children with HIV-1 infection-
caloric intake, thyroid and growth hormones, lipid metabolism and resting energy expenditure, also 
play a role in the recovery of growth parameters during HAART. 
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Abstract 
Introduction: Growth failure is one of the most common presenting signs in children with human 
immunodeficiency virus {HIV) disease and forms a sensitive indicator of disease progression in 
children with AIDS. Highly active antiretroviral therapy (HAART) is not only associated with a 
significant decrease in viral load and a subsequent rise in CD4+ T-cell counts in HIV-1 infected 
children, but also with increased height and weight. However, the underlying mechanisms of catch-
up growth during HAART are yet unknown. Methods: Height and weight measurements, blood 
sample analyses for HN-1 RNA and peripheral blood CD4+ T-cell counts were obtained twice within 
a month before the start of HAART, and after 12, 24, 36, and 48 weeks of treatment. Serum levels 
of IGF-1, IGFBP-3, cortisol, free thyroxine and TN F-a were measured before the start of the therapy 
and after 24 weeks. In addition, serum levels of IGF-I and IGFBP-3 were determined after 48 weeks. 
Results. Twenty-seven HN-1 infected children with a median age of 5.5 years (range: 0.3-14.9 
years) were included. Overall, no significant changes in height and BMI z-scores were observed. 
However, in a subgroup of patients with a change in height or BMI z-scores above the 75th 
percentile after 48 weeks, a significant change in height and BMI z-scores was observed. The 
median baseline plasma viral load of 68,800 copiesjml decreased to less than the detection limit of 
500 copies/ml in 80% of the children after 48 weeks. TN F-a levels were elevated ( 44 pg/ml) at 
baseline and decreased significantly to 37 pg/ml after 24 weeks. At baseline elevated TNF-a levels 
were observed in 78%, which decreased to 55% after 24 weeks. Baseline levels of free T4 and 
cortisol were within the normal range and did not change during therapy. Baseline serum levels of 
IGF-1 and IGFBP-3 were within the normal range, but IGF-1 levels tended to be lower than IGFBP-3 
levels. Both levels increased significantly after the initiation of therapy. IGFBP-3 levels decreased 
after 48 weeks whereas IGF-1 levels stabilized. The increase in the levels of !GF-1 levels was 
significantly higher in the subgroup of children in whom body mass index and height z-scores 
increased. Conclusion: Hypothyroidism and adrenal axis abnormalities are not associated with 
restoration of growth after the initiation of antiretroviral therapy in HIV-1 infected children. The 
combination of relatively high serum levels of IGFBP-3 and relatively lower IGF-11evels suggests the 
presence of a GH resistant state. During treatment with a PI-containing regimen, decreased levels of 
IGFBP-3 and stabilization of IGF-1 levels after a significant initial increase suggest restoration of 
normal sensitivity to GH and a recovery to an anabolic condition. 
Introduction 
Growth failure is one of the most common signs of pediatric human immunodeficiency virus (HIV) 
disease and is one of the most sensitive indicators of disease progression in children with AIDS. 
Increased morbidity and mortality has been observed in HN-1 infected children with poor growth. 
(1-15) The introduction of highly active antiretroviral therapy (HAART) consisting of a protease 
inhibitor and two nucleoside analogues has resulted in significant improvements in the morbidity and 
mortality in both HN-1 infected adults and children. (16-19)1n HN-1 infected children administration 
of HAART is not only associated with a significant decrease in HIV-1 viral load and an increase in the 
number of CD4+ T-cells, but also with height and weight gain. (20-25) Since the rate of growth is 
closely related to the level of HN-1 replication in HN-1 infected children, recovery of growth can be 
partly attributed to the decreases of viral load in children treated with HAART. (15, 26) However, the 
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mechanism of increased growth during HAART are not yet understood. It has not been investigated 
whether the influence of therapy on factors causing growth failure in HIV-1 infected children, such 
as inadequate caloric intake, endocrine disorders (thyroid dysfunction and growth hormone (GH) 
deficiency), chronic or recurrent infections, malabsorption, abnormal cytokine production, altered fat 
metabolism and increased total energy expenditure, may play a role in the recovery of growth during 
HAART. 
Hormones that infiuence growth postnatally include GH and insulin-like growth factor I 
(IGF-I) as well as thyroid hormone and glucocorticoids. Excessive levels of glucocorticoids or very 
low levels of thyroid hormone result in growth retardation during childhood. These hormones play a 
permissive role in promoting growth stimulated by GH and IGF-I. IGF-I mediates the growth 
promoting actions of GH, a pituitary hormone with highly fluctuating blood levels due to a pulsatile 
release. (27) The blood concentration of IGF-I is more stable due to the binding to carrier proteins. 
In serum and other biological fiuids, the IGFs are complexed to specific, structurally homologous 
binding proteins (IGFBPs). IGFBP-3 is the major !GFBP in postnatal serum. (28) Tumor necrosis 
factor -a (TNF-a) is a pro-inflammatory and immunomodulatory cytokine with an increased 
production rate in the presence of infectious diseases and malignancies. TN F-a also strongly inhibits 
lipoprotein lipase and adipocyte gene expression. Chronically high levels of TNF-a have been 
associated with the development of cachexia. 
The aim of this study was to evaluate changes in endocrinological and immunological 
factors and to analyze their association with recovery of growth during HMRT. Height, weight and 
serum levels of cortisol, the free fraction of circulating thyroxine (free T4), IGF-1, IGFBP-3, TNF-cx, 
HIV-1 RNA and CD4+ T-cells were determined at baseline and 24 and/or 48 weeks after the 
initiation of HAART. 
Methods 
Selected growth parameters, clinical data and laboratory results were analyzed as part of a 
prospective, open, uncontrolled, multicenter study to evaluate the clinical, immunologic and virologic 
response to HMRT consisting of indinavir, zidovudine, and lamivudine in children with HIV-1 
infection. (20) The study protocol was approved by the medical ethical committees of all 
participating centers. Written informed consent was obtained from parents or legal guardians. HIV-1 
infected children w~h an HIV-1 viral load of more than 5000 copiesjml and/or a CD4 cell count 
below the age-specific reference values were included. (29) Height and weight measurements and 
blood samples for HIV-1 RNA and CD4+ T-cell count were obtained twice within a month before the 
start of HAART, and after 12, 24, 36, and 48 weeks of treatment. Blood samples for IGF-1, IGFBP-3, 
cortisol, free T4 and TNF-a were obtained before start of the therapy and after 24 weeks. Serum 
IGF-I and IGFBP-3 levels were also determined after 48 weeks. Serum samples were stored at -70°C 
until assayed. 
Statistics 
Statistical calculations were performed with the SPSS statistical analysis software program (version 
9.0). The BMI was calculated from height and weight values as defined by BMI~ weight (kg)/height2 
(m2). BMI provides an indication of the nutritional status of the patients. Compared to the two other 
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measurements for weight-for-height, i.e. kg/m and kg/m3, BMJ has the desired lower correlation 
with height and higher correlation with weight and skinfold thickness. (30) Z-scores were used to 
express the deviation in SD units from the Dutch reference curves for age and gender. (31, 32) Z-
scores represent the number of standard deviations above or below the median of the parameter for 
that sex and age. The z-scores for weight, height, BMI, IGF-1 and IGFBP-3 were calculated by 
means of the SDS software program (version 2.0, Erasmus University, Rotterdam, 1996). 
Because absolute CD4+ T-cell counts are highly dependent on the age of the patients 
relative CD4+ T-cell counts in relation to the median of the age-specific reference values (29) were 
calculated by dividing the individual value at the different time-points by the median of the reference 
value at the different time-points. Results are expressed as a percentage of normal. Virologic 
responders were defined as those who reached an undetectable viral load ( <500 copies/ml) at week 
12 after the initiation of HAART, which was maintained during the follow-up period. 
The relations between growth parameters, CD4+ T-cell counts, TNF-o:, IGF-1, IGFBP-3, cortisol, free 
T4 thyroid hormone and HIV-1 RNA concentrations were analyzed using the Wilcoxon signed-rank 
test, Mann-Whitney U test, and Spearman rank correlation test. All p-values are two-tailed. 
Laboratory procedures 
HIV-1 RNA was measured using the Amplicor HIV-1 monitor test version 1.5 Roche Diagnostic 
Systems. CD4+ T-cell counts were obtained by standard fiow cytometric methods. Total serum IGF-1 
concentrations were measured by radioimmunoassay (SM-C-RIA-Cf, Biosource) The intra- and 
interassay coefficients of variation were 4,1-6,1% and 9,6%, and RIA sensitivity was 0,25 ng/ml. 
Serum IGFBP-3 was determined by a two site immunoradiometric assay (IGFBP-3 IRMA DSL-6600, 
Diagnostic Systems Laboratories inc.) The intra-assay coefficient of variation was 1,8-3,9%, the 
interassay coefficient of variation was 0,5-1,9%, and the low detection limit was 0,5 ng/ml. Serum 
cortisol was evaluated by a solid-phase chemiluminescent enzyme immunoassay (Immulite Cortisol). 
The intra- and interassay coefficients of variation were 6,8-9,0% and 9,9-10,3%. The sensitivity was 
approximately 0,2 !19 (5,5 nmol/1). Serum free fraction of circulating thyroxine (T4) was measured 
by a direct labeled antibody competitive immunoassay technique (Amerlite MAB FT4 assay). The 
inter- and intra-assay coefficients of variation were 4,2-9,0% and 3,5-7,6%, and the low detection 
limit was 0,7 pmol[l. Serum TNF-o: was quantified by a solid phase Enzyme Amplified Sensitivity 
Immunoassay (TNF-o: EASIA, Biosource). The intra- and interassay coefficients of variation were 3,7-
5,2%. The minimum detectable concentration was 3 pg/ml. 
Results 
Patients 
Twenty-seven HN-1 infected children were included. They all completed at least 48 weeks of 
HAART. Baseline characteristics of these 27 children are presented in table 1. The median age of 
these children was 5.5 years (range: 0.3-14.9 years). Rfteen children had received prior treatment 
with NRTI's, mostiy with zidovudine for an average of 22.5 months (range 1-43 months). Pretreated 
children were significantly older at baseline than NRTI-naive children (p=0.02) with a median age of 
7.4 years and 4 years respectively. Twenty-four children received HAART containing indinavir and 2 
NRTIS' s and 3 children received HAART containing nelfinavir and 2 NRTI's. In 4 children i~dinavir 
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was changed to nelfinavir and in 1 child to indinavir and ritonavir, because of a viral load rebound 
after a median duration of 24 weeks. 
Table 1: Baseline characteristics of study patients (n-27) 
Median age in years (range) 
Sex: male/female 
Racejethnicity 
Non white 
White 
Route of acquisition 
Perinatal 
Blood products 
Unknown 
CDC Classification (33) 
N 1/2/3 
A 1/2/3 
B 1/2/3 
c 1/2/3 
Prior treatment 
No 
ZDV 
2 NRTI's 
Treatment 
IDV /ZDV /3TC 
NAI/ZDV/3TC 
NAI/d4T/ddl 
Median HN-1 RNA copies/ml (range) 
Median CD4+ T-cell count in 109/1 (range) 
Median CD4+ T-cell count as% of normal (range) 
Height and BMI z-score changes 
5.5 (0.3-14.9) 
16/11 
23 (85%) 
4 (15%) 
19 (70%) 
4 (!5%) 
4 (15%) 
1/4/1 
3/6/2 
0/3/1 
0/3/3 
12 (44%) 
13 (48%) 
2 (7%) 
24 (89%) 
2 (7%) 
1 (4%) 
68,800 (3,170 - 820,000) 
440 (10-3580) 
44% (0-143) 
In the total group no significant changes in height and BMI z-scores were observed. Median (range) 
height z-scores were -1.3 SD (-3.7 to 1.61) at baseline, -1.3 SD (-3.5 to 1.18) after 24 weeks and -1 
SD (-3.3 to 0.8) after 48 weeks of therapy. Median (range) BMI z-scores were -0.1 SD (·2.4 to 1.7) 
at baseline, 0.19 SD (-2.9 to 1.8) after 24 weeks and 0.13 SD (-2.3 to 1.4) after 48 weeks. However 
in a subgroup of children with a change in height z-scores above the 75th percentile after 48 weeks 
(n = 12), i.e the children with the highest growth velocity from baseline to week 48, the median 
(range) change in height z-scores was 0.46 SD (0.05 to 1.99) after 48 weeks (p=0.002). The median 
(range) change in BMI z-scores after 48 weeks in the children with a change in BMI z-score above 
the 75th percentile after 48 weeks (n = 6) was 1.16 SD (0.91 to 1.25) (p=0.03). 
Virological response rate 
The median baseline plasma viral load of 68,800 copiesjml (range: 3,170 - 820,000) decreased to 
less than the detection limit of 500 copies/ml in 74% of the patients after 24 weeks and in SO% 
after 48 weeks. Twenty children were virologic responders ( < 500 copies/ml at week 12) and seven 
children virologic non-responders. 
147 
Chapter 13 
ln?n?UnologiGalresponse 
The median absolute CD4+ T-cell count (range) of 440 x 109/1 (10-3580) increased to 630 x 109/1 
(10-4380) after 24 weeks and to 840 x 109/1 (10-3520) after 48 weeks. CD4+ T-cell counts 
expressed as percentage of normal (range) of 44% (0%-143%) increased to 66% (1%-99%) after 
24 weeks and to 72% (1 %-161 %) after 48 weeks. 
Cortisol and free T4 
Both cortisol and free T4 levels did not change significantly during HAART. Before the initiation of 
therapy, and after 24 weeks of therapy they were within the normal range (cortisol morning 
samples, 200- 600 nmolfl and free T4 11-25 pmol/1). The median (range) baseline level of cortisol 
was 278 nmolfl (123 - 765 nmolfl). After 24 weeks of therapy the median (range) cortisol level was 
350 nmol/1 (136- 633 nmolfl) (p;0.741). All cortisol samples were drawn in the morning. 
The median (range) baseline of free T4 was 18,5 (12.8- 24.2 pmol/1). After 24 weeks of therapy 
median (range) free T4 was 18.9 (13.2- 23.5 pmolfl) (p;0.791). 
TN F-a 
At baseline elevated TNF-a levels (>30 pg/ml) were observed in 21 of the 27 patients (78%). The 
median baseline TNF-a concentration of 44 pg/ml (range, 7-164 pg/ml) decreased to 37 pg/ml 
(range, 6-79 pg/ml) after 24 weeks (p;0,025). After 24 weeks elevated TNF-a levels (>30 pg/ml) 
were detected in 15 of the 27 patients (55%). During therapy TN F-a levels decreased in 18 children. 
TNF-o: levels increased in 9 children. When children who had an acute infection at one or both time 
points (n;9) were excluded from analyses, TNF-a levels decreased from a median of 48.5 pg/ml 
(range 13-164) at baseline to a median of 27 pg/ml (range 6-79 pg/ml) (p;0.01). In the group of 
children with an acute infection at one or both time points, no significant decrease was seen. 
The decrease in TNF-o: levels during therapy was not different between children with no or moderate 
immunodeficiency and children with severe immunodeficiency at baseline. Neither did we observe a 
difference between virological responders and non-responders in the decrease in TNF-o: levels during 
therapy. 
IGF-1 and IGFBP-3 
IGF-1 increased significantly during therapy from a median (range) of 13.2 nmol/1 (2.2-99) at 
baseline to 22.8 (3.4-113) nmol/1 after 24 weeks (p<O.OOl). After 48 weeks median IGF-1 levels 
stabilized with a median (range) of 22.5 nmol/1 (7.7-64.5). Corrected for age and sex, z- scores of 
IGF-1 also increased significantly during therapy from a median of -Q.65 SD (range, -5,00 to 3.20) at 
baseline to + 1.50 SD (range, -4.01 to 3.84) after 24 weeks of therapy (p;0.001) and 0,60 SD 
(range, -2,50 to 4,20) after 48 weeks of therapy. 
IGFBP3 increased significantly during therapy from a median (range) of 92 nmolfl (38-198) 
at baseline to 123 nmol/1 (36-244) after 24 weeks (p;0.001). After 48 weeks median IGFBP-3 levels 
decreased to a median (range) of 95 nmolfl (28-143). Corrected for age and sex, SD scores of 
IGFBP-3 also increased significantly during therapy from a median of 1.4 SD (range, -2,50 to 2.60) 
at baseline to 1.90 SD (range, -3.3 to 3.4) after 24 weeks of therapy (p;0.005) and decreased after 
48 weeks to 0.70 SD (range, -4.50 to 2.20) after 48 weeks of therapy. 
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In two pubertal children a large increase in IGF-1 (by 62 and 42 nmol/1, respectively) and in IGFBP-3 
(by 97 and 67 nmol/1, respectively) was observed. Exclusion of these children did not alter the 
results. 
IGF-1, IGFBP-3 and growth 
In children with a change in height z-scores above the 75th percentile after 48 weeks, i.e the 
children with the highest growth velocity from baseline to week 48, a significant larger increase of 
IGF-1 z-scores (p;0.05) was observed during the first 24 weeks of treatment compared to children 
with a change in height z-scores below the 75th percentile. Comparison of the changes in IGF-1 z-
scores between children with changes of BMI z-scores above and below the 75th percentile also 
resulted in a significant larger increase of IGF-1 z-scores (p;0.03) during the first 24 weeks of 
treatment in the children with the highest increase of BMI z-scores. IGFBP-3 z-scores were not 
different between the two groups. 
The median changes in height and BMI z-scores and the differences in changes of IGF-1 
and IGFBP-3 between children with a change above and below the 75th percentile are presented in 
Table 2. 
Table 2: Changes in height and BMI z-scores in relation to changes in IGF-1 and IGFBP-3 
z-scores 
Change of height z-scores Change of BMI z-scores 
>75th <75th p- >75th <75th P-
percentile percentile percentile percentile 
n;12 n;15 n;6 n;21 
Median change 0.46 SD -0.22 SD 1.16 SD -0.1 SD 
of height/BMI (0.05 to 1.99) ( -1.2 to 0.03) (0.91 to 1.25) (-3.4 to 0.64) 
z-score 
Median change 1.39 SD 0.02 SD (-1.27 0.05 2.7 SD 0.5 SD 0.04 
of IGF-1 (range) (0.26 to 3.37) to 2.09) (1.0 to 3.4) (-1.3 to 2.4) 
Median change 0.7SD 0.1 SD (-1.4 to 0.16 1.6 SD 0.4SD 0.34 
of IGFBP-3 ( -0.02 to 3.8) 2.4) ( -0.02 to 3.8) (-1.4 to 2.5) 
(range) 
IGF-1, IGFBP3 and immunological status 
Although not significantly different, severely immunocompromised children (CDC classification stage 
3 (33)) had lower baseline IGF-1 and IGFBP-3 levels compared to children with moderate or no 
immunodeficiency. In severely immunocompromised children median baseline IGF-1 and IGFBP-3 z-
scores were -2.1 and -0.06 SO, respectively, and in children without severe immunodeficiency 
baseline IGF-1 and IGFBP-3 z-scores were 0.69 and 1.69 SD, respectively. In both groups a 
significant increase in IGF-1 and IGFBP-3 was observed after 24 weeks of therapy. (Figures 1A and 
1B) IGFBP-3 z-scores in severely immunocompromised children were normal (-0.06 SD) whereas 
IGF-1 z-scores in these children were relatively low ( -2.1 SD). 
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Figure 1 A: Median IGF-1 z-scores (IQR) and B: median IGFBP-3 z-scores (IQR) from baseline to 48 weeks after 
the initiation of therapy in patients with no to moderate immunodefia"ency (CDC classificabOn stage 1 and 2) and 
ln patients with severe lmmunodeflclency {CDC dassificabOn stage 3}. 
IGF-1, IGFBP3 and virologica!jinfectious status 
No relation between plasma viral load or TNF-u and !GF-1 or !GFBP-3 levels was found. In addition, 
no difference in the increase of IGF-1 or IGFBP-3 was found between virological responders and 
non-responders_ 
Serum albumin 
Since an improvement in the nutritional condition of children can also result in an increase of IGF-1 
levels, we analyzed changes in the serum levels of albumin. Serum albumin levels were normal at 
baseline and further increased after the initiation of therapy from a median (range) of 35 g/1 (25-50) 
at baseline to 42 g/1 (26-47) after 48 weeks of tiherapy. 
Discussion 
In this study we analyzed changes in endocrinological and immunological factors in relation to catch-
up growth after the initiation of HAART in HIV-1 infected children. Most children showed a good 
clinical, virological and immunological response to the therapy. (20) In contrast to other reports on 
recovery of growth after the initiation of protease inhibitor containing therapy, in this cohort for the 
total group no significantly high increases of height and BMI were observed in comparison with age-
and sex-matched controls. (23-25) This may be due to the small sample size and to tihe lack of data 
on growth before the initiation of therapy. The reports on recovery of growth after the start of 
treatment with a protease inhibitor containing regimen all compared changes in growth rates 
between the period before and tihe period after the initiation of tiherapy. (23-25) 
Endocrine dysregulation seems to play an important role in growtih failure in HIV-1 infected 
children. Several endocrine abnormalities, such as hypothyroidism and abnormal GH and IGF-1 
concentrations have been documented. (1, 8) (34-45) The results of our study indicate tihat baseline 
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serum levels of IGF-1 and IGFBP-3 are within the range of normal (median: 0.65 SD and 1.4 SD 
respectively). Serum levels of IGF-1 increased significantly during the first six months of therapy 
from a median of 13.2 nmolfl at baseline to 22.8 nmol/1 after 24 weeks. After 48 weeks IGF-1 levels 
stabilized to a median of 22.5 nmolfl. Corrected for age and sex, z- scores of IGF-1 also increased 
significan~y during therapy from a median of --Q.65 SD at baseline to + 1.50 SD after 24 weeks of 
therapy and 0,60 SD after 48 weeks of therapy. 
The increases in IGF-1 levels were significantly higher in children in whom the body mass index and 
length (after correction for age and sex) increased the most. 
Serum IGF~l levels at baseline were relatively low in comparison to baseline levels of 
IGFBP-3. We hypothesize that this discrepancy is caused by an increased 24-hour GH production. 
Although we did not measure GH production, the observation that IGFBP-3 levels were normal 
supports this concept, since IGFBP-3 concentrations are strongly dependent on GH production. The 
synthesis of IGF-1 by the liver is not only stimulated by GH, but is also dependent on factors within 
the liver itself, including viral activity, infections, and nutritional status. Since we did not observe a 
significant improvement in the nutritional status or the extent of the liver function, decreased viral 
activity and decreased exposure to infections may partly explain the increased levels of IGF-1 during 
therapy. However, no difference was found between the virological responders and non-responders. 
Neither did we observe an association between viral load or TNF-o: and changes in IGF-1 levels. The 
combination of relatively high serum levels of IGFBP-3 and low IGF-1 levels suggests the presence of 
a GH resistant state at baseline. This conclusion is consistent with previous studies. (46, 47) Frost et 
al. also found elevated GH concentrations and decreased IGF-1 levels. Mulligan et al. demonstrated 
that the IGF-1 response to exogenously administered GH was blunted in AIDS despite the 
observation that these patients had normal IGF-1 levels. Similar results have been found in critically 
ill patients and patients with GH insensitivity syndrome. ( 48, 49) The normal GH responses to 
provocative testing in combination with low IGF-1 levels that have previously been reported by 
Schwartz et al. and Laue et al., could also be explained by GH insensitivity. (1, 43) The decrease in 
IGFBP-3 and stabilization of IGF-1 levels after an initial significant increase suggests restoration of 
the sensitivity for GH and a return to an anabolic state. 
Arpadi et al. and Pollack et al. reported a strong relation between the rate of growth and 
the level of HIV-1 replication in HIV-1 infected children. (15, 26) We did not observe an association 
between virological response and an increase of !GF-1 and IGFBP-3. Although serum levels of TNF-
a, a marker of active viral infection, significantly decreased during therapy, TNF-a was also not 
associated with changes in the levels of !GF-1 or IGFBP-3. This may be explained by the restoration 
of GH sensitivity during therapy, independent of the level of viral load reduction. 
In contrast to other studies that reported thyroid dysfunction in HIV-1 infected children, 
free T4 levels were normal and did not change during therapy. (1, 8, 35, 37, 43) Morning cortisol 
levels also were normal. This was also reported by Laue et al. and Schwartz et al.. (1, 43). This 
suggests that cortisol is not associated with recovery of growth. Although a normal level of cortisol 
does not imply normal responsiveness of the glucocorticoidreceptor, the absence of elevated levels 
of cortisol indicates a normal responsiveness of the glucocorticoid-receptor. 
In conclusion, we found that baseline serum levels of IGF-1 and IGFBP-3 are within the 
range of normal, but increased significantly after the initiation of therapy in this cohort with a high 
percentage of children with an optimal virological response (80%) and a significant decrease of TNF-
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a. The combination of relatively high serum levels of IGFBP-3 and low IGF-1 levels suggests the 
presence of a GH resistant state at baseline. The decrease in IGFBP-3 serum levels and the 
stabilization of IGF-1 levels after an initial significant increase suggests restoration of the sensitivity 
to GH and return to an anabolic condition during protease inhibitor containing therapy. 
Baseline levels of free T4 and cortisol were within the normal range and did not change during 
therapy, suggesting that hypothyroidism and adrenal axis abnormalities are not associated with 
recovery of growth after the initiation of therapy. Further research is needed to investigate whether 
other factors causing growth failure, such as inadequate caloric intake, abnormalities in lipid 
metabolism and total energy expenditure, may also play a role in the recovery of growth parameters 
during HMRT and to confirm our hypothesis on the restoration of the sensitivity for GH. 
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Abstract 
Background: Prolonged administration of indinavir (IDV) is associated with the occurrence of a 
variety of renal complications in adults. These well documented side-effects have restricted the use 
of this potent protease inhibitor in children. Design: A prospective study to monitor IDV related 
nephrotoxicity in a cohort of 30 HIV-1 infected children treated with IDV. Methods: Urinary pH, 
albumin, creatinine, the presence of erythrocytes, leucocytes, bacteria, and crystals, and culture 
were analyzed every three months for 96 weeks. Serum creatinine levels were routinely determined 
at the same time points. Steady state pharmacokinetics of IDV were done at week 4 after the 
initiation of IDV. Results: The cumulative incidence of persistent sterile leucocyturia (;::75 cells/~L in 
at least 2 consecutive visits) after 96 weeks was 53%. Persistent sterile leucocyturia was frequently 
associated with a mild increase in the urine albumin/creatinine ratio and by microscopic hematuria. 
The cumulative incidence of serum creatinine levels more than 50% above normal was 33% after 96 
weeks. Children with persistent sterile leucocyturia more frequently had serum creatinine levels of 
50% above normal (p=0.02) than those children without persistent sterile leucocyturia. In children 
younger than 5.6 years, persistent sterile leucocyturia was significantly more frequent(p= 0.05) than 
in older children. A higher cumulative incidence of persistent leucocyturia was found in children with 
an AUC >19 (mg/L *h) or a peak serum level of IDV >12 (mg/1) (p=O.OS and p=0.02, respectively). 
In 4 children IDV was discontinued because of nephrotoxicity. Subsequently, the serum creatinine 
levels decreased, the urine albumin/creatinine ratios returned to zero and the leucocyturia 
disappeared within 3 months. Conduslon: Children treated with IDV have a high cumulative 
incidence of persistent sterile leucocyturia. Children with persistent sterile leucocyturia more 
frequently had an increase in serum creatinine levels of more than SO% above normal. Younger 
children have an additional risk for renal complications. The impairment of the renal function in 
these children occurred in the absence of clinical symptoms of nephrolithiasis. We conclude that IDV 
associated nephrotoxicity must be monitored closely especially in children with risk factors such as 
persistent sterile leucocyturia, age <5.6 years, an AUC of IDV >19 (mg/L*h) and a Cmax 
>12(mg/L). 
Introduction 
Indinavir (IDV) is a potent HIV-protease inhibitor, which has successfully been used in adults in 
combination with nucleoside reverse transcriptase inhibitors to suppress infections by HIV-1. 
Discontinuation of the antiretroviral therapy rapidly results in virological rebound, decreased immune 
function and the redevelopment of AIDS-defining illness. Thus, antiretroviral drugs such as IDV need 
to be continued for many years. This necessitates a careful surveillance for long-term toxicity of the 
medication. 
The experience with the administration of IDV to HIV-1 infected children has been limited, 
because of the absence of a pediatric formulation and the well documented side-effects of the drug 
on the upper and lower urinary tract in adults. Indinavir is metabolized by the liver, but 
approximately 20% of a single oral dose is excreted unchanged in the urine. (1) PH dependent 
crystallization of IDV in renal tubuli may cause renal symptoms such as kidney stones, fiank pain 
(even without evident stone formation), interstitial nephritis, elevation of the serum creatinine, 
dysuria and asymptomatic urine abnormalities such as hematuria, leucocyturia and crystalluria. IDV 
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crystals may i[[Jcit an inflammatory response in the tubuli, leading to sterile leucocyturia and renal 
insufficiency. (2-7) To minimalize renal side effects of IDV an increased ftuid intake is advised. (8) 
The incidence of IDV associated nephrolithiasis in adults varies from 4 to 43%. (2, 9) Renal 
complications (including nephrolithiasis) by IDV are found in 0 to 80% (10-15) and nephrolithiasis in 
0-20% (10, 12-15) of the children who have been treated with this drug. 
Renal and urological symptoms of IDV crystals have been correlated with the serum levels of IDV. 
(16) In children sufficiently high area under the plasma-concentration curves (AUCs) for IDV are 
required to achieve trough levels (13, 17) which are associated with an optimal virological response. 
(18-20) The risk of nephrotoxicity in children might therefore be higher than in adults. 
In contrast to symptomatic nephrolithiasis, other renal complications such as leucocyturia, 
microscopic hematuria and crystalluria usually do not lead to a decision to discontinue IDV, although 
an association between recurrent severe leucocyturia and renal damage by IDV induced crystalluria 
has been reported in adults. (6, 21) 
Currently it is unknown whether and when these asymptomatic signs of renal damage lead 
to renal complications and long-term renal damage. This prospective study was performed to 
monitor renal and urinary complications in a cohort of 30 HIV-1 infected children treated with IDV. 
We hypothesized that IDV related nephrotoxicity might occur more frequently in children than in 
adults due to the higher risk for cellular damage to the still developing renal system. 
Methods 
In 1997 a prospective, open, uncontrolled, multicenter study was initiated to evaluate the clinical, 
immunological and virological response to combination therapy consisting of IDV, zidovudine and 
lamivudine in HlV-1 infected children (15). Children >3 months of age and one of the following 2 
items: a decreased CD4+ T-cell count (<1 year: <1750/mm3, 1-2 years: <1000/mm3, 3-6 years: 
<750/mm3, >6 years: <SOO/mm3) or a HlV-1 RNA load >5000 copies/ml were included. The follow-
up period was 96 weeks after the initiation of IDV. Two years after the initiation of this multicenter 
study a separate study was started in one of the participating centers to analyze additional urinalysis 
parameters with a follow-up period of 96 weeks. 
The Ethics Committee of the University Hospital Rotterdam approved the study. Patients 
and their caretakers provided written informed consent. 
Laboratory parameters 
The routinely analyzed laboratory parameters of the children included dipstick analysis for urinary pH 
(at urine pH values below 5 solubility of indinavir increases (22)), erythrocytes, leukocytes and 
bacteria at baseline (before the use of IDV) and every three months thereafter. Routine biochemistry 
tests included serum creatinine. Steady state pharmacokinetics of IDV (400 mg/m2 q8h) were 
determined at week 4 after the initiation of IDV. This procedure was repeated when a dosage 
adjustment of IDV was necessary to normalize the area under the curve-concentration {AUC) curve 
to adult values (20 mg/L *h, range 10-30 mg/L *h). (17) 
Demographic parameters, IDV start date and stop date, IDV dosing regimens, urinary tract 
symptoms, concomitant treatment, HN-1 RNA and CD4+ T -cell counts were recorded on structured 
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data collection forms. Nephrolithiasis related symptoms included renal colic, flank pain, the passing 
of a stone, and gross hematuria. 
Additional laboratory tests were performed in children included in one center, from March 
1999 onwards. Urinary pH was measured by means of calibrated electrode technique. Urine albumin 
and creatinine were measured to calculate the albumin to creatinine ratio as an indicator of renal 
damage. Urine light microscopy for presence of IDV crystals under a polarized filter was perfomed 
and urine cultures were performed in patients with a positive dipstick test or microscopy for bacteria. 
Sterile leucocyturia is considered to be caused by damage of renal tubuli. Therefore we 
considered this as the principal endpoint this study. Leukocyturia was defined by the presence of a 
dipstick test with more than 75 cells/J..tl. Persistent sterile leukocyturia was present when ieukocyturia 
with negative urine cultures was found at at least two consecutive visits, after the start of IDV. In 
children with more than 150 leucocytes/).!1 at at least two visits and a negative urine culture a renal 
ultrasound was performed. 
Analysis 
Cumulative incidences of persistent leucocyturia and serum creatinine more than 50% above age 
and sex specific normal values (23) were calculated with Kaplan-Meier analysis. The infiuences of 
pharmacokinetic factors were determined with the logrank test. The relation between the occurrence 
of persistent leucocyturia and an increased creatinine and between persistent leucocyturia and 
nephrolithiasis related symptoms were analyzed using the Fisher's exact test. In order to describe 
urine abnormalities associated with Jeucocyturia, we performed a cross-sectional analysis 12 weeks 
after the start of the measurement of the additional urinalysis. 
Results 
Thirty HN-1 infected children were enrolled between April 1997 and April 2000. Fifteen children 
were available for additional analyses between March 1999 and March 2001. The other fifteen 
children were not available for additional analyses for various reasons: enrollment in another center 
than the center where the additional analyses were performed (n=8), discontinuation of IDV (n=6: 
five children because of virological failure and one because of nephrotoxicity) and age > 18 years 
(n=1). Baseline characteristics of the children are presented in Table 1. 
A good clinical, immunological and virological response was observed in all children who 
were treated with IDV. Most of the children needed 600 mg/m2 q8h of IDV to obtain an AUC of IDV 
between 10 and 30 mg/l *h. The median (IQR) AUC was 19 (14-28) mg/L*h with a median (IQR) 
peak level of 9 (6-12) mg/l. Baseline and follow-up serum creatinine and urinalysis data were 
available from 30 children in whom IDV was initiated. 
The cumulative incidence of persistent sterile leucocyturia (;2 times ~75 ceiiS/Jl./) 
Eleven out of thirty (37%) children developed persistent sterile leucocyturia (two times or more <:75 
leucocytesfJ.ll). The cumulative incidence after 96 weeks was 53% with a mean time to leucocyturia 
of 74 weeks (95% confidence interval: 61-87 weeks) of combination therapy containing IDV. (Figure 
1A) 
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The infiuence of age and sex on the cumulative incidence of persistent sterile leucocyturia was 
determined. Children were divided into two groups: younger and older than the median age of 5.6 
years. Figure 1B shows that children younger than 5.6 years had a significantly higher cumulative 
incidence of persistent sterile leucocyturia than children older than 5.6 years (p=0.05). Sex did not 
infiuence the incidence of leucocyturia. 
Table 1: Patient charocteristics 
Characteristic 
Age (years) Median (range) 5.6 (2.4-9.9) 
Male N (%) 15 (50) 
Body Mass Index (kg/m2) Median (IQR) 16 (14-17) 
HIV-1 RNA (copies/ml) Median (IQR) 127,500 (18,400-661,000) 
CD4 cells (cells/!!L) Median (IQR) 610 (230-880) 
IDV regimen 
• 400 mg/m2 tid N (%) 8 (27) 
• 500 mg/m2 tid N (%) 11 (37) 
• 600 mg/m2 tid N (%) 7 (23) 
• <:700 mg/m2 tid N (%) 4 (13) 
• 500/100 mg/m2 bid* N (%) 
Serum creatinine (!lmoi/L) Median (IQR) 24 (19-38) 
Urine 
Leukocytes > 75 cells/!!L N (%) 0 (0) 
Erythrocytes> 60 cells/!!L N (%) 0 (0) 
*IDV/ritonavir 
The cumulative incidence of a change of serum creatinine more than 50% above age and sex 
specific normal values 
Six out of thirty (20%) children had a change of serum creatinine more than 50% above age and 
sex specific normal values. The cumulative incidence after 96 weeks was 33% with a mean time to 
creatinine increase of 90 weeks (9S% confidence interval: 82-98 weeks) of combination therapy 
containing !DV. (Figure 1C) 
Relation between persistent sterile /eucocyturia and an increase of serum creatinine 
One of the nineteen (S%) children without persistent sterile leucocyturia had a change in serum 
creatinine more than SO% above age and sex specific normal values, whereas S of 11 (4S%) 
children with persistent sterile leucocyturia had a change in serum creatinine more than SO% above 
age and sex specific normal values (p=0.02). The median (IQR) time to a creatinine increase among 
patients with leucocyturia was 24 (0-48) weeks. 
Relation between persiStent sterile leucocyturia and pharmacokinetic parameters 
Children with an AUCo.s of IDV higher than the median AUC of 19 (mg/L*h) had a significantly higher 
cumulative incidence of persistent sterile leucocyturia compared with those with an AUC ::::;19 
(mg/L*h) (p=0.05). After 96 weeks 8 of the 12 (67%) children with an AUC>19 (mg/L*h) had 
persistent sterile leucocyturia, in controst with 2 of 16 (13%) of the children with an AUC<19 
(mg/L*h). The cumulative incidences were 79% and 19%, respectively after 96 weeks. (Figure lD) 
161 
Chapter 14 
'$ 
> 
' • ·~ i. 
Figure 1A 
,_,,----------------, 
.8 
Wock5 after !'ilnrtof IDV 
Figure 1C 
,_,,------------------, 
Week:> oftor :;tart or IDV 
Figure 1E 
,_,,----------------, 
·' 
p:0.01 
~ .-----+----+-----' 
j 0,0 !-l-l-~--,o--.,;t,.·_--_·"',--...,--c,;--;:;--;:;;--:! 
a • • • oo n • • 'oo 
Week:> ~Iter otnrtor IDV 
162 
Figure 18 
,_,,----------------, 
p:O.OS 
-!' 
> ·' r------.-- +---- _. 
~ t----!----+-----· 
6 o ,o !-"-:<a:----.,.:----.,.c---:•,---:,~,--n,--,.:c-~.,,---,!,, 
Woeks Wtcrsbrtof IDV 
Figure 10 
,_,,----------------, 
.8 
Weeks nfter stM or IDV 
Figure 1A: Cumulative ino"dence of persistent 
sterile leucocyturia. Figure 1.8: Cumulative. 
inodence of persistent sterile leucocyturia in 
children < 5.6 years (dotted line) and in 
children >S.6years. Figure 1.C: Cumulative. 
inodence of children with creatinine increase 2 
50% above age and sex spedfic normal values. 
Figure 1D: Cumulative incidence of persistent 
sterile leucocyturia in children with AUC of ID'v 
-519 (dotted line) or> 19 (mg/L ·*h). Figure 1£; 
Cumulative inodence of persistent stenle. 
leucocyturia in children with Cmax -512 ( dotteo 
line) or> 12 (mg/L). 
NephrotoXJdty in HIV-1 infected children treated with indinavir 
Relation between persistent sterile leucocyturia and nephrolithiasis related symptoms 
Four of the 21 (19%) children without persistent sterile leucocyturia presented with urological 
symptoms, whereas 7 of 9 (78%) children with persistent sterile leucocyturia had symptoms during 
the follow-up time (p=0.003). 
Hematuria 
Persistent hematuria (2x ~60 cells/~!) was not detected in any child. 
In addition to the standard analyses performed in the 30 children, urine creatinine, urine albumin, 
quantitative pH measurements and crystalluria were analysed in 15 children. At the time of the start 
of the additional analyses, these children were using IDV for a median of 75 weeks (interquartile 
range (!QR): 8-77 weeks). 
A cross-sectional analysis at week 12 after the start of the initiation of additional analysis 
showed that in these children (median time on IDV (IQR): 87 (20-89) weeks) 33% of the patients 
had a change of serum creatinine more than 50% above age and sex specific normal values, 43% of 
the patients had leucocyturia, 21% had microscopic hematuria, 54% had crystalluria and 29% had 
an albumin/creatinine ratio ~ 3.5 gjmmol. Urine cultures were all negative for bacteria. 
In Figure 2 urine abnormalities associated with leucocyturia at week 12 are presented. An increase 
of serum creatinine levels of more than 50% above age and sex specific normal values, an 
albumin/creatinine ratio ~ 3.5 gjmmol and hematuria were obseJVed more frequently in children with 
leucocyturia. The median (IQR) albumin/creatinine ratio of children with and without persistent 
leucocyturia was 0.7 (0.6-2.5) and 2.8 (1.2-10.6) respectively. In contrast IDV crystalluria was not 
detected more frequently in children with leucocyturia. The presence of symptoms, urinary pH>5, 
and the presence of crystalluria were not associated with persistent sterile leucocyturia. 
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Symptoms of nephrotoxicity after discontinuation of IDV because of nephrotoxidty 
In four of the fifteen children IDV was discontinued because of nephrotoxic symptoms (n=2) or 
nephrolithiasis on renal ultrasound (n=2). In these children serum creatinine (~mol/1) levels 
decreased from a median (IQR) of 54 (49-75) at the last observation during the use of !DV to 39 
(28-42) 12 weeks after discontinuation of IDV (p=0.07). The albumin/creatinine ratio decreased 
from 16 (8-44) to 0.7 (0.4-2.1) g/mmol (p=0.07). Leucocyturia disappeared within 3 months after 
the discontinuation of IDV. Figure 3 shows the serum creatinine levels and the albumin/creatinin 
ratios of the four children that discontinued IDV because of nephrotoxicity. Urine albumin/creatinine 
ratio increases preceded serum creatinine increases and may therefore may be an early marker of 
renal impairment. 
In three other children that discontinued IDV for other reasons (virological failure1 n=2 and 
because of the poor taste of IDV, n=l) serum creatinine levels did not decrease, whereas the 
albumin/creatinine ratio showed a decrease from 3.94 (0.51-11.2) to 0 g/mmol (p=0.10). 
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We here present the first study to monitor nephrotoxicity in HIV-1 infected children with a prolonged 
treatment with IDV. We hypothesized that IDV related nephrotoxicity might occur more frequently in 
children than in adults due to the higher risk for cellular damage to the still developing renal 
system. 
In our study a cumulative incidence of persistent sterile leucocyturia (;,2x :,: 75 cellsfld) of 
53% was observed after 96 weeks. This persistent sterile leucocyturia was frequently accompanied 
by a mild increase of the urine albumin/creatinine ratio and microscopic hematuria. The cumulative 
incidence of an increase in serum creatinine levels more than 50% above normal was 35% after 96 
weeks. Children with persistent sterile leucocyturia more frequently had an increase of serum 
creatinine levels of more than 50% above normal (p=0.02). This suggests that persistent sterile 
leucocyturia is an early indication for the development of renal damage. 
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Recently Gagnon et al. found a significant reduction in the renal function of 3 adults with 
recurrent severe leucocyturia. Our data confirm the observations in adults of Gagnon et al., that 
reduction of renal function is associated with recurrent severe leucocyturia, but not with isolated 
hematuria or crystalluria. (21) Renal damage resulting in leucocyturia and an increased creatinine 
may be a result of irritation of the tubular epithelium. This is supported by the pathologic finding of 
tubulointerstitial nephritis in patients on therapy with IDV. (4, 24, 25) 
The prevalence of persistent leucocyturia in adults screened on the same nephrotoxicity 
monitoring program was 22% (personal communication), which is substantially lower than we 
observed in children. One might hypothesize that IDV crystals more easily congest in the small tubuli 
of young children which may lead to a higher incidence of nephrolithiasis. The more frequent 
presence of persistent sterile leucocyturia in younger children confirms this observation. However, 
nephrolithiasis was only diagnosed by renal ultrasound in two asymptomatic children with persistent 
sterile leucocyturia (26). Renal ultrasounds of the other children with persistent leucocyturia showed 
no nephrolithiasis. Since it is well documented that the occurrence of IDV nephrolithiasis increases 
with a poor hydration status and high environmental temperatures (27), the Dutch climate with 
relatively moderate temperatures may contribute to a lower incidence of nephrolithiasis in our 
patients. Persistent leucocyturia might have been prevented by an increased fluid intake. Since it is 
more difficult to achieve a large fluid intake in young children, a relatively small fluid intake in 
younger children may be the cause of the more frequent occurrence of persistent sterile leucocyturia 
in children younger than 5.6 years (cumulative incidence after 96 weeks: 78%). 
We did not observe an association between IDV crystalluria and leucocyturia. Since IDV 
crystals can develop in the urine canister (28), it is possible that crystalluria refiects the time lapse 
between urine collection and urinalysis. 
We observed a higher cumulative incidence of persistent leucocyturia in children with an 
AUCo.s of IDV of >19 (mg/L *h) and in children with a peak level of IDV higher than 12 (mg/L). This 
is in accordance with previous publications on the relation between levels of IDV and urological 
complications in adults. An AUC of IDV less than 20 (mg/L *h) is associated with virological failure 
(17). This observation complicates the treatment of HIV-1 infected children with IDV: to achieve 
optimal virological suppression an AUC higher than 20 (mg/L *h) is required, but to avoid persistent 
leucocyturia an AUC less than 19 (mg/L *h) is needed. 
These observations suggest that IDV may be less useful in the treatment of HN-1 infected 
children. However, IDV is a very potent protease inhibitor which in combination with nucleoside 
analogues gives an excellent long-term clinical, virological and immunological response in adults and 
in children. (15, 29, 30) We therefore propose to monitor nephrotoxicity very closely in children 
treated with !DV and change therapy only in the case of overt signs of renal impairment. In this 
respect it is reassuring that the signs of renal impairment are reversible after discontinuation of IDV. 
Serum creatinine levels decreased in the four children with signs of nephrotoxicity which 
discontinued IDV. The urine albumin/creatinine ratio returned to zero in all patients. It still remains 
unclear whether renal impairment is reversible in all stages of damage or that a chronic renal 
insufficiency will develop above a critical level of cellular damage. 
We conclude that prolonged therapy with IDV is associated with a high risk for persistent 
sterile leucocyturia in children especially in those younger than 5.6 years. The presence of sterile 
leucocyturia is associated with a significant increase in serum creatinine levels. A high AUC (> 19 
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(mg/L*h)) and high peak levels (>12 (mg/L) of IDV are associated with the occurrence of 
leucocyturia. Therapeutic drug monitoring of IDV serum levels is therefore essential to estimate the 
risk of nephrotoxicity. Children with risk factors for the development of nephrotoxicity such as an 
age <5.6 years, AUC of IDV> 19 (mg/L*h), Cmax >12 (mg/L)) should be monitored routinely by 
means of urinalysis and analysis of serum creatinine levels. 
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Case reports 
A 3-year old girl diagnosed with HIV-1/AIDS was treated with indinavir (500 mg/m2 q8h), zidovudine 
(120 mg/m2 q8h) and lamivudine (4 mg/kg q12h) because of a high viral load (33,100 copiesfml). 
Pharmacokinetic analysis of indinavir showed a large area under the curve-concentration (AUC) and 
a high Cmax: 39 h*mg/L and 13.55 mg/1 respectively. The dosage of indinavir was not reduced 
because of the absence of clinically overt toxicity. The girl subsequently showed a good virological 
and immunological response to therapy. Urinalysis before the start of therapy was normal. 
Leukocyturia (51-250 leukocytesf.ul), without proteinuria, hematuria or crystalluria was detected 9 
months after initiation of therapy and persisted during the next 11/z years. Urine cultures were 
repeatedly negative. There were no clinical symptoms of nephrotoxicity (fiank pain, renal colic). 
Renal and liver function tests were normal. A renal ultrasound was performed after 27 months of 
therapy because of the persistent leucocyturia and showed medullary calcifications and cortical 
atrophy in both kidneys. Indinavir was subsequen~y switched to nelfinavir. The fiuid intake was 
increased to increase the solubility of indinavir in the urine. In addition, vitamin C (15 mg/kg q6h) 
was administered because of a potential favourable influence on the solubility of indinavir in urine 
(at urine pH values below 5 solubility of indinavir increases (1)). Three months later, leukocyturia 
decreased to 0-10 leukocytesM and a renal ultrasound showed a partial resolution of medullary 
calcifications and a normal cortex. 
A 4-year old girl with HIV-1/AIDS started HIV-treatment with indinavir (500 mg/m2 q8h), 
zidovudine (120 mg/m2 q8h) and lamivudine (4 mg/kg q12h) in 1997. The AUC and Cmax of 
indinavir were higher as compared to normal values for adults: 27 h*mg/L and 16.27 mg/1 
respectively. The dosage of indinavir was not decreased because of the absence of clinical signs of 
toxicity. Urinalysis before the initiation of therapy was normal. After 3 years of therapy a renal 
ultrasound was performed because of a persistent sterile leukocyturia (>250 leukocyteS/J.tl) and 
microscopic hematuria (11-50 erythrocytes/~!) without other urinary complications or laboratory 
abnormalities. This revealed multiple calcifications in the papillae and cortical atrophy of both 
kidneys. (Figure 1) Indinavir was switched to nelfinavir and the fluid intake was increased. Vitamin C 
(15 mg/kg q6h) was administered. 
Three months later, leukocyturia and microscopic hematuria decreased to 0-10 
leukocytes/~1 and 0-10 erythrocytesM respectively and the renal ultrasound had improved. A 
decrease of medullary calcifications and a normal cortex was observed. 
Indinavir is a potent HIV-protease inhibitor, which is widely used in combination with nucleoside 
reverse transcriptase inhibitors to treat HIV-1 infected adults and children. Indinavir crystals cause 
nephrolithiasis in 4-28% of patients, who typically present with flank pain and microscopic 
hematuria. (2,3) It is not yet clear, whether indinavir induced urine abnormalities in asymptomatic 
patients with a normal renal function should hav~ consequences for continuation or dosage 
adjustment of this therapy. Gagnon et al. suggested that recurrent severe leukocyturia in adults may 
be an indicator of renal damage by indinavir, even in the absence of crystalluria. However, three of 
their five patients with leukocyturia had a significanW increased serum creatinine. (4) The renal 
ultrasound of our patients showed severe cortical atrophy and extensive calcifications despite the 
absence of an increase in serum creatinine. We observed that these abnormalities were reversible 
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after discontinuation of indinavir, increased fluid intake and administering vitamin C. Nevertheless 
we cannot exclude that this would also be the case in a more advanced stage of renal damage. 
Elevated plasma concentrations of indinavir have been associated with urological 
complications (renal colic, fiank pain or haematuria) (5). The high AUC and/or the high Cmax may 
thus have contributed to the nephrotoxicity in these two children. We therefore advise to routinely 
monitor plasma concentrations of indinavir in children and to adjust the dosage in order to reach 
normal adult plasma concentrations. In addition we propose to regularly perform renal ultrasounds 
in children who are treated with indinavfr and who have an abnormal urinalysis. 
Figure 1 In a 4-year-old girl undergoing treatment with indinavlr; renal ultrasound was performed because of 
persistent leukocyturia. There were no clinical symptoms of nephrolithiasis and renal function was normal. 
Ultrasound of the right kldney shows calcifications in all papillae and a decreased thickness of the cortex, 
maximum of 0.3 em. 
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Abstract 
Background: The use of protease inhibitors (Pis) in patients with HlV-1/ AIDS has been associated 
with peripheral lipodystrophy, hyperlipidemia and insulin resistance. To date, all studies in this field 
have been performed in adults, whereas no data are available in children. Objective: To evaluate the 
infiuence of 18 months or more of highly active antiretroviral therapy (HAART), using one protease 
inhibitor and two nudeoside-analogue reverse transcriptase inhibitors, on the serum levels of lipids 
and glucose in HlV-1-infected children. Methods: Twenty children were included. Serum levels of 
fasting triglyceride, total cholesterol, high density lipoprotein cholesterol (HDL), low density 
lipoprotein cholesterol (LDL) and free fatty acids were evaluated at two timepoints: within the first 
month of HAART and at follow-up, after 18 months or more. Serum levels of fasting glucose, insulin 
and C-peptide were only evaluated at follow-up. Results: After 18 months or more of HAART serum 
levels of total cholesterol, HDL and LDL were significantly increased compared with baseline values. 
The total cholesterol/ HDL ratio, triglyceride and free fatty add concentrations remained stable over 
time. The fasting glucose, insulin and C-peptide serum levels were normaL Conclusion: Lipid 
abnormalities similar to those seen in adults treated with protease inhibitors are also observed in 
HlV-1-infected children. 
Introduction 
Protease inhibitors (Pis) have made a major contribution to the successful management of patients 
with HIV-1/ AIDS. Administration of PI containing regimens results in an improvement of virological 
and immunological parameters, clinical outcome and survival (1-3). 
Since the registration of Pis in 1996, a syndrome of hyperlipidemia, insulin resistance and 
peripheral lipodystrophy has been documented in HlV-1-infected adults (4, 5). The pathogenesis of 
this syndrome remains unclear. It is still unknown whether these abnormalities are caused by Pis or 
that the effect of other antiretroviral drugs may also play a role. Recently, Brinkman and colleagues 
hypothesized that mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase 
inhibitors may be a key factor in the pathogenesis of lipodystrophy (6). 
The prevalence of this syndrome is still unknown. Many investigations reported only the 
prevalence of one aspect of the syndrome, since the three major symptoms (hyperlipidemia, insulin 
resistance and peripheral lipodystrophy) do not coexist in all patients and can be encountered in 
various combinations. The prevalence of insulin resistance and of lipodystrophy in PI recipients, after 
a median or a mean period of fourteen months of PI use, has been estimated at 61% and 64% 
respectively (4, 5). An important factor in the analysis of the prevalence of lipodystrophy is the 
timing of the syndrome in relation to the start of antiretroviral therapy (7). Studies with a longer 
follow-up report a higher prevalence than those with a short follow-up period. 
Currently only two reports are available on the prevalence of this syndrome among children 
(8, 9). In one study abnormal body-fat distribution was seen in 1.5 % of 1644 children receiving a 
PI, versus 0.4% of 1069 children with therapy without Pis (8). In our study, in twenty children with 
prolonged therapy (> 18 months) with HAART, we did not observe clinical symptoms of 
lipodystrophy. However, we did not use standardised measurements, like waist/ hip ratio, skinfold 
thickness measurements and dual-energy x-ray absorptiometry. Watson and colleagues measured 
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the serum cholesterol levels in children and found a rise in mean non-fasting levels from 3.38 mmolfl 
before to 4.68 mmolfl after (a not specified period of) PI use (9). 
The aim of the current study was to evaluate the influence of HAART on serum levels of 
lipids and glucose in HN-1-infected children treated for more than 18 months with an indinavir (IDV) 
or nelfinavir (NFV) containing regimen of HAART. 
Methods 
We analysed relevant laboratory data from the Dutch prospective open uncontrolled multicentre 
study on the efficacy of HAART in HN-1-infected children (10). 
Serum levels of fasting triglyceride, total cholesterol, HDL, LDL and free fatty acids were 
evaluated at two timepoints: within the first month of HAART (with the exception of two children) 
and at follow-up, after 18 months or more. In this article the values within the first month of HAART 
wil! be indicated as 'baseline valuesr. Serum levels of fasting glucose, insulin and C-peptide were only 
evaluated at follow-up. These laboratory parameters were not stable enough to be analysed 
retrospectively. 
Patients 
Children between the ages of 3 months and 18 years were eligible for enrolment in the Dutch 
multicentre study. Children were included when plasma HN-1 RNA tests were positive on two 
subsequent occasions (children less than 18 months old) or when the HN serology was positive 
(children more than 18 months old) in the presence of one of the following abnormal test results: a 
mean HIV-1 viral load of more than 5000 copies/ml (mean of two measurements with less than four 
weeks in between) and/or a CD4 cell count below 1 year: <1750/mm3, 1-2 years: <1000/mm3, 3-6 
years: <750/mm3, >6 years: <500/mm3• Patients were excluded when they had been pretreated 
with antiviral agents other than zidovudine and/or didanosine or zalcitabine. There were no 
restrictions with regard to gender, ethnicity, or route of acquisition of HIV·l infection. 
Additional inclusion criteria for this study were: the use of HAART for 18 months or more, 
no use of corticosteroids, fasting values at baseline and a fasting condition at follow-up. Fasting was 
defined as a fasting period of at least three hours. 
Laboratory analysis 
Serum was obtained within the first month of HAART after a 12 h overnight fasting period and was 
stored at -80°C. Serum triglyceride, total cholesterol, HDL and free fatty acid levels were determined 
retrospectively by a commercial photoenzymatic assay (Hitachi, Boehringer-Mannheim, Germany). 
The second timepoint of blood sampling was after 18 months or more of HAART. These samples 
were taken after a fasting period of at least three hours. Triglyceride and total cholesterol were 
determined using another commercia! photoenzymatic assay (Dimension, Dade, USA); free fatty 
acids and HDL using Hitachi (Boehringer-Mannheim, Germany). Serum levels of LDL cholesterol were 
calculated by the method of Friedewald eta! (11). 
Glucose levels were determined by a commercial glucose hexokinase assay (Dimension, 
Dade, USA). Serum insulin and C-peptide levels were determined by a commercial 
radioimmunoassay (Medgenix, Biosource, Belgium). 
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Statistical analysis 
Statistical calculations were performed with the SPSS statistical analysis software program (version 
8.0). Comparison of lipid levels at both timepoints was performed by the Wilcoxon signed rank test. 
Correlation of lipid, glucose, insulin and C-peptide levels at follow-up was assessed using the 
Spearman rank correlation test. Comparison of lipid levels at baseline in pretreated and naive 
children was performed using the Mann-Whitney U-test. P values of < 0,05 were considered to 
indicate statistical significance. 
Results 
Twenty HIV-1-infected children, nine boys and eleven girls, were included in this study. Twelve 
children received IDV from the beginning, whereas two children were treated with NFV. five children 
switched from IDV to NFV treatment during the course of these 18 months, because of lack of 
tolerance for IDV. One child changed to a combination of IDV plus ritonavir (RTV) after twelve 
months of IDV use, because of virological failure. Additional patient characteristics at both 
timepoints are indicated in Table 1. 
Serum lipid levels of total cholesterol, HDL and LDL were significantly increased after 18 
months or more of HAART (p values: <0.001). The total cholesteroi/HDL ratio, fasting triglyceride 
and free fatty acids levels remained stable over time (Table 2). 
A high fasting triglyceride concentration of 2.8 mmol/1 was found in one patient, who used 
a combination of IDV and RTV. In this child the fasting triglyceride concentrations within the first 
month of IDV use and before the switch to a combination of IDV and RTV were 0.7 mmol/1 and 1.3 
mmol/1 respectively. 
Comparison of the serum lipid levels within the first month of HAART in pretreated and 
naive children showed significantly lower serum levels of total cholesterol and LDL in pretreated 
children (p values: 0.031 and 0.025 respectively). 
Two patients had fasting glucose concentrations of more than 7.1 mmol/1 at follow-up. 
Serum glucose levels were normal after an oral glucose tolerance test in the first patient. In the 
other patient an oral glucose tolerance test was not done. 
The Spearman Correlation Test showed a negative correlation between the serum levels of 
free fatty acids and glucose, insulin and C-peptide at follow-up (coefficient: -0.52, -0.77 and -0.87; 
p-values: 0.032, 0.001 and 0.001, respectively). 
Discussion 
Since the registration of Pis in 1996 a syndrome of hyperlipidemia, insulin resistance and peripheral 
lipodystrophy has been reported in HIV-1-infected adults. Several reports have been published about 
the cause, pathogenesis, severity and prevalence of this syndrome(6, 12, 13). However thus far, 
these studies were only performed in adults. This is the first report in HIV-1-infected children, in 
which increased cholesterol levels and normal glucose tolerance are observed. 
The aim of this study was to evaluate serum lipids and glucose after 18 months or more of 
HAART in children with HN-1-infection. This is more complex than the evaluation of these laboratory 
parameters in adults, because levels of glucose, insulin and lipids are age-dependent (14-16). 
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Table 1: Patient characteristics within first month of HAART and at follow-up 
Demography and antropometry 
Sex: Male/ female 
Race: - African 
Caucasian 
Asian 
Other 
Age(years) 
Standard deviation (z-scores) of BMI 
Ginical stage {CDC-dassification)* at start HAART: 
N1/N2 
A1/A2/A3 
81/82 
C2/C3 
Pr/or treatment 
No pr/or treatment 
Pr/or treatment: number (duration of use in months): 
- Zidovudine 
- Zidovudine + Zaldtabine 
- Zidovudine + D1danosine 
Surrogate markers 
CD-4 cell percentage{%) 
HIV-1 RNA (copies/mf) 
Protease inhibitor 
Indinavlr 
Nelfinavir 
Indinavlr + Ritonavlr 
Duration of protease inhibitor use (months) 
Combination of reverse transcr/ptase inhibitors 
Zldovudine + Lamivudine 
Didanosine + Stavudine 
Lamivudine + Stavudine 
Rrst timepoint 
{51 month of HMRT) 
(n~20) 
9/11 
12 
4 
1 
3 
5.8 {1.1-16.5) 
0.12 (-2.9-1.4) 
2/1 
2/4/3 
1/3 
1/3 
9 
9 {21, range: 8-118) 
1 {18) 
1 {21) 
27(1-72) 
715 {480-11800) 
18 
2 
0 
1 (0.25-3) 
18 
1 
1 
Second timepoint 
(:::18 months of HMRT) 
(n~20) 
7.3 (2.8-18.2) 
-0.02 {-2.1-2.0) 
37{18-55) 
500 (500-67600) 
12 
7 
1 
22 {18-24) 
14 
4 
2 
Data are numbers or medians (ranges) *Clinical and Immunologic catagories as defined by the US 
Centers for Disease Control and prevention (CDC) (22) 
Despite the additional complexity in the analysis, we found a significant increase in serum levels of 
total cholesterol, HDL and LDL after 18 months or more of HAART in HIV-1-infected children. 
To date it has not been clarified whether these metabolic changes are the result of HAART 
or whether the HIV-1-infection itself is responsible. Hypertriglyceridemia and low levels of total 
cholesterol, HOL and LDL have been detected in HIV-1-infected patients without prior antiretroviral 
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therapy, especially in the late phase of the disease (17). Therefore, one would expect a more 
Table 2: Metabolic data of 20 children using HAART 
Metabolic parameters A"rst timepoint Second timepoint P-value 
(<1 month of HMRT) ~18 months of HMRT) 
Total cholesterol (mmof/1) 3.0 {1.7-4.3) 4.7 (3.2-6.5) 0.001 
HDL (mmof/0 0.8 {0.4-1.2) 1.3 (0.7-2.5) 0.001 
LDL (mmof/1) 1.7 (0.8-4.6) 2.7 {1.7-4.9) 0.001 
Cholesterol/ HDL ratio 3.6 (2.2-6.5) 3.4 (2.2-6.6) 0.514 
Tn"glycerlde (mmof/1) 0.5 {0.2-2.2) 0.8 (0.1-2.8) 0.167 
Free fatty adds (mmol/1) 0.6 (0.2-1.3) 0.5 (0.1-2.0) 0.808 
Glucose (mmof/1) NA 5.0 (3.7-7.4) 
Insulin (mU/1} NA 11 (5-72) * 
C-pepb"de (mmof/1} NA 0.7 {0.3-3.4) * 
Data are medians (ranges) NA: not available * Data not available for one patient 
significant rise in levels of total cholesterol, HDL and LDL in patients with an advanced stage of 
disease, who are succesfully treated with HAART, as compared to children in an early phase of HIV/ 
AIDS. Thus, the significant rise in total cholesterol, HDL and LDL in children with HIV/ AIDS may not 
only be attributed to the effects of HAART, but may be also partially be the result of a normalisation 
of pre-existing lipid abnormalities. 
An explanation for the absence of a significant rise in serum triglycerides (and at the same 
time a limitation of the design of this study) is that we did not collect fasting values of serum lipids 
before the start of HAART. Churchill eta/ have documented, that serum triglyceride levels have a 
normal course with a peak after four weeks of PI use (18). Thus, it may be possible that we have 
missed the peak at our first timepoint. 
It is difficult to discriminate the metabolic effects of Pis from those of other antiretroviral 
drugs in this study. Most children received a combination of a PI, zidovudine and iamivudine. 
Zidovudine and lamivudine are also reported to cause lipodystrophy and lipid abnomnalities (19). 
Before starting HAART, eleven children were pretreated with zidovudine. These pretreated children 
had significan~y lower levels of total cholesterol and LDL at baseline than naive children, suggesting 
that zidovudine itself may have an effect on the lipid metabolism. 
Although our patient group was too small to evaluate any differences between the various 
Pis on the selected metabolic parameters, we observed a high triglyceride level of 2.78 mmolfl in 
one patient receiving a combination of IDV and RTV. Similar to other studies, this may suggest that 
RTV is a more likely cause of elevated triglyceride levels than other Pis. (4, 20) 
Our data show that the fasting glucose, insulin and C-peptide values were normal. 
Unfortunately these values were only analysed at follow-up. Therefore we could not confirm a 
potential rise in serum levels. In two children a fasting glucose concentration of more than 7.1 
mmoljl was detected. However, one child did have a normal oral glucose tolerance test, whereas we 
did not perform this test in the other child. These high values of glucose may have been 
coincidental. Alternatively, these patients may have taken food in the three hours fasting period. 
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Further investigations are necessary to determine, whether insulin resistance is present in HIV-1-
infected children on HAART. 
In summary, we found an increase in serum levels of total cholesterol and LDL after PI use 
in HIV-1-infected children, as was previously observed in adults (4, 21). However in contrast with 
adults, a marked increase in HDL, but normal glucose were observed (5, 13). 
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Chapter 17 
In Chapter 1 we describe the background and initial goals of the studies presented in this thesis. In 
1997, the increasing number of children with HIV/AIDS in The Netherlands stimulated three 
university children's hospitals (in Amsterdam, Rotterdam and Utrecht) to coordinate their efforts to 
optimize the diagnosis, therapy and care of these children. fls part of this initiative a multidisciplinary 
working group was formed. At the same time a collaborative open-label multicenter trial was started. 
The aim of this study was to evaluate the clinical effects, the virological response rate, 
pharmacokinetic and pharmacodynamic aspects of selected antiretroviral agents and the extent of 
immunereconstitution in response to combination therapy consisting of indinavir, zidovudine and 
lamivudine. A team of experts in immunology, virology, pharmacology, internal medicine and 
pediatrics specialized in HIV/AIDS was created in order to rapidly apply new concepts in the field of 
care, cure and research in adults into the field of pediatrics. In addition, a multidisciplinary team was 
created to provide care for children with HIV/AIDS in the Sophia Children's Hospital in Rotterdam. 
This team includes nurse specialists, a social worker, research physicians and pediatric infectious 
disease experts. The leading principle in the design of the study was that care of HIV infected 
children should be organized in a structured scientific way and that research projects should 
predominantly serve to improve the quality of life of children with HIV/AIDS. 
In chapter 2 we present an overview of the content of this thesis, which contains the 
results of a comprehensive set of studies on the epidemiology of HIV-1 infection in children in The 
Netherlands, the effectiveness of prevention of transmission of infection from mother to child, the 
pharmacokinetic and pharmacodynamic aspects of HAART in children, the effects of HAART on the 
well-being and growth of children, selected aspects of the immunereconstitution, which is associated 
with the use of HAART in children and prospective analyses of side-effects of HAART. 
In 1995 a prospective surveillance of all children who were pre- or perinatally exposed to HIV or 
postnatally diagnosed with HIV infection was started in The Netherlands. Pediatricians reported new 
children monthly to the Dutch Pediatric Surveillance Unit. In chapter 3 we show the effects of 
implementation of the guidelines to prevent perinatal transmission in The Netherlands in the period 
from 1995 until 2000. An increase in the number of children who were perinatally exposed to HIV 
was observed and the percentage of children who became infected after exposure simultaneously 
decreased from 20% in 1995 to only 4% in 1999. This improvement reflects the increased 
understanding of the pathogenesis and treatment of HIV infection and of the mode of prevention of 
mother-to-child transmission. The risk on mother-to-child transmission, which is 15-30% without 
interventions (1-4), can be reduced to 0-3% by the administration of highly active antiretroviral 
medication to mother and by the administration of zidovudine to the child during the first weeks of 
life. When the maternal viral load is above 1000 copiesjml at the time of delivery an elective 
cesarean section should be performed, which may in combination with antiretroviral prophylaxis 
reduce the risk for transmission to almost 0%. (5-9) The decrease in transmission from 20% to 4% 
can be attributed to a great extent to the increase in the use of HAART by pregnant HIV-1 infected 
women in this period from 0% to 70%. We therefore conclude that the Dutch guidelines to prevent 
mother-to-child transmission of HIV-1 infection have been well implemented and are efficacious. 
In chapter 4 we present data on the cumulative number of children living in The Netherlands who 
were diagnosed with HIV infection, on their mode of transmission, their risk factors and their clinical 
features from the start of the AIDS epidemic in the 1980's until 2000. The increase in the number of 
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newly detected HJV-1 infected children during the period 1995-1997 reached a plateau during the 
period 1998-2000. This may be due to a more active approach in the counseling and screening for 
HIV in pregnant women. Since 1999 women at risk for infection with HIV (women originating form a 
country with a generalized HIV epidemic and women having sexual contacts with men at risk for 
infection with HIV) are counseled and advised to undergo an HIV test. In 86% of the children one or 
both parents originated from a country with a generalized HIV epidemic. Most children (81 %) were 
infected by mother-to-child transmission. Fourty-eight percent was born in The Netherlands. The risk 
for transmission of HJV could be significantly reduced when the mother was tested prenatally for HIV 
and treated according to the guidelines. In 2000 Postma et al. evaluated the cost-effectiveness of 
universal HJV-screening of pregnant women in Amsterdam. (10) They showed a favorable cost-
effectiveness of universal HIV-screening of pregnant women. However, the actual costs of the 
treatment of HIV infected children are not known. Therfore, accurate estimates of the cost-benefit 
analysis are not yet possible. We have therefore recently initiated a study to analyze the costs for 
the care and treatment of HIV-1 infected children in The Netherlands in collaboration with Postma. 
Our data indicate that one or both parents of 86% of the children originate from a country with a 
generalized HIV epidemic. It therefore seems unnecessary to screen all pregnant women in The 
Netherlands as was recently advised by the Ministry of Health. A screening program in individuals 
belonging to risk-groups is in our opinion a much more cost-effective solution. 
One or both parents of 95% of the newly detected HIV-1 infected children originated from 
other countries than The Netherlands. The treatment of these children is complicated by difficulties 
in communication and by major differences between the families of these children and the 
indigenous Dutch population in social, cultural and economical aspects. These differences demand a 
very intensive and family specific approach with attention for the transcultural aspects. It is obvious 
that this very intensive approach is associated with substantially higher costs in the care for HIV 
infected children, than in the care for adults with HIV/AlDS. 
It has been well known that the pharmacokinetics and pharmacodynamic aspects of many drugs are 
very different in children as compared to those in adults. One can therefore not assume that 
successful medical treatment in adults will be always beneficial in children. Therefore, the 
administration to children of new agents such as the HIV-1 protease inhibitors, should be preceded 
by detailed pharmacokinetic and pharmacodynamic evaluations. The goal of this approach is to 
ensure similar efficacy and equal or less toxicity compared to those reported in adults. In chapter 
5, the pharmacokinetics of the protease inhibitor indinavir in children are described. We showed the 
presence of substantial interindividual differences in the different pharmacokinetic parameters such 
as AUC, Cmax and Cmin. The higher metabolic clearance and the increased volume of distribution of 
indinavir resulted in suboptimal drug levels in many of the HJV-1 infected children. A number of 
studies previously showed a relation between the concentration of indinavir and the virological 
response rate. (11-13) 
We describe in chapter 5 the presence of a relation between an AUC of indinavir above 20 
mg/l*h and the virological success rate. Because of the major age-related individual differences in 
the pharmacokinetics of indinavir, one needs to monitor the levels of indinavir in plasma shortly after 
the start of an indinavir containing regimen and to adjust the indinavir dose when necessary in stead 
of using a fixed dosis regimen for each child. There has been some concern that the risk of indinavir-
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induced nephrological toxicity (kidney stones, hematuria, and fiank pain) in children may be higher 
than in adults. Urological toxicity is the result of precipitation of indinavir crystals and this is 
correlated with the peak level of indinavir in plasma. (14) Although indinavir peak levels were higher 
in children compared to adults none of the children developed kidney stones within the first 6 
months of treatment. However, in chapters 14 and 15 nephrological side-effects of indinavir in 
children were analyzed in more detail and were found to be present in a high percentage of the 
children. In addition, a relation between drug levels and the incidence of nephrological toxicity was 
observed. 
The unpredictable interindividual differences in the pharmacokinetics of protease inhibitors (and 
probably also other antiretroviral drugs) in children underscore the importance of therapeutic drug 
monitoring (TDM) in children treated with indinavir to prevent suboptimal drug levels resulting in 
virological failure and to prevent toxicity caused by high drug levels. Research on the relation 
between drug levels of protease inhibitors and differences in metabolism by cytochrome P450 3A 
isoenzymes may elucidate the cause of these interindividual differences. This may in the future be 
helpful in the prediction of an optimal drug dose. The use of micro-arrays, which will enable the 
parallel analysis of large numbers of genetic polymorphisms in different metabolic pathways may in 
the future contribute towards better understanding and prediction of these differences in the 
metabolism of protease inhibitors. 
In chapter 6 we show that twice daily indinavir administered in combination with the 
protease inhibitor ritonavir results in higher AUC's and trough levels of indinavir through the 
inhibition of CYP450 3A metabolism by a low-dose of ritonavir (100 mg/m2). This study forms the 
basis for future studies with simplified twice daily regimens in children. However, again the 
pharmacokinetics of indinavir and low-dose ritonavir differed widely between individual children 
underlining the necessity for TDM. 
Although there are definite clinical benefits from TDM, many pediatricians fail to use ~ as a regular 
clinical tool mainly because of practical problems with sampling. There are at least five different 
sampling strategies that can be used to perform TDM: analysis of full drug exposure (AUC), through 
levels, both peak and through levels, population based pharmacokinetic approaches (concentration 
ratios as used in the Dutch Athena cohort) or sophisticated PK modelling. Although it seems 
acceptable to study trough levels when one is analyzing virological efficacy, it is important to realize 
that trough levels are not a reliable indicator for virological response rates due to the inaccurate 
recording of the time when the last medication was taken. Another problem is that the trough level 
is not always similar to the Cmin and there may also be variation between trough levels in the 
evening and morning. In addition, the lower quantitation range of assays can be less accurate than 
in the middle or the highest range. To check toxicity levels in children one needs to analyze the 
Cmax. The time to sample the Cmax will vary from 1-4 hours depending on the Tmax for individual 
drugs and individual pharmacokinetics. Mathematical modelling can be performed from a sample 
taken at a random time point with knowledge of the patient's exact dosing times for the past couple 
of days. From one sample one can derive the AUC, the Cmax, and Cmin and the clearance for the 
patient. The difficulty of this approach is that different models are needed for each combination of 
drugs and that different metabolic rates are encountered at different ages. A large amount of data is 
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required to validate these models. It may be possible to generate reliable results by modeling of a 
simplified curve using drug levels at three time-points. Currently the only way to bypass these 
problems is to perfonm a full PK curve to determine the AUC and the other parameters such as Cmax 
and Cmin. This is a laborious, difficult and expensive procedure which contributes to the large 
expenses needed to perform appropriate care for HIV-1 infected children. 
TOM is currently an inappropriate method for nucleoside reverse transcriptase inhibitors due to the 
difficulties in the measurement of intracellular phosphorylation. Nucleoside analogues are activated 
intracellularly by the addition of three phosphate groups. Measurement of the levels of 
triphosphorylated intracellular NRTI's is laborious and requires a large number of polymorphonuclear 
cells (and a large volume of blood), which makes this technique not useful in children. We recently 
developed a method using a Malditof massspectrometer to measure intracel!ular drug !eveis of 
nucleoside analogous' with only 12,500 cells (0.3 ml plasma). In addition, this method is very 
promising because it has the potency to become an automated process. With this technique it will be 
possible in the future to analyze the relation between intracellular levels of NRTI's and virological 
response rates. 
In chapter 7 we describe another application of TDM: the use of TDM to assess adherence to 
therapy. Adherence to therapy is required to obtain an optima! long-term virological response rate in 
HIV-1 infected children. An accurate assessment of the level of compliance is complicated by the 
limitation of the currently available methods. Plasma concentrations of protease inhibitors outside 
the limits of the reference values indicate non-adherence to antiretroviral therapy in adults. We 
observed that the compliance rates calculated as the percentage of samples that fulfilled the criteria 
for compliance using only the lower CORALs (concentration ratio limit consisting of the 5th percentile 
of population data obtained in adults) of indinavir or nelfinavir in children and the virological 
response rate are associated. This method may therefore be useful to assess non-compliance in 
children. However, it is based on population data obtained in adults. Population data obtained in 
children should be assembled to calculate concentration ratio limits in children. Since we observed a 
large interindividual variability in the pharmacokinetics of protease inhibitors, the use of 
concentration ratio limits consisting of the 5th percentile of population data obtained in children may 
not be the most optimal method. Optimization of this method may be possible by calculating CORALs 
in relation to the child's own PK curve. This will be analyzed and correlated to other adherence 
assessment strategies, which are currently used. These strategies include electronic pill boxes that 
registrate the dates and times a bottle was opened, and multidisciplinary support by specialized 
pediatricians, nurses, social workers and by the genera! practitioner and family home care. 
Adherence to therapy is supported by structured discussions with parents and children in which 
information on the importance of adherence to the therapy is given. In Belgium, recently an 
interactive cartoon on video with information on HIV infection, medication and adherence was 
developed for children of different ages. This video will be used during the routine visits to the nurse 
specialized in HIV/AIDS at our outpatient department. The focus of attention during these visits will 
be adherence to the antiretrovira! therapy. To optimize the support structure for children with 
H!V/AIDS, we are currently analyzing the data obtained by a structured social background 
questionnaire. In this questionnaire the family's social network including, friends and other care-
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givers is analyzed. The frequency and quality of support, the level of education, employment and the 
financial situation are explored. This questionnaire will be used in the future to prospectively, 
analyze risk factors for non-compliance with antiretroviral therapy. 
Since the introduction of protease inhibitors in 1996, combination therapies including two reverse 
transcriptase inhibitors and a protease inhibitor have rapidly become standard therapy for HIV-1 
infected adults. The data on efficacy of these combinations in children with HIV-1 infection are 
limited and are predominantly derived from studies with small numbers of children. In chapters 9 
and J.O the clinical, virological and immunological response rates in children with HIV/AIDS treated 
with HAART are studied with a follow-up period of 24 and 96 weeks respectively. The results of the 
treatment using PI"s and NNRTTs have been excellent. Since the introduction of this therapy in 1997 
only one child at a very advanced stage of disease in the initial phase of therapy died. Currently 
(January 2002), all other children are in an excellent clinical health. The two-year follow-up data 
indicate, that 69% of the children have a viral load below 500 copies/ml, and that 50% have a viral 
load below 40 copies/mi. These results are comparable with those obtained in adults. However, the 
majority of pediatric studies show inferior virological responses in comparison with those in adults. 
Several factors have been associated with a higher risk for virological failure. These include 
pharmacokinetic parameters (low plasma blood levels of protease inhibitors are associated with 
virological failure), inadequate adherence to antiretrovira! therapy and differences in baseline 
characteristics (prior antiretroviral treatment, younger age, and high baseline viral load). It is striking 
that all four pediatric studies in which dosages of the administered PI were adjusted after 
pharmacokinetic evaluation report superior virological response rates compared with studies in which 
fixed dosages were used (chapter 8). The inferior virological response rates, which have been 
reported in HIV-1 infected children treated with HAART form a refiection of the challenges which are 
encountered in the treatment of children with HIV-1/AIDS. Difficulties with adherence and with the 
pharmacokinetics of protease inhibitors in children demand an intensive, child adjusted approach. 
Because of the necessity for treatment for an indefinite period, adherence will in the future 
increasingly become a problem. Optimizing therapy adherence by means of structured discussions 
with parents and children, using booklets in which stickers can be applied after dosing, and 
therapeutic drug monitoring requires increasing efforts from the multidisciplinary team. We recently 
started to use of electronic pill boxes in order to offer additional information on therapy adherence. 
Our social worker is analyzing the social backgrounds of the families of our children to identify social-
economic factors that may interfere with adherence to therapy. This eventually may result in child 
and family-specific interventions. In addition, a cost-effectiveness analysis of this intensive 
intervention program will be performed. 
Twice daily regimens and (in the future) once daily regimens of HMRT may contribute 
towards a better therapy adherence. We are currently initiating new studies in which twice-daily 
therapy with two NRTI's and dual Pis versus a regimen with three NRTI's (abacavir, zidovudine and 
lamivudine) is used and in which adherence is measured with TDM, electronic pill boxes and 
structured interviews. The aims of future studies will include a lower pill burden, medication with less 
side-effects, improved support by a child-specific approach (for example by means of an interactive 
cartoon) and improved adherence by increased attention specifically directed to this issue by a 
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specialized nurse. In addition, the infiuence of therapy (swallowing pills, side-effects, stigmatising) 
on the quality of life is curren~y analyzed with the validated PEDsQol questionaires. 
In chapter 11 the immunological responses to HAART are described. Since data on long-term T-cell 
dynamics in HIV-1 infected children on HAART were not available, it was still unclear to what extent 
the number of CD4+ T-cells of H!V-1 infected children could be normalized. CD4+ T-cell numbers in 
HIY-1 infected children on HAART recover more rapidly than CD4+ T-cells in HIV-1 infected adults. 
This observation has been attributed to the relatively large thymus and the better thymus function in 
young children. Our study is the first in which recovery of CD4+ T-cell counts is related to reference 
values for lymphocyte subpopulations. In general, absolute CD4+ T-cell counts are used in pediatric 
studies on T-cell repopulation during HAART, since CD4+ T-cells as percentages of total T-cell 
counts are influenced by the major changes in the number of CDS+ T-cells which are encountered in 
HIV-1 infected patients. However, analyses ofT cell repopulation in groups of children with different 
ages are hampered by the fact that CD4+ T-cell counts are highly dependent on the age of the 
patients. Reference values in younger children are much higher and have a large range compared to 
those in older children. (15) Hence, younger children need to produce larger numbers of CD4+ T-
cells to achieve their normal age-related CD4+ T-cell counts. The calculation of CD4+ T-cel! counts 
as percentage of normal absolute values thus results in an independent parameter for the degree of 
CD4+ T-ee!! restoration. Using this method it appears from our data that CD4+ T-ee!! counts in older 
children are restored to the same degree relative to their normal values as in younger children. Even 
children with extremely low CD4+ T-ee!! counts at baseline did reach normal values during the 96 
weeks of follow-up. Reconstitution of the immune system is predominantly caused by the production 
of naive CD4+ T-cells. In addition to the quantitative improvement of the immune system, the T-ee!! 
function also improved after stimulation with CD3 mAb plus CD28 mAb. This indicates that there is 
also functional improvement ofT cells during HAART. Analyses on the changes of immune activation 
markers and the relation with virological response are ongoing. A remarkable finding was the 
absence of differences between virological responders and non-responders. This phenomenon could 
be explained by the selection of certain viral variants with resistance to protease inhibitors that have 
in-vitro impaired replicative capacity. This dissociation between continuing good clinical and 
immunological response rates in the presence of virological failure has been also observed by others. 
A longer follow-up and additional research are needed to better understand the underlying 
mechanisms of this phenomenon. The results from genotypical resistance analyses should be 
interpreted critically because of the frequent absence of clinical and immunological consequences. 
This is especially the case in heavily experienced patients who are left without treatment options. 
Dysregulation of growth is a common feature of HIV-1 infection in children. Since growth seems to 
be one of the most sensitive indicators of disease progression in HIV~ 1 infected children, growth 
after the initiation of HAART is an important parameter in children. In chapter 12 we describe the 
effects of therapy on growth in our cohort. We observed a positive effect of HAART on height and 
weight in children with HIV-1 infection. In contrast to studies with mono- and duo-therapy in which 
the positive effect of growth was only temporarily, this effect is sustained for at least 96 weeks and 
is associated with the successful application of HAART resulting in long-term viral load reduction and 
an increase of CD4+ T-cell counts. The etiology of the HIV-1 related growth dysregulation is 
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complex. Abnormal funcbon of the thyroid gland, the somatomedine axis, the lipid metabolism and 
abnormal resting energy expenditure may also contribute to diminished growth. We therefore 
studied the endocrinological and immunological mechanisms underlying the recovery of growth in 
HN-1 infected children treated with HAART. 
In chapter 13 we describe the results of this study. We determined cortisol, thyroid and 
growth hormones, and TNF-o: serum levels. Hormones that infiuence growth postnatally indude 
growth honmones and insulin-like growth factor I (IGf.. I) as well as thyroid honmone and 
glucocorticoids. Excessive levels of glucocorticoids or very low levels of thyroid hormone during 
childhood result in growth retardation. These hormones play a permissive role in promoting growth 
stimulated by growth hormone and IGF-l. Tumor necrosis factor -o: (TNF-o:) is a pro-infiammatory 
and immunomodulatory cytokine with an increased production rate in the presence of infectious 
diseases and malignancies. TNF-o: also strongly inhibits lipoprotein lipase and adipocyte gene 
expression. Chronically high levels of TN F-a have been associated with the development of cachexia. 
To determine changes in the growth hormone (GH) axis IGF-I and IGFBP-3 levels were measured. 
IGF-1 and its most important binding protein IGFBP-3 are known to be GH-dependent and have the 
major advantage that their concentrations are fairly constant throughout the day. Baseline levels of 
free T4 and cortisol were within the normal range and did not change during therapy, suggesting 
that hypothyroidism and adrenal axis abnormalities are not associated with recovery of growth after 
the initiation of therapy. Baseline serum levels of IGF-1 and IGFBP-3 are within the range of normal, 
but increased significantly after the initiation of therapy in this cohort with a high percentage of 
children with an optimal virological response (80%) and a significant decrease of TNF~a. The 
combination of relatively high serum levels of IGFBP-3 and low IGf..1levels suggests the presence of 
a GH resistant state at baseline. The decrease in IGFBP-3 serum levels and the stabilization of IGF-1 
levels after an initial significant increase suggests restoration of the sensitivity to GH and return to 
an anabolic condition during protease inhibitor containing therapy. Further research is needed to 
investigate whether other factors causing growth failure, such as inadequate caloric intake, 
abnormalities in lipid metabolism and total energy expenditure, may also play a role in the recovery 
of growth parameters during HAART and to confirm our hypothesis on the restoration of the 
sensitivity for GH. 
Antiretroviral drugs such as indinavir need to be continued for many years thus underscoring the 
importance of a careful surveillance for long-term toxicity. The protease inhibitor indinavir may cause 
symptoms of nephrolithiasis through the formation of indinavir crystals. However, damage to the 
tubular epithelium may occur without symptoms. This sub-clinical phase can be followed by 
symptomatic renal injury. Symptomatic nephrotoxicity by the use of indinavir has been well 
described but little is known about the relevance of leucocyturia during the use of indinavir. 
In chapter 14 we present the first study to monitor nephrotoxicity in HN-1 infected 
children on a prolonged treatment with indinavir. We observed a cumulative incidence of persistent 
sterile leucocyturia of 53% after 96 weeks (in children younger than 5.6 years: 78%) and a 
cumulative incidence of an increase in serum creatinine levels more than 50% above normal of 35% 
after 96 weeks. Children with persistent sterile leucocyturia more frequently had an increase in 
serum creatinine levels of more than 50% above normal. This suggests that persistent sterile 
leucocyturia is an early indication for the development of renal damage. We observed a higher 
188 
Summaty and discussion 
cumulative incidence of persistent sterile leucocyturia in children with an AUC of indinavir of > 19 
mg/L *h and in children with a peak level of indinavir higher than 12 mg/L. Because of our previous 
observations which showed that an AUC of indinavir less than 20 mg/L *h was associated with 
virological failure, this complicates the treatment of HIV-1 infected children with indinavir. To 
achieve optimal virological suppression an AUC higher than 20 mg/L *h is required, but to avoid 
persistent leucocyturia an AUC less than 19 mg/L *h is needed. These observations suggest that 
indinavir may be less useful in the treatment of HIV-1 infected children. However, indinavir is a 
potent protease inhibitor, which in combination with nucleoside analogues gives an excellent long-
term clinical, virological and immunological response in adults and in children as is showed by us in 
chapters 9 to 13. We therefore propose to monitor nephrotoxicity very closely and change therapy 
only in the case of overt signs of renal impairment. In this respect it is reassuring that the signs of 
renal impairment are reversible after discontinuation of indinavir. Since nephrotoxicity does not occur 
during the first 3 months of the therapy an alternative strategy could be an induction-maintenance 
regimen in which indinavir is used during the initial first months of therapy to strongly suppress 
virological replication followed by an easier, but less potent drug regimen. 
In chapter 15 we describe two cases of indinavir associated asymptomatic nephrolithiasis 
and cortex atrophy in HIV-1 infected children. Renal ultrasounds were performed because of 
persistent sterile leucocyturia in five children. In two children extensive calcifications and severe 
cortical atrophy were detected on ultrasound despite the absence of an increase in serum creatinine. 
We observed that these abnormalities were reversible after discontinuation of indinavir. Nevertheless 
we cannot exclude that this would also be the case in a more advanced stage of renal damage. In 
these two children a high AUC and Cmax of indinavir were observed. Since elevated plasma 
concentrations of indinavir have been associated with urological complications, the high AUC and 
Cmax may thus have contributed to the nephrotoxicity in these children. This observation 
underscores the need for routinely performed urinalysis and therapeutic drug monitoring in children 
treated with indinavir. In addition, we propose to regularly perform renal ultrasounds in children who 
are treated with indinavir and woh have an abnormal urinalysis. 
A syndrome of hyperlipidemia, insulin resistance and peripheral lipodystrophy has been reported in 
HIV-1 infected adults since the registration of protease inhibitors in 1996. The prevalence of this 
syndrome is still unknown since many investigators only studied the prevalence of one aspect of the 
syndrome, because the three major symptoms (hyperlipidemia, insulin resistance and peripheral 
lipodystrophy) do not coexist in all patients and can be encountered in various combinations. An 
important factor in the analysis of the prevalence of lipodystrophy is the timing of the syndrome in 
relation to the start of antiretroviral therapy. Studies with a longer follow-up report a higher 
prevalence than those with a shorter follow-up. To date it has not been revealed whether these 
metabolic changes are the result of HAART of if HIV-1 infection itself is responsible. Chapter 16 
contains a study on changes in serum lipid levels and glucose-metabolism. Serum lipid levels of total 
cholesterol, HDL and LDL were significantly increased after 18 months or more of HAART. Serum 
glucose, insulin and C-peptide levels were normal. Hypertriglyceridemia and low levels of total 
cholesterol, HDL and LDL have been detected in HIV-1 infected patients without prior antiretroviral 
therapy, especially in the late phase of the disease. Therefore, one would expect a more significant 
rise in levels of total cholesterol, HOL and LDL in patients with an advanced stage of disease, who 
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are successfully treated with HMRT as compared to children in an early phase of HIV infection. 
Thus, the significant rise in the serum levels of total cholesterol, HDL and LDL may not only be 
attributed to the effects of HMRT, but may also partially be the result of a normalization of pre-
existing lipid abnormalities. While among adults high incidences of clinically overt lipodystrophy are 
reported, we did not observe overt clinical symptoms of peripheral lipodystrophy and/or central 
obesity in our study. The absence of clinical signs of lipodystrophy should be further supported by 
analyses of objective standardized measurements, such as the waist/hip ratio's, the skinfold 
thickness measurements and dual-energy X-ray absorptiometry. Child-specific factors, like the 
presence of growth hormones or the absence of sex hormones may reduce the risk for peripheral 
lipodystrophy in children. Future research should focus on this issue, since it may contribute to the 
elucidation of the mechanism causing lipodystrophy in adults. In addition, differences in lipid 
metabolism between different protease inhibitor containing and protease inhibitor sparing treatment 
regimens should be investigated. In order to be able to perform this kind of studies large numbers of 
children are needed. Therefore these analyses should be performed in an international multicenter 
trial, for example in the European Paediatric European Network for Treatment of AIDS (PENTA). 
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In hoofdstuk 1 worden de achtergronden en de initiele doelstellingen beschreven van de studies, 
die in dit proefschrift gepresenteerd worden. In 1997 bundelden de drie academische 
kinderziekenhuizen (in Amsterdam, Rotterdam en Utrecht) die geconfronteerd werden met een 
toenemend aantal kinderen met HIV /aids hun krachten om te komen tot een optimalisering van de 
behandeling en de zorg voor deze kinderen. Als onderdeel van dit initiatief werd een 
multidisciplinaire werkgroep gevormd. Tegelijkertijd werd gestart met een gezamenlijk studieprotocol 
in aile academische centra in Nederland. Het doel van deze studie was het evalueren van het 
klinische effect, het virologische effect, de farmacokinetische en farmacodynamische aspecten van 
geselecteerde antiretrovirale middelen en de mate van herstel van het immuunsysteem volgend op 
het instellen van een combinatiebehandeling bestaande uit indinavir, zidovudine en lamivudine. Er 
werd een team van experts gevormd op immunologisch, virologisch en farmacologisch gebied en de 
terreinen van de interne geneeskunde en de kindergeneeskunde om nieuwe inzichten op het gebied 
van zorg, therapie en onderzoek bij volwassenen snel te kunnen toepassen en evalueren bij 
kinderen. Tegelijkertijd werd in het Sophia Kinderziekenhuis in Rotterdam een multidisciplinair team 
gevormd waarbij als taak gesteld werd de zorg voor kinderen met HIV/aids te optimaliseren. Dit 
team bestaat uit een gespecialiseerde verpleegkundige, een maatschappelijk werker, arts-
onderzoekers en kinderarts-infectiologen. Het belangrijkste principe bij de opzet van de landelijke 
studie was dat de zorg voor met HIV ge"infecteerde kinderen georganiseerd zou moeten worden op 
een geprotocolleerde (wetenschappelijke) manier en dat onderzoeksprojecten dienstbaar moeten 
zijn aan de verbetering van de kwaliteit van Ieven van kinderen met HIVjaids. 
In hoofdstuk 2 wordt een overzicht gegeven van de inhoud van dit proefschrift, dat 
bestaat uit een serie studies op het gebied van de epidemiologie van HIV-1-infectie in Nederland, de 
effectiviteit van de preventie van de overdracht van HIV van moeder op kind, de farmacokinetische 
en farmacodynamische aspecten van krachtige antiretrovirale combinatietherapie bij kinderen, de 
effecten van deze therapie op het welbevinden en de groei bij met HIV geTnfecteerde kinderen, 
geselecteerde aspecten van immuunreconstitutie als gevolg van krachtige antiretrovirale 
combinatietherapie en een prospectieve analyse van de bijwerkingen van deze therapie. 
In 1995 werd in Nederland gestart met de prospectieve registratie van aile kinderen die pre- of 
perinataal aan HIV geexposeerd waren of postnataal gediagnosticeerd waren met een infectie door 
HIV. Kinderartsen meldden nieuwe kinderen elke maand aan het Nederlands Signalerings-Centrum 
Kindergeneeskunde. In hoofdstuk 3 worden de effecten gepresenteerd van de implementatie van 
de richtlijnen ter preventie van perinatale transmissie van HIV in Nederland gedurende de periode 
1995 tot 2000. Er werd een stijging waargenomen van het aantal kinderen dat perinataal aan HIV 
geexposeerd was. Het percentage met HIV geTnfecteerde kinderen na perinatale expositie daalde in 
de periode 1995-2000 van 20% tot 4%. Deze verbetering vormt een refiectie van de toegenomen 
kennis van de pathogenese en behandeling van HIV infecties en van de wijze van transmissie. Het 
risico van perinatale overdracht van moeder op kind, dat zonder interventies 15-30% bedraagt (1-4), 
kan gereduceerd worden tot minder dan 2% door de behandeling van de moeder met krachtige 
antiretrovirale combinatietherapie en door de profylactische behandeling met zidovudine van het 
kind gedurende de eerste levensweken. Als de maternale hoeveelheid virus ten tijde van de partus in 
het bloed boven de 1000 kopieen/ml is, wordt een electieve sectio caesarea geadviseerd. De 
combinatie van een electieve sectio caesarea en antiretrovirale profylaxe aan het kind reduceert het 
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risico op transmissie van HIV tot bijna 0%. (5-9) De daling van het percentage door perinatale 
transmissie ge"infecteerde kinderen onder de aan HIV geexposeerde kinderen van 20% tot 4% kan 
deels verklaard worden door de toename van het gebruik van krachtige antiretrovirale 
combinatietherapie door met HIV ge"infecteerde zwangere vrouwen. Dit gebruik steeg in dezelfde 
periode van 0% in 1995 tot 70% in 1999. Wij concluderen dat de Nederlandse richtlijnen voor de 
preventie van de overdracht van HIV van moeder op kind goed worden toegepast en dat deze 
richtlijnen effectief zijn. 
In hoofdstuk 4 worden gegevens gepresenteerd over het cumulatieve aantal kinderen in 
Nederland dat met HIV gediagnosticeerd werd, de wijze van transmissie, de risicofactoren en de 
klinische toestand vanaf de start van de aidsepidemie in de jaren '80 van de vorige eeuw tot het jaar 
2000. De stijging van het aantal nieuw met HIV geTnfecteerde kinderen gedurende de periode 1995-
1997 werd niet verder doorgezet tijdens de periode 1998-2000. Dit zou veroorzaakt kunnen zijn door 
een actievere benadering in de advisering en screening naar HIV bij zwangere vrouwen. Sinds 1999 
wordt aan vrouwen met een verhoogd risico op HIV (vrouwen afkomstig uit een gebied met een 
gegeneraliseerde HIV- epidemie, vrouwen met sexueel contact met een man met een verhoogd 
risico op HIV) geadviseerd een HIV-test te ondergaan. Bij 86% van de met HIV gediagnosticeerde 
kinderen was een of beide ouders afkomstig uit een gebied met een gegeneraliseerde HIV-epidemie. 
De meeste kinderen (81 %) waren ge'infecteerd door overdracht van moeder op kind. Vierentachtig 
procent werd in Nederland geboren. Het risico op transmissie van HIV had aanzienlijk gereduceerd 
kunnen worden wanneer de moeder voor de geboorte getest was op HIV en bij een bewezen HIV-
infectie volgens de richtlijnen behandeld was. In 2000 hebben Postma en co-auteurs een 
kosteneffectiviteitsstudie verricht naar universele screening van HIV onder aile zwangere vrouwen in 
Amsterdam. (10) In deze studie werd aangetoond, dat een universele screening in Amsterdam zeer 
waarschijnlijk kosteneffectief is. Een probleem bij de analyse was dat er onvoldoende gegevens 
beschikbaar waren met betrekking tot de kosten van de behandeling van met HIV geTnfecteerde 
kinderen. Dit maakte een betrouwbare schatting van de kosten-baten-analyse onmogelijk. Wij zijn 
daarom recent in samenwerking met Postma gestart met een studie om de kosten van de 
behandeling van met HIV ge'infecteerde kinderen te analyseren. 
Uit onze gegevens blijkt dat bij 86% van de kinderen een of beide ouders afkomstg is uit 
een gebied met een gegeneraliseerde HIV-epidemie. Het lijkt daarom onnodig om aile zwangere 
vrouwen in Nederland te screenen, zeals recent door de minister van Volksgezondheid, Welzijn en 
Sport werd geadviseerd. Een screeningsprogramma onder zwangere vrouwen die tot risiscogroepen 
behoren is naar onze mening een oplossing die vee! kosten-effectiever is. Een of beide ouders van 
95% van de nieuwe met HIV gediagnosiceerde kinderen is afkomstig uit een ander land dan 
Nederland. De behandeling van deze kinderen wordt bemoeilijkt door problemen in de communicatie 
en door grate verschillen in sociaal, cultureel en economisch opzicht tussen de gezinnen van deze 
kinderen en de autochtone Nederlandse populatie. Deze situatie maken een zeer intensieve en 
gezins-specifieke benadering met aandacht voor de transculturele aspecten noodzakelijk. Het is 
duidelijk dat een dergelijke leidt tot veel hogere kosten in de zorg voor met HIV ge'infecteerde 
kinderen dan in de zorg voor volwassenen met HIV/aids. 
De farmacokinetische en farmacodynamische aspecten van vee! geneesmiddelen vertonen grate 
verschillen tussen kinderen en volwassenen. Het is daarom niet vanzelfsprekend dat een succesvolle 
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behandeling met geneesmiddelen bij volwassenen, bij kinderen tot hetzelfde resultaat leidt. De 
toepassing van nieuwe middelen bij kinderen, zoals de HIV-1-protease remmers, zou derhalve vooraf 
gegaan moeten worden door een gedetailleerde evaluatie van de farmacokinetische en 
farmacodynamische aspecten. Het doel van deze benadering is het bereiken van een gelijke 
effectiviteit en een gelijke of geringere toxiciteit in vergelijking met die bij volwassenen. 
In hoofdstuk 5 wordt de farmacokinetiek beschreven van de protease-remmer indinavir 
bij kinderen. Waarbij aanzienlijke interindividuele verschillen gevonden worden in de verschillende 
farmacokinetische parameters, zoals "area-under-the-time-curve concentration" (AUC), topspiegels 
en dalspiegels. De hogere metabole klaring en het grotere distributievolume van indinavir resulteren 
in suboptimale spiegels van indinavir bij veel HIV-1 geTnfecteerde kinderen. In een aantal eerdere 
studies bij volwassenen is een duidelijke relatie aangetoond tussen de concentratie van indinavir in 
het bloed en de virologische respons. (11-13) In hoofdstuk 5 wordt aangetoond, dat een AUC van 
indinavir hager dan 20 mg/L *h geassocieerd is met een goede virologische respons. De grate 
leeftijdsafhankelijke individuele verschillen in de farmacokinetiek van indinavir, noodzaken tot 
routinematige bepaling van indinavir-spiegels in het bleed kort na de start van de behandeling. Bij te 
lage of te hoge spiegels dient een dosis aanpassing plaats te vinden. Aanvankelijk bestond de vrees 
dat het risico op aan indinavir gerelateerde nefrotoxiciteit (nierstenen, hematurie en fiankpijn) bij 
kinderen hager zou zijn dan bij volwassenen. Deze nefrotoxiciteit is het gevolg van precipitatie van 
indinavir-kristallen en is gecorreleerd aan hoge indinavir-topspiegels in plasma. (14) Hoewel de 
indinavir- topspiegels bij kinderen hager zijn dan bij volwassenen, werden aanvankeiijk bij geen van 
de kinderen nierstenen gevonden. Echter, in de hoofdstukken 14 en 15 is door middel van 
nauwkeuriger prospectief onderzoek naar de nefrotoxiciteit van indinavir bij kinderen gebleken dat 
een hoog percentage van de kinderen urologische bijwerkingen ondervindt van de behandeling met 
indinavir. Ook werd een relatie gevonden tussen de bloedspiegels van indinavir en de incidentie van 
nefro!ogische toxiciteit. 
De onvoorspelbare interindividuele verschillen in de farmacokinetiek van protease-remmers 
(en waarschijnlijk oak van andere antiretrovirale middelen) bij kinderen onderstrepen het belang van 
het meten van medicatiespiegels in het bloed bij kinderen die behandeld worden met indinavir. Dit 
kan bijdragen aan het voorkomen van suboptimale medicatiespiegels met virologisch fa len als gevolg 
daarvan, terwijl eveneens toxiciteit veroorzaakt door te hoge spiegels voorkomen kan worden. 
Onderzoek naar de relatie tussen medicatiespiegels van protease-remmers en verschillen in het 
metabolisme door cytochroom P450 3A isoenzymen, zal in de toekomst mogelijk leiden tot beter 
inzicht in de oorzaak van de interindividuele verschil!en. Oit zou mogelijk kunnen leiden tot een a 
priori predictie van de optimale dosering van protease-remmers. De micro-arraytechniek, waarmee 
parallelle analyse van grate aantallen genetische polymorfismes in verschillende metabole systemen 
mogelijk is, zou in de toekomst kunnen bijdragen aan een beter begrip en predictie van de 
individuele verschillen in het metabolisme van protease-remmers. 
In hoofdstuk 6 wordt beschreven dat een twee-maal-daagse dosering van indinavir in 
combinatie met de protease-remmer ritonavir resulteert in hogere AUC's en dalspiegels door de 
inhibitie van het CYP450 3A metabolisme door een lage dosis ritonavir (100 mg/m2). Deze studie 
vormt de basis voor toekomstige studies met een vereenvoudigde twee-maal-daagse dosering bij 
kinderen. De farmacokinetiek van indinavir in combinatie met een !age dosis ritonavir liet echter 
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opnieuw grate interindividuele verschi!len zien. Ee§n en ander onderstreept opnieuw, die de noodzaak 
voor het routinematig bepalen van medicatiespiegels bij kinderen. 
Hoewel de noodzaak voor het meten van medicatiespiegels in het voorgaande hoofdstuk 
duidelijk aangetoond is, worden spiegelbepalingen vanwege praktische problemen door nog slechts 
weinig kinderartsenjaidsbehandelaren toegepast. Er bestaan tenminste vijf verschillende strategieen 
voor het analyseren van medicatiespiegels: analyse van AUC; analyse van de dalspiegels; bepaling 
van zowel piek- als dalspiegels; op populatie gegevens gebaseerde farmacokinetische benaderingen 
(concentratieratio's zoals gebruikt in het Nederlandse Athena cohort) en geavanceerde berekeningen 
van de farmacokinetiek. Het meten van dalspiegels lijkt een acceptabele methode om de virologische 
effectiviteit te meten. Tach dient men zich ervan bewust te zijn dat dalspiegels niet altijd een 
betrouwbare maat zijn voor virologische effectiviteit zeker wanneer het tijdstip van laatste inname 
onjuist geregistreerd is. Een ander probleem is dat de dalspiegel niet altijd gelijk is aan de laagste 
concentratie en dat er een variatie bestaat tussen ochtend- en avonddalspiegels. Daarnaast kan de 
onderste detectiegrens van de meetmethode minder accuraat zijn dan het middelste en hoogste 
detectiegebied. De hoogste concentratie in het bleed (Cmax) dient bepaald te worden om van 
toxiciteit bij kinderen te voorkomen. De tijd waarop hiertoe na inname van het geneesmiddel bloed 
afgenomen moet worden, verschilt per middel van 1 tot 4 uur. Dit is afhankelijk van de, per middel 
verschillende, tijdsduur waama de hoogste spiegel bereikt wordt en van individuele farmacokinetiek. 
Mathematische modellering kan toegepast worden op een willekeurig bloedmonster indien de exacte 
tijd van inname bekend is en een model op basis van populatiegegevens bestaat. Uit een 
bloedmonster kunnen door deze methode aile farmacokinetische parameters berekend worden. Het 
probleem van deze methode is dat verschillende modellen nodig zijn voor elke combinatie van 
geneesmiddelen en dat het metabolisme van de geneesmiddelen leeftijdsafhankelijk is. Hierdoor zijn 
grate hoeveelheden gegevens nodig om de modellen te valideren. Mogelijk kan men in de toekomst 
een vereenvoudigde farmacokinetiekcurve toepassen met een lager aantal bloedafnames. Op dit 
moment is de afname van een volledige farmacokinetiekcurve de enige mogelijkheid om een AUC, 
Cmax en Cmin te bepalen. Dit is een arbeidsintensieve, gecompliceerde en dure procedure, die 
mede leidt tot de hoge uitgaven die noodzakelijk zijn voor de zorg voor met HN-1 ge"infecteerde 
kinderen. 
Het bepalen van medicatiespiegels in het bleed is een ongeschikte methode ter bepaling 
van de effectiviteit van nucleoside reverse transcriptase-remmers (NRTI's). Deze NRTI's worden 
intracellulaire gefosforyleerd door de toevoeging van drie fosfaat-groepen. Het bepalen van de 
spiegels van getrifosforyleerde intracellulaire NRTI's is zeer arbeidsintensief. Bovendien is hiervoor 
een groat aantal polymorfonucleaire cellen (en een grate hoeveelheid bleed) nodig, hetgeen deze 
methode ongeschikt maakt voor gebruik bij kinderen. Recent is door ons een techniek ontwikkeld 
waarbij een Malditof-massaspectrometer gebruikt wordt voor het bepalen van intracellulaire spiegels 
van NRTI's met slechts 12.500 cellen (0,3 ml plasma). Daarnaast is deze methode veelbelovend 
vanwege de mogelijkheid tot automatisering ervan. Met behulp van deze techniek zal het in de 
toekomst mogelijk zijn de relatie tussen intracellulaire spiegels van NRTI's en de virologische 
effectiviteit te analyseren. 
In hoofdstuk 7 wordt een andere toepassing van het gebruik van medicatiespiegels 
beschreven: het meten van therapietrouw. Therapietrouw is noodzakelijk voor het bereiken van een 
optimale virologische respons bij met HIV-1 geTnfecteerde kinderen. Een adequate beoordeling van 
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de mate van therapietrouw word! gecompliceerd door de beperkingen van de beschikbare 
methodes. Plasmaconcentraties van protease-remmers buiten de grenzen van referentiewaarden 
wijzen op een slechte therapietrouw bij volwassenen met betrekking tot de antiretrovirale 
behandeling. De mate van therapietrouw, berekend als percentage van de bloedmonsters, die 
voldeed aan de criteria voor therapietrouw, waarbij de laagste CORAL (concentratie ratio grens 
bestaande uit het Se percentiel van populatiedata van vo!wassenen) van indinavir of nelfinavir 
gebruikt werd, was bij kinderen geassocieerd met de mate van virologische respons. Deze methode 
zou gebruikt kunnen worden bij de beoordeling van therapie-ontrouw bij kinderen. Zij is echter 
gebaseerd op populatiegegevens bij volwassenen. Het is in de toekomst noodzakelijk oak bij 
kinderen populatiedata te genereren om zo concentratieratiogrenzen te kunnen berekenen. Vanwege 
de grate interindividuele variabiliteit van de farmacokinetiek van protease-remmers bij kinderen, is 
het gebruik van concentratieratio-grenzen gebaseerd op populatiedata van kinderen waarschijnlijk 
niet de beste methode. De methode zou bij kinderen mogelijk verbeterd kunnen worden door he! 
berekenen van CORAL's in relatie tot de individuele curve van elk kind. Dit zal geanalyseerd en 
gecorreleerd worden aan andere methoden voor het meten van therapietrouw die op dit moment 
gebruikt worden. Onder deze andere methoden vallen het gebruik van elektronische pillendozen die 
de datum en tijd registreren waarop de fles geopend is, en multidiscipiinaire ondersteuning door 
gespecialiseerde verpleegkundigen, kinderartsen, maatschappelijk werkers, huisartsen en 
gezinszorg. Therapietrouw wordt ondersteund door gestructureerde discussies met ouders en 
kinderen waarin informatie wordt gegeven met betrekking tot het belang van therapietrouw. In 
Belgie is een interactieve videoband gemaakt met informatie over HIV-infectie, medicatie en 
therapietrouw ten behoeve van kinderen op verschillende leeftijdsniveau's. Het gebruik van deze 
video zal geTmp!ementeerd worden in de bezoeken aan de gespecialiseerde verpleegkundige op de 
polikliniek. Tijdens deze bezoeken zal de nadruk gelegd worden op het verbeteren van 
therapietrouw. Om de gezinsondersteuning te verbeteren wordt op dit moment gebruik gemaakt van 
een gestructureerde sociale netwerkkaart. De resultaten van dit onderzoek zullen in de toekomst 
verder geanalyseerd en gevalideerd moeten worden. In de enquete wordt het sociale netwerk van 
een gezin, inclusief familie, vrienden en zorgverleners, geanalyseerd met betrekking tot de 
frequentie en kwaliteit van de ondersteuning, het opleidingsniveau van ouders, de arbeidssituatie en 
de financiele situatie. 
Sinds de introductie van protease-remmers in 1996 is combinatietherapie met twee nucleoside 
reverse transcriptase-remmers en een proteaseremmer in snel tempo de standaardtherapie 
geworden bij volwassenen. De gegevens met betrekking tot de effectiviteit van deze combinaties bij 
HN-1 geTnfecteerde kinderen zijn beperkt en zijn hoofdzakelijk tot stand gekomen door studies met 
een gering aantal kinderen. In de hoofdstukken 9 en 10 worden de klinische, virologische en 
immunologische resultaten van de behandeling van met HIV-1-ge·infecteerde kinderen gedurende 
respectievelijk 24 en 96 weken geanalyseerd. De resultaten van de behandeling met protease-
remmers en nucleoside reverse transcriptase-remmers zijn uitstekend. Sinds de introductie van deze 
therapie in 1997 is slechts een kind overleden. Dit kind was al in een zeer gevorderd stadium van de 
ziekte op het moment van de start van de therapie. Op dit moment (januari 2002) zijn aile andere 
kinderen in een uitstekende klinische conditie. De gegevens na behandeling gedurende twee jaar 
tonen dat 69% en 50% van de kinderen een onmeetbaar lage hoeveelheid virus in het bloed hebben 
198 
Samenvatting en discussle 
bij een detectiegrens van respectievelijk 500 en 40 kopieen/ml. Deze resultaten zijn vergelijkbaar 
met de resu!taten die bij volwassenen beschreven worden. Een meerderheid van de studies naar de 
effectiviteit van antiretrovirale behandeling van met HIV-1 geTnfecteerde kinderen laat echter een 
inferieure virologische respons zien. Verschillende omstandigheden zijn geassocieerd met virologisch 
falen: fanmacokinetische parameters (lage bloedspiegels van protease remmers), slechte 
therapietrouw en verschillende factoren voor aanvang van de therapie (voorbehande!ing, lagere 
leeftijd, hoge hoeveelheid virus in het bloed). Het is opvallend dat aile vier pediatrische studies, 
waarin de dosering van de protease-remmers is aangepast, na evaluatie van farmacokinetische 
parameters een superieure virologische respons beschrijven ten opzichte van de studies waarin 
vaste doseringen toegepast werden (hoofdstuk 8). De inferieure virologische resultaten bij 
kinderen die met krachtige antiretrovirale therapie behandeld worden, zijn een afspiegeling van de 
uitdagingen in de behandeling van met HN-1 ge"infecteerde kinderen. Problemen met therapietrouw 
en met de farmacokinetische eigenschappen van protease-remmers bij kinderen eisen een 
intensieve, op kinderen toegespitste benadering. Vanwege de noodzaak van de behandeling 
gedurende een nag onbekende duur, zal therapietrouw in de toekomst toenemend een probleem 
gaan vormen. Verbetering van therapietrouw door gestructureerde gesprekken met ouders en 
kinderen, het gebruik van boekjes, waarin stickers geplakt kunnen worden na inname van de 
medicatie, en het meten van medicatiespiegels vereisen steeds meer inspanningen van het 
multidisciplinaire team. Recent werd gestart met het gebruik van elektronische pillendozen om tot 
aanvullende informatie te komen met betrekking tot therapietrouw. De sociale netwerkkaart wordt 
door de maatschappelijk werkster geanalyseerd om socio-economische factoren die met 
therapietrouw zouden kunnen interfereren op te sporen. Deze analyses moeten individueel en in 
relatie tot elkaar gevalideerd worden, hetgeen zou moeten leiden tot kind- en gezinsspecifieke 
interventies. Daarnaast zal een kosteneffectiviteitsanalyse van dit intensieve interventieprogramma 
uitgevoerd worden. 
Twee-maal-daagse medicatteschema's en (in de toekomst) een-maal-daagse schema's 
zullen bijdragen aan een betere therapietrouw. Op dit moment wordt gewerkt aan nieuwe studies 
waarin een twee-maal-daagse therapie met twee NRTI's en een combinatie van indinavir en ritonavir 
vergeleken worden met een twee-maal-daags medicatieschema bestaande uit drie NRTI's (abacavir, 
zidovudine en lamivudine). In deze studie wordt therapietrouw gemeten met behulp van 
medicatiespiegels, elektronische pillendozen en gestructureerde interviews. Het doe! van 
toekomstige studies zal zijn een geringere hoeveelheid pillen, een lagere innamefrequentie, minder 
bijwerkingen, verbeterde ondersteuning door een kind-specifieke benadering (bijvoorbeeld door de 
interactieve videoband) en verbeterde therapietrouw door meer aandacht voor therapietrouw door 
een gespecialiseerde verpleegkundige. Daarnaast zal de invloed van therapie (het slikken van pillen, 
bijwerkingen, stigmatisering) op de kwaliteit van Ieven geanalyseerd worden met de voor kinderen 
gevalideerde PEDsQoL-vragenlijst. 
In hoofdstuk 11 wordt de respons van het immuunsysteem op krachtige antiretrovirale 
combinatietherapie beschreven. Gegevens ten aanzien van de immunologische respons op therapie 
op langere termijn ontbraken waardoor het onduidelijk was in welke mate het aantal CD4+ T-cellen 
herstelde. Het aantal CD4+ T-cellen bij met HN-1 ge"infecteerde kinderen herstelt sneller dan bij 
met HN-1 geinfecteerde volwassenen. Dit werd toegeschreven aan de relatieve grate thymus en de 
betere functie van de thymus bij jonge kinderen. Onze studie is de eerste waarin het herstel van het 
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aantal CD4+ T-cellen gerelateerd is aan de normaalwaarden voor lymfocytensubpopulaties. Over het 
algemeen worden in kinderstudies over T-cel repopulatie tijdens therapie absolute aantallen CD4+ 
T-cellen gebruikt, omdat het aantal CD4+ T-cellen als percentage van het totale aantal T-cellen 
beinvloed wordt door grate veranderingen in het aantal CDS+ T-cellen tijdens therapie. De analyses 
van T-celrepopulatie in groepen kinderen met verschillende leeftijden worden beperkt doordat de 
normaalwaarden voor het aantal CD4+ T-cellen sterk leeftijdsafhankelijk zijn. Normaalwaarden bij 
jonge kinderen zijn veel hager en hebben een grater bereik in vergelijking met oudere kinderen. (15) 
Jongere kinderen moeten daardoor grotere aantallen CD4+ T-cellen produceren om hun 
(leeftijdsafhankelijke) normale aantal CD4+ T-cellen te bereiken. De berekening van het aantal 
CD4+ T-cellen als percentage van normaalwaarden resulteert in een leeftijdsonafhankelijke 
parameter voor immuunrepopulatie. Op deze manier berekend, blijkt dat het aantal CD4+ T-cellen in 
relatie tot hun normaalwaarde bij jonge kinderen even goed herstelt als bij oudere kinderen. Zelfs 
kinderen met extreem lage aantallen CD4+ T-cellen bij aanvang van de therapie bereikten normale 
aantallen CD4+ T-cellen na 96 weken therapie. Immuunreconstitutie wordt hoofdzakelijk bereikt 
door de productie van naieve CD4+ T-cellen. Naast het kwantitatieve herstel van het 
immuunsysteem, wordt oak een herstel van de T-celfunctie na stimulatie met CD3 mAb plus CD28 
mAb waargenomen. Dit suggereert dat oak een functioneel herstel optreedt na start van de 
therapie. Verder analyses met betrekking tot veranderingen in immuunactivatiemarkers en de relatie 
hiervan met virologische respons worden nag uitgevoerd. Een opmerkelijke bevinding was de 
afwezigheid van verschillen tussen kinderen met een goede virologische respons ten opzichte van 
degenen met een slechte virologische respons. Dit fenomeen zou verklaard kunnen worden door de 
selectie van bepaalde virusmutanten die resistent zijn tegen protease-remmers en die in-vitro een 
verminderde replicatiecapaciteit hebben. De dissociatie tussen een goede k!inische en 
immunologische respons in de aanwezigheid van virologisch falen is oak waargenomen door 
anderen. Een langere follow-up duur en nader onderzoek zijn noodzakelijk voor een beter begrip ten 
aanzien van de onderliggende mechanismen van dit fenomeen. De resultaten van genotypische 
resistentieanalyse zouden kritisch ge'interpreteerd moeten worden vanwege de vaak afvvezige 
klinische en immunologische consequenties. Dit geldt met name voor de uitgebreid voorbehandelde 
patienten waarvoor weinig alternatieven overblijven. 
Disregulatie van groei is een vee! voorkomend verschijnsel van een HIV-1-infectie bij 
kinderen. Groei is 88n van de meest sensitieve indicatoren voor ziekteprogressie bij met HIV-1 
geTnfecteerde kinderen. Herstel van groei na start van krachtige antiretrovirale combinatietherapie is 
derhalve een belangrijke parameter. In hoofdstuk 12 worden de effecten van therapie op groei in 
ons cohort beschreven. Antiretrovirale therapie had een positief effect op lengte en gewicht. In 
tegenstelling tot studies met mono- en duotherapie waarin dit positieve effect op groei slechts 
tijdelijk gezien werd, werd herstel van groei waargenomen gedurende tenminste 96 weken. Herstel 
van groei is geassocieerd met een succesvolle toepassing van de therapie, met een langdurige 
suppressie van de virusreplicatie en met een stijging van het aantal CD4+ T-cellen. De etiologie van 
aan HIV-1 gerelateerde disregulatie van groei is complex. Een abnormale functie van de schildklier, 
afwijkingen in de groeihormoonas, het vetmetabolisme en een abnormaal energiemetabolisme 
zouden kunnen bijdragen aan een verminderde groei. Derhalve werd door ons een aantal 
endocrinologische en immunologische factoren geanalyseerd die ten grondslag zouden kunnen 
liggen aan het waargenomen herstel van de groei na therapie. In hoofdstuk 13 worden de 
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resultaten van deze studie waarbij contsol, schildklier- en groeihormonen en TNF-a spiegels in het 
bleed werden bepaald. Hormonen die de groei na de geboorte beTnvloeden zijn groeihormoon en 
insuline-achtige groeifactor-1 (IGF-1), schildklierhormoon en glucocortcoco"iden. Excessieve 
glucocortico"idspiegels of lage schildklierhormoonspiegels kunnen op de kinderleeftijd voor een 
achterblijvende groei zorgen. TNF-a is een pro-inflammatoir en immunomodulerend cytokine dat in 
verhoogde mate geproduceerd wordt bij infecties en maligniteiten. Daamaast remt TNF-o: 
lipoproteinelipase en de genexpressie van adipocyten. Chronisch hoge TNF-a- spiegels zijn 
geassocieerd met het ontwikkelen van cachexie. Om veranderingen in de groeihormoonas te 
analyseren werden IGF-1- en !GFBP-3-spiegels bepaald. Van !GF-1 en het belangrijkste IGF-1 
bindende eiwit IGFBP-3 is bekend dat deze sterk afhankelijk zijn van groeihormoon. Deze hebben 
het belangrijke voordeel dat de concentraties constant zijn over de dag. De cortisol- en 
schildklierhormoonspiegels waren binnen de norm en veranderden niet na behandeling, hetgeen 
suggereert dat afwijkingen in schildklierhormoon en in de bijnieras geen rol spelen bij het herstel 
van de groei gedurende therapie. IGF-1 en IGFBP-3 spiegels in het bloed waren niet afwijkend maar 
stegen significant in het beloop van de behandeling. De TN F-a spiegels daalden significant tijdens de 
therapie. De combinatie van relatief hoge IGFBP-3-spiegels en lage IGF-1-spiegels suggereert dater 
sprake is van groeihormoon resistentie. De daling van IGFBP-3-spiegels en stabilisering van IGF-1 
spiegels wijzen in de richting van een herstel van de gevoeligheid voor groeihormoon een het 
intreden van een anabole conditie. Verder onderzoek is noodzakelijk om te onderzoeken of andere 
factoren die aan de disregulatie van groei gerelateerd zijn -calorische inname, vetmetabolisme en 
energiemetabolisme- ook een rol spelen bij het herstel van groei tijdens therapie en om deze 
hypothese ten aanzien van het herstel van de gevoeligheid voor groeihormoon te bevestigen. 
Antiretrovirale geneesmiddelen zeals indinavir dienen gedurende vele jaren gecontinueerd te 
worden. Een zorgvuldige surveillance ten aanzien van bijwerkingen op de lange termijn is derhalve 
noodzakelijk. De protease-remmer indinavir kan klachten van nierstenen veroorzaken door de 
formatie van indinavir kristallen. Daarnaast kan schade aan het epitheel in de tubulus ontstaan 
zonder klinische symptomen. Deze subklinische fase kan gevolgd worden door symptomatische 
nierschade. Symptomatische nefrotoxiciteit door het gebruik van indinavir is in de literatuur bij 
volwassenen goed gedocumenteerd. Over de relevantie van leucocyturie gedurende het gebruik van 
indinavir is echter weinig bekend. In hoofdstuk 14 wordt de eerste prospectieve studie beschreven 
naar nefrotoxiciteit bij met HIV-1 ge"infecteerde kinderen, die langdurig met indinavir behandeld 
werden is. De cumulatieve incidentie van persisterende steriele leucocyturie bedroeg 53% na 96 
weken therapie met indinavir. Bij kinderen jonger dan de mediaan van 5,6 jaar was de cumulatieve 
incidentie 78%. Daarnaast werd bij 35% van de kinderen na 96 weken een cumulatieve incidentie 
van een stijging van het serum-kreatinine van meer dan 50% boven de leeftijdsafhankelijke 
normaalwaarde gevonden. Kinderen met een persisterende steriele leucocyturie hadden vaker een 
stijging in het serum-kreatinine van meer dan 50% boven normaal. Dit suggereert dat persisterende 
steriele leucocyturie een vroege indicator is voor het ontwikkelen van nierschade. Een hogere 
cumulatieve incidentie van persisterende steriele leucocyturie werd gevonden bij kinderen met een 
AUC van indinavir > 19 (mg/L *h) en bij kinderen met een topspiegel van indinavir hager dan 12 
(mg/L). Dit compliceert de behandeling van met HIV-1 geinfecteerde kinderen met indinavir, omdat 
wij eerder hebben beschreven dat een AUC van indinavir < 20 (mg/L*h) geassocieerd is met 
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virologisch falen. Om optimale virologische suppressie van HIV te bereiken is een AUC > 20 
(mg/L *h) nodig, maar om het risico op nefrotoxiciteit te verkleinen is een AUC < 19 (mg/L *h) nodig. 
Deze observaties suggereren dat indinavir minder bruikbaar is bij de behandeling van met HIV·1 
ge·infecteerde kinderen. Indinavir is echter een zeer krachtige protease-remmer, die in combinatie 
met nudeoside-analoga een uitstekende lange termijn klinische, virologische en immunologische 
response bewerkstelligt bij zowel volwassenen als bij kinderen zeals gedemonstreerd is in de 
hoofdstukken 9 tot en met 13. Gesteld wordt derhalve voor nefrotoxiciteit zorgvuldig te monitoren 
en indinavir aileen te vervangen indien een verslechtering van de nierfunctie optreedt. Dit is ons 
inziens zonder risico's, omdat de gerapporteerde nierschade reversibel is na het staken van de 
behandeling met indinavir. Nefrotoxiciteit komt nauwelijks voor gedurende de eerste drie maanden 
na start van de behandeling. Een altematieve strategie zou derha!ve kunnen bestaan uit een 
inductie-onderhoudsschema, waarbij indinavir gedurende de eerste maanden van de behandeling 
gebruikt wordt om de virusreplicatie krachtig te onderdrukken, gevolgd door een eenvoudigere en 
minder toxische, maar oak minder krachtige combinatie. 
In hoofdstuk 15 worden twee ziektegeschiedenissen beschreven van door indinavir 
veroorzaakte asymptomatische nefrolithiasis en cortexatrofie bij met HIV-1 gelnfecteerde kinderen. 
Een echografisch onderzoek van de nieren werd bij vijf kinderen verricht in verband met het bestaan 
van persisterende steriele leucocyturie. Bij twee kinderen werden uitgebreide calcificaties en ernstige 
atrofie van de cortex waargenomen op de echo ondanks de afv..rezigheid van een stijging van het 
serum kreatinine. Deze afv..rijkingen waren reversibel na staken van indinavir. Desondanks kan niet 
uitgesloten worden dat bij een verder gevorderd stadium van nierschade een blijvende reductie van 
de nierfunctie kan optreden. Bij deze twee kinderen werd een hoge AUC en Cmax van indinavir 
gemeten. De hoge bloedspiegels kunnen hebben bijgedragen aan het ontstaan van nierschade. De 
door ons gerapporteerde observatie onderstreept de noodzaak voor het routinematig verrichten van 
urine-onderzoek en het meten van serumspiegels van indinavir. 
Een syndroom bestaande uit hyperlipidemie, insulineresistentie en perifere lipodystrofie is 
reeds sinds de reglstratie van protease-remmers in 1996 beschreven bij met HIV-1 ge"infecteerde 
volwassenen. De prevalentie van dit syndroom is nog steeds onbekend doordat veel onderzoekers 
slechts een aspect van het syndroom onderzochten en doordat de drie hoofdsymptomen 
(hyperlipidemie, insulineresistentie en perifere lipodystrofie) niet altijd samen voorkomen bij aile 
patienten. Een belangrijke factor in de analyse van de prevalentie van Jipodystrofie is het tijdstip van 
optreden na start van de behandeling met protease-remmers. In studies met een langere follow-up-
tijd wordt een hogere prevalentie vastgesteld dan in studies met een kortere follow-up-tijd. Het is 
nag steeds niet opgehelderd of de metabole veranderingen het gevolg zijn van de therapie of van de 
HIV-1-infectie zelf. 
In Hoofdstuk 16 wordt een studie gepresenteerd naar de veranderingen in serumspiegels 
van lipide- en glucosemetabolisme. Totaal cholesterol, HDL- en LDL-cholesterol in serum stegen 
significant na toediening van krachtige antiretrovirale combinatietherapie gedurende tenminste 18 
maanden. De serumspiegels van glucose, insuline en C-peptide waren normaal. Hypertriglyceridemie 
en lage serumspiegels voor totaal cholesterol, HDL en LDL zijn eerder beschreven bij met HIV-1 
ge·infecteerde patienten, met name bij patienten in een verder gevorderd stadium van de ziekte. Een 
sterkere stijging van het totale, HDL- en LDL-cholesterol zou derhalve verwacht kunnen worden bij 
kinderen in een verder gevorderd stadium van de ziekte na start van de behandeling in vergelijking 
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met kinderen in een minder gevorderd stadium. De significante stijging van het serum totaal, HOL-
en LDL-cholesterol zou dus oak het resultaat kunnen zijn van een normalisatie van pre-existente 
afwijkingen in het lipidenspectrum. Hoewel bij volwassenen hoge incidenties van klinisch zichtbare 
lipodystrofie gemeld worden, zijn bij de kinderen in de studie nag geen zichtbare symptomen van 
lipodystrofie en/of centrale obesitas waargenomen. De afwezigheid van klinische aanwijzingen voor 
lipodystrofie dient ondersteund te worden door de analyse van objectieve gestandaardiseerde 
metingen, zoals middel-heup-ratio's, huidplooimetingen en "dual energy X-ray absorptiometry". De 
aan- of afwezigheid van specifieke factoren bij kinderen, zoals de aanwezigheid van groeihormoon of 
de afwezigheid van geslachtshormonen, zou het risico op het ontstaan van perifere lipodystrofie bij 
kinderen kunnen verminderen. Toekomstig onderzoek zou zich moeten richten op het ophelderen 
van het mechanisme dat ten grondsiag ligt aan lipodystrofie bij volwassenen. Daamaast dienen 
verschillen in het vetmetabolisme tussen verschillende behandelingsstrategieen vergeleken te 
worden. Om dit soort studies te kunnen verrichten zijn grate aantallen kinderen nodig. Deze 
analyses zouden kunnen plaatsvinden in internationaal verband, bijvoorbee!d in het " Paediatric 
EuropeanNetwork for Treatment of AIDS" (PENTA). 
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Conclusions and future perspectives 
Chapter 19 
In this chapter we briefly summarize our conclusions and we present our ideas concerning the future 
directions of care and research in children with HIV/AIDS. In Table 1 the major conclusions and the 
future directions for research are summarized. 
During the past four years a multidisciplinary team became responsible for the care of 
children with HN/AIDS in the Sophia Children's Hospital in Rotterdam. This team includes nurse 
specialists, a social worker, research physicians and pediatric infectious disease experts. In these 
years we carefully delineated the responsibilities of the different team members. The nurse specialist 
focuses on adherence, providing information on the disease and its treatment and making home 
visits. The social worker organizes contacts with organizations outside the hospital, collects 
information on social background (with the social background questionnaire) and provides support in 
economical and family problems. The research physician's responsibility includes the organization of 
a structured approach, correct data collection, the writing of study protocols, and the analysis and 
publication of data. The pediatric infectious disease experts provide state-of-the-art medical care and 
supervision of all activities in collaboration with the other members of the team. Central point of 
attention is optimization of adherence to therapy. This starts with the assessment of therapy by 
structured discussions with parents and children, by the use of electronic pill boxes that registrate 
the dates and times a bottle was opened, and by therapeutic drug monitoring. Adherence to therapy 
is further enhanced by providing information on the importance of this aspect of the therapy. In 
Belgium, recently an interactive cartoon on video with information on HIV infection, medication and 
adherence has been developed for use in children of different ages. With financial support of the 
Sophia Foundation in Rotterdam, we will start to use this interactive computer program to further 
optimize the care for and the compliance with therapy in our children. To obtain a better 
understanding of social and economic factors contributing towards adherence to therapy, we are 
currently analyzing data derived from a social background questionnaire. Since adherence to 
medication often decreases over time, further improvements in the level of care will be necessary to 
maintain optimal long-term treatment results. An individualized and flexible approach towards 
treatment regimen will be essential to optimize adherence to HAART. 
Since the social situation of a family may have a tremendous impact on the ability to 
consistently access care and adhere to medication regimens, a family outpatient department should 
be established in which both parents and children are seen by doctors, nurses and social workers. In 
this respect the absence of financial resources for a psychologist as a member of the 
multidisciplinary team restricts our opportunities to provide optimal care. Increased understanding of 
the family's social situation will result in the possibility to apply individualized interventions. 
Improved communication with local pediatricians and the family's general practitioners resulting in 
involvement and participation in the treatment of the families will further optimize long-term 
treatment. Currently protocols for improved communication and collaboration between all parties 
involved are developed. An emerging problem is the increasing number of children reaching 
adolescence resulting in adolescent specific adherence problems (denial of disease, rebellious 
behavior). Special attention, support and adolescent talk groups may be able to help these children 
through their puberty specific problems. However, experiences and different strategies should be 
shared and monitored in a structured way. Because of the limited numbers of adolescents in one 
country, this should be performed in a national or maybe even international context. For younger 
children that are dependent on their parents or caregivers for an adequate treatment, adherence 
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problems should be followed-up very carefully. The development of protocols on strategies of 
interventions taken in the case of non-adherence in collaboration with Child Welfare Council, home-
care organizations, jurists and judiciary should warrant optimal care for children with incapable or 
unwilling parents. 
Finally, we have shown in this thesis that the treatment of HN-1 infected children under 
the conditions as mentioned above can be as successful as that in adults. This will lead to an optimal 
clinical response (no opportunistic infections, recovery of growth), optimal virological suppression, a 
maximal recovery of the immunesystem and generally mild and transient side-effects of the 
antiretroviral drugs. 
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Epidemiology • In the period from 1995-2000 the percentage of HIV-1 infected • Continuing registration to observe whether this percentage may be 
children after exposure to HIV-1 decreased from 20% to 4%, further decreased by the administration of HAART to pregnant women 
suggesting that the Dutch guidelines to prevent mother-to-child who are infected by HIV and to monitor possible toxicity associated with 
prevention are well Implemented and efficacious. prenatal exposure to antiretrovlral medication. 
• The increase In the number of HIV-1 infected children during the • Cost-benefit analysis of universal screening on HIV in pregnant women 
period 1995-1997 reached a plateau in the period 1998-2000. versus a more focussed program to test of pregnant women belonging to 
• Eighty-six percent of the children originated from a country with a high risk groups . 
generalized HIV epidemic. • Analyses of the costs of the care and treatment for children with 
• Eighty-one percent of the children was Infected by mother-to-child HIV/AIDS . 
transmission. 
Pharmacology • The unpredictable interlndlvldual differences In the • Monitoring of lndinavir plasma levels shortly after the start of lndlnavir in 
pharmacokinetics of protease Inhibitors in children underscore the stead of using a fixed dose regimen. 
importance of TOM in children treated with indinavlr to prevent • The development of a simplified pharmacokinetic curve using drug levels 
suboptimal drug levels resulting in virological failure and to prevent at less time-points and yet still obtaining reliable estimates for 
toxicity caused by high drug levels. pharmacokinetic parameters. 
• Future research on the relation bet\.1/een drug levels of protease Inhibitors 
and differences in metabolism by cytochrome P450 3A isoenzymes may 
elucidate the cause of these interlndividual differences. 
• Twice dally indinavlr administered in combination with ritonavir • Study of the clinical, virological and immunological effectiveness of an 
results in higher AUC's and trough levels of indlnavir by the indinavir/ritonavlr containing regimen. 
inhibition of CYP450 3A metabolism by low·dose ritonavlr. • Development of simplified regimens Including less frequent dosing of 
• Again the pharmacokinetics of lndinavlr and low-dose ritonavir NRTI's . 
differed widely bet\.1/een Individual children underscoring the • Intracellular measurement of drug levels will be necessary to evaluate 
necessity to perform TOM. whether adequate druglevels of NRTI's are preserved. 
• A novel technique requiring a little volume of blood is currently developed 
by our group using a Malditof Massspectrometer. 
• Therapeutic drug monitoring In relation to concentration ratio limits • Population data obtained in children should be generated to calculate 
consisting of the 5th percentile of population data obtained in concentration ratio limits in children. 
adults may be useful to assess non-adherence in children. • Optimization of this method may be possible by calculating CORAls in 
relation to the child's own PK curve. This will be analyzed and correlated 
to other adherence assessment strategies, which are currently used. 
Major conclusions Future directions and research 
Clinical, • No opportunistic Infections were observed. • Studies with tvJice (or in the future once)-dally regimens with more active 
• Virological response rates (69% <500 coples/ml, 50% <40 protease inhibitors, with lower pill burden, and less side-effects, which 
virological and coplesjml) after 96 weeks are comparable to those in adults. will result in improved adherence. 
• Poor compliance is associated with poor virological respons, • Improved support by a child specific approach. 
immunological • Study on the quality of life with the PEDs QoL questionnaire and 
validation of this questionnaire. 
aspects • Improvement of compliance by improvement of support (psychologist, 
social background analysis, interactive computer program, adolescent talk 
groups), lower pHI burden, less side-effects. 
• Increase in height and weight (expressed as standard deviation • Study with a larger number of children to Investigate the underlying 
scores) associated with successful application of HAART. This Is principles of the recovery of growth after the Initiation of HAART 
associated with an increase of IGF-1, but not with cortisol, thyroid (including caloric Intake, lipid metabolism and resting expenditure) 
hormone and TN F-a changes. 
• Normalization of CD4+ T-een counts (mainly by an Increase of • Studies on other aspects of immunoreconstitution: cytotoxic T-cell 
naive CD4+ T-cells) in children of all age groups. Even in children responses, cytokine profiles and activation markers. 
with extremely low CD4+ T-cell counts at baseline. • Studies on the relation between genotypic resistance and clinical and 
• Differences in immunological response behveen virological Immunological response rates . 
responders and non-responders were not observed. 
• Functional improvement of the immune system (stimulation with 
CD3 mAb plus CD28 mAb). 
Major conclusions Future directions and research 
Side-effects • In children treated with 'mdlnavir 53% experienced persistent • Close monitoring of nephrotoxicity and change of the therapy In the case 
leucocyturia after 96 weeks associated with loss of renal function. of Joss of renal function. 
• Persistent leucocyturia was more frequent in children <5.6 years, • Since the cumulative incidence of persistent leucocyturia increases after 3 
children with AUC > 19 mg/l or Cmax > 12 mg/L months, the concept of a highly active Induction regimen (with lndinavir) 
• Increased total cholesterol, HDL and LDL cholesterol were followed by an Jess toxic and simplified maintenance regimen should be 
observed after > 18 months of HAART. This may be due to a explored. 
normalization of pre-existing lipid abnormalities. • Prospective study on changes in lipid metabolism, waist/hip ratio's and 
• Glucose, Insulin and C-peptide levels were normal. skin fold thickness . 
• No overt clinical symptoms of peripheral lipodystrophy and/or • Analysis of differences in biochemical and clinical parameters between 
central obesity were observed. different medication regimens. 
• Study of the underlying pathophysiological mechanisms that may clarify 
the difference In the prevalence of lipodystrophy between adults and 
children (i.e, the presence of growth hormone, the absence of sex 
hormones). 
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En dan is er opeens de dag dat je het dankwoord mag schrijven. Een mooi moment waarin in 
vogelvlucht vooral veel leuke en gezellige, maar oak spannende en minder leuke belevenissen nag 
eens in gedachten passeren. 
Als eerste wil ik Prof. dr. R. de Groot bedanken. Beste Ronald, jij gaf mij "zomaar van de straat 
geplukt" vele kansen. De kans om een goed lopende studie draaiend te houden en verder uit te 
bouwen. De kans om me in dit zich snel ontwikkelende veld te verdiepen door veel congresbezoek. 
De kans om kennis te maken met de wereld van het wetenschappelijke onderzoek met a! haar leuke 
kanten, maar oak met al haar politiek. Als ik jouw slogan "Never ever give up" oak maar een beetje 
toepas, kom ik vast een heel eind. 
Dr. D.M. Burger, beste David, van jou heb ik gedurende mijn hele promotietraject heel veel geleerd. 
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graag heel hartelijk bedanken voor de enthousiaste en motiverende hulp bij het tot stand komen van 
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J.M. Vossen, J.J.P. Schrander, D.M. Burger, C.M.R. Weemaes, R. de Groot, N.G. Hartwig, H. 
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en de gastvrijheid! 
Marja Suur, minstens duizend keer ben ik je dankbaar geweest voor het op z'n Suur's opzetten, 
organiseren en starten van de studie. Alles klopte tot in de puntjes en was goed georganiseerd 
waardoor het mogelijk was om de studie soepel van jou over te nemen. Ze!fs zonder je 
aanwezigheid heb je me veel geleerd over het organiseren van studies. 
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